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ABSTRACT 
The link between genomic variation and disease was first recognised over 50 years ago, 
fuelling research into the underlying genetic basis of rare and complex genetic 
disorders, disease susceptibility and altered drug response. Interest in polymorphis1n 
studies has undergone a rapid revival with the recent completion of the Human Genome 
Project, the advent of sequence databases and the development of computer-based tools 
designed to detect polymorphisms, all of which are expected to facilitate this area of 
research. 
Of particular interest in the study of disease susceptibility and adverse drug responses 
are enzymes involved in the 1netabolism of xenobiotics such as the glutathione S-
transferases (GSTs). The GST superfa1nily belongs to the group of phase II 
detoxification enzymes that facilitate the detoxification of various carcinogens, 
therapeutic drugs, environmental toxins and products of oxidative stress with which 
hu1nans are daily faced. Eight classes of soluble human GSTs, with as many as five 
isoforms per class, have been defined (Alpha, Kappa, Mu, Omega, Pi, Sigma, Theta and 
Zeta). Although there is some overlap between classes, each GST isoform possesses 
unique substrate specificities hence the GSTs are able to provide an effective defence 
against the potentially damaging effects of a range of xenobiotics and endogenously 
produced toxic compounds. 
Polyinorphisn1s in the GSTs have the potential to alter an individual's susceptibility to 
carcinogens and toxins, and influence the efficacy and toxicity of drug treatment. A 
nun1ber of polymorphisms have been described in the human GSTs and whilst some 
appear innocuous, others have been implicated in altering susceptibility to diseases such 
as cancer and Parkinson's Disease, and influencing response and resistance to drugs, 
simply through altered activity and expression levels. As these polymorphisms have 
generally been identified by chance, the extent of genetic polymorphism in the human 
GST genes remains unknown. The recent developments in bioinformatic approaches to 
polymorphism detection were therefore applied to the GST superfamily. The following 
chapters describe the discovery of polymorphisms in the Alpha (Chapter 3), Mu 
(Chapter 4) and O1nega (Chapter 5) class GSTs using this approach. 
Vl 
Five polymorphisms were identified in the Alpha class GSTs - the silent GSTAJ 
p.K125K polymorphism; p.Pl l0S, p.Tl 12S and p.E210A in GSTA2 and p.L71I in 
GSTA3 (Chapter 3). Although the GSTA2 polymorphisms had previously been 
recognised as sequence variants, they had not been the subjects of further investigations. 
Allele frequencies for each of the five variants were determined in four populations 
(Australian European, Bantu Africans, Creole Africans and Southern Chinese) 
representing three of the world's major ethnic groups - Caucasians, Chinese and 
Africans. Of these, the GSTA2 p.Tl 12S and GSTA3 p.L 711 polymorphisms were found 
to be quite rare. Enzymatic characterisation revealed significant alterations in enzyme 
function were introduced by the GSTA2 p. S 110 variant. 
Two Mu class polymorphisms in the GSTM3 gene - p.G147W and p.V224I, were 
identified and characterised in Chapter 4. Again, despite previous recognition, these 
polyn1orphisms have not been extensively characterised. Genotyping results for these 
two polyinorphisms, in addition to a known intronic deletion, revealed a distinct 
difference between the allelic profiles of the Southern Chinese compared to that of the 
Australian European and two African populations. The p.V224I polymorphism was 
found to be relatively co1nmon, with the p.V224 variant being the common variant in 
the Australian European and African populations, whereas the p.1224 variant was 
co1nmon in the Southern Chinese population. The known intronic deletion was also 
found to be relatively cormnon in the Australian European and African populations, yet 
was absent fro1n the Southern Chinese population. In contrast, the extremely rare 
p.G147W polyinorphis1n was only identified in three Southern Chinese individuals. 
Enzyinatic characterisation revealed that the p.1224 variant was responsible for 
significant functional changes, but the p.Wl47 variant did not dramatically alter enzyme 
function. However, when the p.W147 and p.1224 polymorphisms were combined, a 
significant decrease in specific_ activity was observed. 
Three novel polyinorphisms in the newly characterised GST Omega class genes are 
described in Chapter 5 - p.A140D and p.E155del in GSTOJ and p.N142D in GST02. 
Whilst the p.Al40D GSTOJ and p.N142D GST02 were relatively common in the four 
populations genotyped, the p.E155del GSTOJ polymorphism was quite rare, and only 
one individual in the Southern Chinese population was found to be homozygous for this 
deletion. Unfortunately due to protein purification proble1ns, further investigation into 
.. 
Vll 
the GST02 polymorphism was prevented. Through enzymatic characterisation of the 
GSTOJ allelic isoforms, it was demonstrated that the p.El55del polymorphism was 
responsible for a significant increase in transferase and thiolreductase activities. In 
contrast, the p.A140D polymorphis1n did not appear to have any functional effects on 
GSTO 1-1, however as a substrate unique to GSTO 1-1 has not yet been identified, and 
its monomethylarsonous reductase activity was unable to be measured, the possibility 
that this polymorphism 1nay alter enzyme activity must be kept in mind. 
This study has revealed a 1noderate level of genetic polymorphism in the GST Alpha, 
Mu and Omega genes through utilisation of a bioinformatic approach, an approach that 
has proved to be rapid and relatively efficient. Characterisation of the enzymatic 
properties has shown that the structure and function of the common allelic isoforms of 
GSTA2, GSTM3 and GSTOJ are significantly altered by four of the polymorphisms 
described here, each of which may exert significant clinical implications. 
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1.1 INTRODUCTION 
The goal of this thesis was to identify novel polymorphisms in xenobiotic metabolising 
enzyines using database analysis. In order to provide an appropriate overview of this 
topic, the literature review is divided into two sections. The first section will review the 
application of database analysis to the area of polyinorphism detection, and the second 
will provide a general review of the glutathione transferases, the family of xenobiotic 
metabolising enzymes that were the subject of the detailed investigation presented in 
this thesis. 
1.2 POLYMORPHISM DETECTION USING DATABASE ANALYSIS 
1.2.1 INTRODUCTION 
With the exception of monozygotic twins, every individual 1s genetically unique. 
Individual response to the daily barrage of drugs, toxins and other environmental or 
dietary co1npounds with which hu1nans are constantly faced, and the resultant effects, 
can differ dramatically due to this genetic variation. The link between genomic 
"The link between genomic variation and disease was recognised over 50 years ago 
[Ingram, 1957], and it has since been recognised that so1ne variations have 
physiological consequences in disease susceptibility and adverse drug reactions. 
However, a resurgent interest in detection of these variations, in particular single 
nucleotide polymorphisms (SNPs ), was not fuelled until the recent sequencing of the 
human genome, the advent of sequence databases and the capacity to detect SNPs in 
silica." 
genome with heritable phenotypes and are likely to facilitate large-scale association 
studies. SNP data is estin1ated to have a major impact on population genetics, drug 
development, forensics, cancer and genetic disease research [Brookes, 1999]. 
Chapter 1 Literature Review 2 
1.2.2 WHY STUDY POLYMORPHISMS? 
Sequence variations - inserts, deletions and single base substitutions - in genomic DNA 
are collectively known as polymorphisms. A locus is considered polymorphic if at least 
two alleles exist at that particular locus and the allele frequency in a population of the 
least common variant is > 1 %, although this guideline is not always strictly followed 
[Brookes, 1999]. Single base substitutions, also known as SNPs, account for 
approximately 90% of DNA polymorphism [Collins et al., 1998] and current estimates 
suggest there is a potential ten million SNPs in the human genome [Kruglyak & 
Nickerson, 2001; Lai, 2001]. Although they have been calculated as occurring every 
1000 bp [Cooper et al., 1985; Kwok et al., 1996], the number of nucleotide differences 
between two chromosomes, known as the nucleotide diversity [Nei & Li, 1979], varies 
between chromoso1nal regions and also between ethnic groups [Horton et al., 1998; 
Naclnnan et al., 1998; Nickerson et al., 1998; Kruglyak & Nickerson, 2001; The 
International SNP Map Working Group, 2001]. Hence some regions are relatively 
devoid of polymorphism and others, such as the HLA class I and MHC II regions, are 
polymorphic hotspots [Guillaudeux et al., 1998; Horton et al., 1998]. 
The n1ajority of polymorphisms are found within non-coding regions [Cooper et al., 
1985; Nickerson et al., 1998] and generally do not affect protein function. However, 
changes close to intron-exon boundaries may affect splicing of mRNA, resulting in the 
deletion of one or more exons, or the creation of cryptic splice sites that result in 
inco1nplete or inactive alternative transcripts [Krawczak et al., 1992]. Some promoter 
region polymorphisms may affect protein function indirectly through altering the rate of 
transcription, altering the function of regulatory sequences that control gene expression 
or the stability or processing of the mRNA transcript of the gene. 
Polymorphisms that influence protein function are more likely to occur in the coding 
sequence of a gene, and each gene is estimated to have four to six of these coding 
region polyn1orphisms [Collins et al., 1998; Cargill et al., 1999]. Approximately 40%-
50% of the SNPs found in coding regions (cSNPs) are non-synonymous - missense 
mutations that change amino acid residues [Cargill et al., 1999; Halushka et al., 1999]. 
Approxi1nately 60% non-synonymous cSNPs have a minor allele frequency below 5% 
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and are more likely to be restricted to specific ethnic groups [Cargill et al., 1999]. It is 
believed that the low proportion of these cSNPs possibly reflects selection against 
deleterious alleles during evolution [Cargill et al., 1999; Halushka et al., 1999]. Only 
an estimated 33%-36% of these non-synonymous polymorphisms are non-conservative 
[Li & Sadler, 1991; Cargill et al., 1999] and it is these that are most likely to either 
affect protein function or stability, depending on the location within the protein, or in 
the case of premature stop codons, shorten the protein. Recent studies have found that 
SNPs in residues involved in maintaining protein stability are significantly more 
predominant than those directly involved in binding and catalysis, and are more likely 
to be associated with disease and other deleterious effects through overpacking, loss of 
H-bonds, backbone strain and buried charge residues [Wang & Moult, 2001; Ramensky 
et al., 2002]. The effects polymorphisms have on a protein can therefore range from 
subtle effects that are only observed under certain circumstances, to changes that have a 
significant phenotypic effect. 
1.2.3 POLYMORPHISM DETECTION METHODS 
1.2.3.1 LABORATORY-BASED TECHNIQUES 
In 1979 the first SNP in a human gene underlying a genetic disorder was reported, a 
nonsense mutation in the ~-globin gene responsible for causing ~-thalassemia [Chang & 
Kan, 1979]. This pro1npted further research into the genetic basis of disease, and a 
number of phenotype directed techniques were developed to discover SNPs that 
contributed to the aetiology of these diseases. These methods are effective for 
identifying highly penetrant single alleles responsible for rare, single locus diseases 
such as cystic fibrosis [Kerem· et al., 1989; Rommens et al., 1989] and Huntington's 
Disease [Gusella et al., 1983; The Huntington's Disease Collaborative Research Group, 
1993]. All of these procedures are based on the amplification of the target DNA 
sequence followed by detection of sequence variations using electrophoresis based 
1nethods that compare either alterations in sequence conformation such as the Single 
Strand Conformation Polymorphisn1 (SSCP) [Orita et al., 1989], Denaturing Gradient 
Gel Electrophoresis (DGGE) [Sheffield et al., 1989] and Heteroduplex Analysis [Keen 
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et al., 1991] methods; or the ability of the product to be cut with different enzymes or 
chemicals such as the Restriction Fragment Length Polymorphism (RFLP), the 
Enzymatic Mismatch Detection Assay (EMD) [Babon et al., 1995; Youil et al., 1996] 
and Chemical Cleavage Analysis [Cotton et al., 1988] methods. These procedures are 
all time-consuming and laborious, and the possibility for upscale and automation is 
limited, but they are still con1monly used for both acade1nic and diagnostic purposes. 
Current polymorphism detection methods have been designed to enable large-scale, 
high throughput genotyping that can be automated [Landegren et al., 1998], and can be 
divided into the 1nethods that are used to distinguish alleles and methods that are used to 
analyse the data [Gut, 2001]. Some of the methods used to distinguish alleles include 
hybridisation, such as the use of molecular beacons [Tyagi et al., 1998]; enzymatic 
methods, which include the ainplification refactory mutation system (ARMS) [Newton 
et al., 1989]; TaqMan technology [Holland et al., 1991; Livak et al., 1995]; primer 
extension [Syvanen, 1999]; Flap endonuclease [Harrington & Lieber, 1994] and 
oligonucleotide ligation assays [Landegren et al., 1988]. The results can then be 
analysed using one of several formats including electrophoresis, plate readers, mass 
spectroscopy [Gut, 2001], denaturing HPLC (DHPLC) [Underhill et al., 1996] and 
arrays [Shuber et al., 1997; Wang et al., 1998]. However, although these methods can 
efficiently detect polyinorphisms, they are not able to specifically locate them and 
follow-up analysis using automated sequencing [Sanger et al., 1977] is required. 
Unfo1iunately, it has been harder to locate genes and associated variants contributing to 
the risk and aetiology of common disease such as diabetes, heart disease, autoimmune 
disease, cancer and psychiatric disorders. These difficulties arise as the risk of 
developing complex diseases is modified and influenced by interactions between a 
variable number of predisposing risk alleles, the environment and an individual's 
lifestyle [Collins et al., 1998]. By studying stretches of DNA containing SNPs 
associated with a disease trait, researchers have begun to reveal relevant genes 
associated with disease. Analysis of polymorphism in these genes helps the 
detennination of risk distribution between populations, estimating what enhances risks 
within susceptible populations and possibly predicting individual risk. Evaluation of 
the functional impact and risks caused by these polymorphisms can provide insight into 
the way a particular disease or disorder works and ultimately lead to personalised 
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pharmacogenetics - the improved management of patients brought about by designing 
genotype-based medical treatment/therapy and prevention strategies. 
1.2.3.2 IN SIL/CO METHODS 
The sequencing of the human geno1ne [ Collins & Galas, 1993; Marshall, 1997; Venter 
et al., 2001] and the advent of 1nodern genomic technology allowing genome-wide 
analysis has fuelled a renewed interest in SNP detection and the subsequent 
development of in silica methods with which to detect them. Access to a myriad of 
DNA sequence information from random sets of individuals and the ability to rapidly 
screen a multitude of candidate genes for polymorphisms using in silica methods has 
opened the way to understanding complex disease. Many parties, both academic and 
industrial, have recognised the impact SNPs may have on branches of science ranging 
from population genetics, evolutionary biology [Cavalli-Sforza, 1998], 
phannacogeno1nics [Evans & Relling, 1999], forensics, cancer, genetic disease research 
[Brookes, 1999], cloning, physical mapping [ Collins, 1999] and association genetics 
[Kruglyak, 1999]. In response, many SNP discovery projects have been initiated, all of 
which are actively seeking to discover, catalogue and map SNPs in every known gene, 
detern1ine allele frequencies in various populations using phenotype directed methods 
and determine the structural and functional impact on the protein encoded. 
1.2.4 COMPUTER-BASED SEQUENCE ANALYSIS PROGRAMS 
1.2.4.1 SEQUENCE DATABASES 
The rapid accumulation of sequence data generated by the Human Genome Project 
[Boguski et al., 1996; Marshall, 1997] and the large-scale sequencing of Expressed 
Sequence Tags (ESTs) [Adams et al., 1991; Hillier et al., 1996] has greatly facilitated 
the discovery of SNPs. The sequence data generated by these projects can be accessed 
through a series of sequence databases such as Genbank [Benson et al., 1996], the 
European Molecular Biology Laboratory (EMBL) Nucleotide Sequence Database 
Chapter 1 Literature Review 6 
[Stoesser et al., 2002] and the DNA Data Bank of Japan (DDBJ) [Tateno et al., 2002], 
all three of which swap information daily [Benson et al., 1996; Stoesser et al., 2002; 
Tateno et al., 2002]. Using these public databases to detect polymorphisms can be 
approached in one of two ways: by searching databases containing EST data, or by 
identifying sequence differences in overlapping regions between large-insert clones 
such as BA Cs (bacterial artificial chromosomes) and PA Cs (PI-derived artificial 
chromosomes) generated by the human genome project [Gu et al., 1998]. The 
Expressed Sequence Tag database ( dbEST) in particular has proved to be an extremely 
valuable tool that has accelerated the discovery and further study of large numbers of 
novel paralogous and orthologous genes and gene variants [Board et al., 1997; Board, 
1998; Fernandez-Canon & Pefialva, 1998; Wittenberger et al., 2001; Bera et al., 2002b] . 
Established in 1992 [Boguski et al., 1993], dbEST is probably the most widely utilised 
sequence database and most rapidly expanding source of new sequence data 
corresponding to both known and unknown expressed genes. Approximately 50% of 
the data is generated through a collaboration between the Washington University 
Genome Center (St Louis) and Merck Pharmaceuticals -[Benson et al., 1996; Hillier et 
al., 1996], data which is also found at the Washington University Genome Center web 
server http: //genome.wustl.edy/gsc/gschmpg.html. The remaining sequences are 
submitted by various independent laboratories. The sequence data comes in the form of 
ESTs, 300-400 bp cDNA sequences produced by high throughput automated single pass 
sequencing of cDNA clones derived from different tissue libraries at three different 
develop1nental stages: fetal, infant and adult [Hillier et al., 1996]. These are 
representative of many different individuals hence provide a means to discover 
polyinorphis1n in a diverse set of samples. Normalised libraries have been constructed 
to reduce the number of highly expressed genes to allow better representation of rare 
messages [Soares et al., 1994; Bonaldo et al., 1996]. Error rates are particularly high at 
2%-3% due to single pass sequencing and the reverse transcriptase used in this process 
[Adains et al., 1991; Gu et al., 1998]. In addition, contaminating vector sequences and 
other spurious sequences are sometimes submitted to the database, causing cDNA 
identification problems [Boguski et al., 1993]. As most genes are expressed in more 
than one tissue type, multiple sequences representing one gene can be generated from 
the different libraries. There are cu1Tently 4,341,023 human ESTs derived from 426 
tissue libraries in the db EST. As this information is not curated, a number of databases 
designed to organise and therefore enrich the information provided by ESTs have been 
Chapter 1 Literature Review 7 
developed, such as UniGene [Boguski & Schuler, 1995; Schuler et al., 1996], the 
Genexpress Index [Houlgatte et al., 1995], the Merck Gene Index [Williamson, 1999], 
the Sequence Tag Alignment and Consensus Knowledge (STACK) resource [Miller et 
al., 1999] and The Institute for Genomic Research (TIGR) Human Gene Index 
[http://www.tigr.org]. These indices have used various procedures to group EST 
sequence information, full-length mRNA and expressed sequence tagged sites ( eSTS) 
into gene clusters - sets of sequences that are likely to represent one gene. ESTs that 
cannot be clustered are considered new, uncharacterised genes [Boguski & Schuler, 
1995]. 
1.2.4.2 SEQUENCE DATABASE ANALYSIS PROGRAMS 
Sequence databases have provided the basis for the development of computer-based 
progran1s designed for SNP discovery, and in the last five years a large number of these 
programs have been released. These programs encompass those that use simple 
alignment/asse1nbly tools [ Altschul et al., 1997] and require subsequent manual filtering 
processes and visual scanning [Board et al., 1998; Gu et al., 1998; Garg et al., 1999; 
Picoult-Newberg et al., 1999], and those that use a suite of programs requiring no 
n1anual scanning [Buetow et al., 1999; Marth et al., 1999; Retief et al., 1999]. 
The si1npler methods are the clustering programs, which can be applied to vanous 
sequence databases and used to assemble and align the data within. Some examples are 
the TIGR Asse1nbler [Sutton et al., 1995], STACK_PACK [Miller et al., 1999], Phrap 
[http://www.geno1ne.Washington.edu/] and Basic Local Alignment Search Tool 
(BLAST) [Altschul et al., 1997]. Of these, the BLAST alignment tool, which accesses 
information in dbEST and performs sequence similarity searches [Altschul et al., 1997], 
has been widely and successfully used in the field of SNP detection [Board, 1998; 
Forsberg et al., 1999; Blackbun1 et al., 2000]. The disadvantage of these simple 
programs is that the information in the sequence databases is highly error prone due to 
base-calling/cDNA synthesis/cloning errors as mentioned above hence there is a 
possibility that any sequence variations identified will be sequencing errors. Successful 
use of EST database mining is dependent upon the strategies used to filter sequence 
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errors from the alignments [Picoult-Newberg et al., 1999]. Filtering processes generally 
involve excluding variants that only occur once, as random errors are not likely to occur 
in the same position, excluding variations that occur in the number of bases 1n a 
repetitive string and excluding those surrounded by poor quality sequence. 
SNP detection methods can be individually designed to meet the requirements of the 
researcher. These methods are developed around core pro grams such as Phred - a base 
calling program that also assesses base quality [Ewing and Green 1998; Ewing et al., 
1998], Phrap - a sequence alignment and contig assembly program that also provides 
quality assessment [http://www.genome.Washington.edu/], Consed - used to view and 
edit alignments and contigs and to view original traces [Gordon et al., 1998], and 
SW AT and Cross_ Match - pre-clustering steps used to search and compare sequences 
against a database [http: //www.phrap.org/]. These programs can be used either 
individually or in any required combination however, depending on the programs used, 
the resulting aligmnents may still require intensive manual analysis. Different 
combinations of these programs have been used with -success, although detection of 
false positives has been reported to be as high as 37%-48% [Picoult-Newberg et al., 
1999; Garg et al., 1999]. Another program known as PolyPhred, which scans 
alignments for heterozygosity, has also been designed for use in conjunction with 
Phred, Phrap and Consed [Nickerson et al., 1997]. This has been used successfully, but 
also requires visual scanning [Nickerson et al., 1997; Nickerson et al., 1998]. 
At the more sophisticated end of the scale, detection of SNPs in sequence databases has 
been fully automated by developing a suite of programs thus removing the need for 
manual filtering and scanning. Some examples include the FAST _PAN strategy, used 
to identify novel gene orthologues and paralogues [Retief et al., 1999], PolyBayes 
[Maiih et al., 1999] used by the SNP consortium, and the widely used SNP Finder 
program [Buetow et al., 1999]. Previously known as the SNPpipeline, the SNP Finder 
program utilises a suite of programs to detect polymorphisms in UniGene clusters. 
These include the Phrap and Phred pro grams described above, and Demiglace, which 
uses five filters to eliminate variations that are not likely to represent true 
polymorphism [Buetow et al., 1999]. Each potential polymorphism is highlighted and 
ranked between 0.01 and 1.0, reflecting the probability that a nucleotide at this position 
is heterozygous. The score is influenced by the number of sequences in the alignment, 
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the source and diversity of the EST libraries in the Uni Gene cluster. Detection of false 
positives using this method has been reported to be relatively low at 18% [Buetow et 
al., 1999]. Access to the original trace data of UniGene sequences is generally 
provided, allowing the user to further verify potentially polymorphic sequences. The 
user is also able to apply this program to independently generated trace data. The SNP 
Finder program is being successfully used by the Cancer Genome Anatomy Project-
Genetic Annotation Initiative (CGAP-GAI) to compile a database of SNPs found in 
cancer related genes and by a number of other laboratories submitting data to dbSNP. 
1.2.5 SNP DATABASES 
Access to the SNPs generated by database mining strategies is required to allow further 
analysis and characterisation by independent laboratories interested in a specific gene or 
disease [Brookes, 1999]. To meet this demand, a wide range of databases has been 
created by various SNP detection projects. These projects are divided into two factions: 
the non-profit government-supported and independent groups who believe that the data 
generated should be freely accessible to the public, and projects supported by industry 
and pharmaceutical companies, such as Celera Genomics, Incyte Pharmaceuticals, 
Orchid Biosciences, Curagen, AlphaGene, Genset, Oxford Molecular Bioinformatics, 
Pangea Systen1s Inc. and Paracel, who believe this information should be patented, in 
order to secure intellectual property, and provided at a cost [Marshall, 1997; Brookes, 
1999]. Both factions are competing to be the first to compile the most complete 
database. Despite this, the non-profit organisations have managed to make many 
databases available to the public in a relatively short time. These encompass those that 
are devoted entirely to specific loci or disease( s ), which can be found at the Human 
Genome Organisation (HUGO) [Cotton et al., 1998; now the Human Genome Variation 
Society (HGVS)], those listing all the known SNPs responsible for genetic disease such 
as the Hu1nan Gene Mutation Database [Krawczak et al., 2000], those that are interested 
in a particular group of genes and those aiming to provide a comprehensive summary of 
SNPs (for extensive list of databases see Baxevanis, 2002 and the URL 
http ://hginp.mrc.ac. uk/Genome Web/human-gen-db-mutation.html). Integration of SNP 
data with information about the gene in which it is found, any known links to disease, 
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1napping information, structural information and links to relevant literature can be found 
at Ensembl - a joint project between EMBL and the European Bioinformatics Institute 
(EBI), the National Center for Biotechnology Information (NCBI), the University of 
California at Santa Cn1z (UCSC), The SNP Consortium (TSC), Online Mendelian 
Inheritance in Man (OMIM) [Hmnosh et al., 2000], Gen.Atlas [Frezal, 1998], GDB 
(GDB™ Human Genome Database at http: //www.gdb.org/) and GeneCards™ [Rebhan 
et al., 1997]. 
The government funded projects have been aided by the Polymorphism Discovery 
Resource (PDR), which was developed through a collaborative effort between the 
National Hu1nan Geno1ne Research Institute (NHGRI), the Center for Disease Control 
(CDC) and the National Institute of Environmental Health Sciences (NIEHS) to 
promote the discovery of polymorphisms in complex disease [Collins et al., 1998]. The 
PDR provides a readily accessible, high utility cohort of cell lines and DNA samples. 
These samples have been collected from 450 diverse and unrelated U.S. individuals 
descended from one or 1nore of the major geographic regions of the world in order to 
1naxin1ise the chances of discovering common DNA sequence variants. These include 
individuals descended fro1n non-Hispanic white Europeans, non-Hispanic black 
Africans, the Ainericas and several Eastern and Southern Asian countries, with a 1: 1 
ratio of males to fen1ales [Collins et al., 1998]. This cohort has been designed on the 
basis that co1nmon polyinorphisms, which occur at high frequency, are found globally. 
It has been estimated that approximately 85% of the worldwide gene variation is 
co1mnon to all hu1nan populations, with differing allele frequencies, with the remainder 
being population specific [Barbujani et al., 1997]. Due to potential ethical problems 
mainly relating to racial discrimination, this resource was not intended for population 
specific medical or anthropological studies, so information regarding an individuals 
medical and ethnic status has not been included [Marshall, 1997; Collins et al., 1998; 
Brookes, 1999]. 
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1.2.5.1 DATABASES PROVIDING A COMPREHENSIVE CATALOGUE OF 
SNPs 
Three databases - the Single Nucleotide Polymorphism database ( dbSNP; 
http: //www.ncbi.nlm.nih.gov/SNP/) [Sherry et al., 2001], the Human Genome Bi-
Allelic Sequences database (HGBASE; http: //www.hgbase.interactiva.de/) [Brookes et 
al., 2000] and to a lesser extent the TSC (http://snp.cshl.org/) [Marshall, 1999], have 
aimed to provide a comprehensive overview of SNPs that is freely accessible to the 
public. Both the dbSNP and HGBASE were launched in 1998, dbSNP by the NCBI 
(U.S.A.) and NHGRI [Sherry et al., 1999], and HGBASE by Interactiva GmbH and the 
research team of Anthony Brookes at the Karolinska Institute [Brookes et al., 2000]. In 
November 2001, HGBASE became known as the Human Genome Variation database 
(HGVbase; http: //hgbase.cgb.ki.se/) [Fredman et al., 2002]. Although there are some 
differences in the way dbSNP and HGVbase are run, both have been designed as 
depositories for all known human cDNA and genomic DNA polymorphisms including 
SNPs, microsatellite repeats and small insertion/deletion polymorphis1ns, regardless of 
whether these affect function or not, and data is constantly exchanged between the two. 
Labs associated with the NHGRI, who use the PDR samples, are the main contributors 
to dbSNP, although submissions from other sources are included. Only data meeting 
submission information require1nents is accepted and there are no requirements for a 
111inin1u1n allele frequency [Sherry et al., 2001]. As of 6th November 2002, 4,889,801 
SNPs had been submitted to dbSNP. HGVbase contains data from literature and other 
public geno1ne databases in addition to accepting unique, high quality, fully validated 
submissions from other polymorphism discovery projects. Both known and suspected 
polymorphisms are listed with the corresponding annotations and as with dbSNP, there 
is no require1nent for minimu1n allele frequencies. On 27th March 2002, HGVbase had 
a total of 1,451,426 entries, and approximately 5 0% of these had been mapped to the 
relevant gene [Fredman et al., 2002]. Both databases provide information about the 
SNP detection method used, the sequence information surrounding the polymorphism, 
specific experimental conditions, frequency information and population details (if 
available) in order to enable further research applications. In addition, HGVbase is 
currently investigating the functional effects of some SNPs and links to all known 
references to the polyinorphisms listed are provided [Brookes et al., 2000; Fredman et 
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al., 2002], as are links to Genbank and EMBL. dbSNP however, does not contain any 
functional or phenotypic effects associated with the variations listed, but does provide 
links to several other databases for this purpose, and can be found at 
http: //ariel.ucs.unimelb.edu.au:80/~cotton/guidel.htm [Sherry et al., 2001]. The 
information in dbSNP is also integrated with other NCBI genomic data and resources 
such as LocusLink, which can also be used to access SNPs in dbSNP that have been 
mapped to a particular gene. 
TSC, a collaborative effort between the Wellcome Trust and eleven pharmaceutical and 
technological co1npanies set up in 1999 [Marshall, 1999], initially aimed to generate at 
least 300,000 SNPs and map half of these over a two-year period [Marshall, 1999]. A 
set of 24 ethnically diverse individuals were screened for SNPs by the Whitehead 
Institute, the Sanger Center and the Washington University School of Medicine, and the 
data was mapped and confirmed by the Cold Spring Harbour laboratories. As with 
dbSNP and HGVbase, information is provided about the sequence flanking the SNP, the 
major and minor alleles, trace data for each sequence and chromosomal mapping. As of 
24th October 2002 approximately 1.8 million SNPs, over one-third the estimated 
number of common SNPs, had been discovered and mapped. 
1.2.5.2 SNP DATABASES DEDICATED TO SPECIFIC GROUPS OF GENES 
Two independent initiatives have been established to detect SNPs in specific groups of 
genes. These include the Environmental Genome Project (EGP) - funded by the 
NIEHS, and the CGAP-GAI - initiated by the U.S. National Cancer Institute. In 
addition to listing all findings on their own web pages, both groups submit SNP data to 
dbSNP. 
The EGP (http://www.niehs.nih.gov/envgeno1n/) was initiated in 1998 to improve 
understanding of human genetic susceptibility to environmental exposures through the 
detection and characterisation of SNPs in genes that are likely to influence the outcome 
of these enviromnental exposures. 554 candidate genes have been selected from 
sequence information provided by the Human Genome Project and other DNA 
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sequencing projects, and collaborators at the University of Utah Genome Center 
(UUGC; http: //www.geno1ne.utah.edu) and the University of Washington Genome 
Center (UWGC; http: //www.genome.washington.edu/projects/egpsnps/) are in the 
process of resequencing these genes. Any SNPs identified are confirmed in multiple 
samples obtained from the PDR. SNP data generated by the UUGC, and recently 
UWGC, is curated in the GeneSNPs database (http://www.genome.utah.edu), which 
includes detailed maps of SNPs in expressed and regulatory regions and, if available, 
allele frequencies and genotype information. Each gene has its own "SNPcard" 
containing an annotated gene n1odel that extends 10 kilo bases both 5' and 3' of the 
expressed region. SNP location and implications are classified and exonic SNPs are 
further annotated. SNP data from other groups focussing on genes relevant to the EGP 
are also included. 
The CGAP-GAI (http://cgap.nci.nih.gov/) was instigated to identify and characterise 
genetic variation in genes important in cancer in order to further our understanding of 
common cancer and its related phenotypes, and to improve detection of diagnosis and 
treatment of cancer. 10,000 SNPs have been identified in candidate cancer genes and 
depending on the validation status, these are described as Candidate (CGAPC), 
Validated (CGAPV), or Confirmed (CGAPCo) SNPs (http://lpg.nci.nih.gov/). 
Candidate SNPs are those that have been detected by the SNP Finder program with a 
score of at least 0.99. 75% of these are expected to represent common variation. If 
these are observed experimentally in eight or fewer individuals representing a diverse 
range of ethnic origins and disease states, the SNPs are declared Validated SNPs. 
However, as only eight samples are tested, only common SNPs are detected. When 
these SNPs have been tested in a minimu1n of five CEPH (Centre d'Etudes 
Polyinorphism Humain; http: //www.cephb.fr) families for Mendelian transmission and 
placed in genetic maps, they are classified as Confirmed SNPs. 
1.2.5.3 OTHER SNP DATABASES 
A multitude of other smaller databases also exist. These include those that have 
compiled SNP infonnation from existing literature, such as 'A Database of Human 
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Genome Variation' (http: //hu1nan.stanford.edu), or from the main databases described 
above such as refseq, which provides an index to a database that has mapped SNPs from 
dbSNP and the GAI onto hu1nan mRNA sequences (http ://lpg.nci.nih.gov/) and 
Go!Poly (Gene Oriented Polymorphism Database; http: /161.139.84.5/gopoly/) [Zhang et 
al., 2001]. Others represent collaborations between researchers and companies and 
contribute their data to the main databases such as The Human SNP database 
(http://www-genome.wi.mit.edu/snp/hu1nan), which collaborates with Affymetrix and 
submits any SNPs identified to dbSNP [Wang et al., 1998]. A list of other databases 
has been compiled by Baxevanis [2002] and at the URL 
http: //hgmp.mrc.ac.uk/Geno1neWeb/human-gen-db-mutation.html. Web-based tools 
such as SNPper (http://bio.chip.org), set up by the CHIP (Children's Hospital 
Infonnatics Program) Bioinformatics Tools [Riva & Kohane, 2001], have also been 
designed to facilitate searching the main SNP databases. 
1.2.6 SUMMARY 
The first goal ofthe SNP detection projects, cataloguing every SNP in every known 
gene, is well underway, with cu1Tent estimates recording that over 1.4 million SNPs 
have been submitted into the public databases and mapped by the International SNP 
Map Working Group [The International SNP Map Working Group, 2001]. The current 
catalogue shows that our ability to find SNPs already surpasses our capacity to 
genotype them by 1000-fold, and although many approaches for genotyping have 
emerged over the last decade, these have not advanced at the same rate as the discovery 
of SNPs [Landegren et al. 1998; Brookes, 2002]. Databases have started to make 
progress with the second goal of determining allele frequencies, but none to date have 
detern1ined haplotypes for linkage studies or functionally characterised these 
po 1 yn1orphisn1s. 
The databases of con1piled SNPs contain a wealth of SNP information in various genes, 
and when used in combination with the various SNP detection programs available, it 
can be expected that many SNPs in a particular gene of interest will be isolated. 
Laboratory-based methods, discussed in § 1.2.3 .1, must then be applied to further 
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characterise the SNPs detected using these programs in different populations. The 
effects of these SNPs can then be evaluated, and in this way the link between SNPs and 
susceptibility to disease and drug response can be advanced. 
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1.3 XENOBIOTIC METABOLISING ENZYMES 
1.3.1 INTRODUCTION 
Drugs, natural or synthetic environmental toxins and dietary carcinogens are just a few 
of the exogenous xenobiotics faced by humans on a daily basis. These are capable of 
causing damage to cells and DNA through interactions with DNA and proteins and, if 
allowed to accumulate, these toxic products can result in cellular death. Just as toxic 
and also capable of contributing to cellular damage and disease are the endogenous 
reactive oxygen species (ROS). ROS are continually generated through many normal 
1netabolic and oxidative processes such as lipid peroxidation, cellular respiration and 
intracellular metabolism of foreign compounds, in addition to generation through 
exogenous sources such as UV exposure and excessive iron salts [Hayes & McLellan, 
1999]. Accumulation of ROS results in a cytotoxic state known as oxidative stress, a 
state that can cause serious cellular damage through targeting DNA, proteins and lipids. 
Accumulation of excessive ainounts of ROS are responsible for the majority of cellular 
damage and subsequent production of hydroperoxides, alkenals and catechol products, 
all of which can contribute to premature aging and disease such as cancer, arthritis and 
neurodegenerative disorders [Beckman & Ames, 1998]. 
In order to prevent damage caused by toxic insults, vanous strategies involving 
sequestering molecules, scavenging molecules and antioxidant enzymes and molecules 
have evolved [Beckman & Aines, 1998; Sheehan et al., 2001]. Three groups of 
enzyn1es in particular have evolved as a defense mechanism against drug and xenobiotic 
detoxification: the Phase I, Phase II and Phase III enzymes. The Phase I enzymes, 
consisting of superoxide dismutase, catalase, thioredoxin peroxidase and predominantly 
the microsomal cytochro1ne P450 1nonooygenases, are responsible for the initial 
oxidation of the exogenous or endogenous toxic compounds. In some instances this 
step activates the toxic compound, hence the resulting metabolites can actually be more 
reactive than the parent compound and require further detoxification. This step is 
carried out by the Phase II enzyines, such as the glutathione S-transferases (GSTs), 
glutathione peroxidases, uridine diphosphate (UDP) -glucuronyl transferases, sulfo-
transferases, epoxide hydrolase, quinone reductase and aldo-keto reductases, which 
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catalyse conjugation, reduction or peroxidation reactions [Hayes & Pulford, 1995; 
Hayes & McLellan, 1999]. Generally, Phase II enzymes catalyse the conjugation of 
activated xenobiotics to an endogenous water-soluble substrate such as glutathione 
(GSH), UDP-glucuronic acid or glycine [Sheehan et al., 2001] in order to solubilise the 
co1npound and thereby facilitate further metabolism. Subsequent excretion from the 
cell into urine or bile [Hayes & Pulford, 1995; Seidegard & Ekstrom, 1997] is achieved 
through the Phase III transporters such as the multidrug-resistance-associated protein 
family (MRP), which consists of nine genes [Cole et al., 1992; Taniguchi et al., 1996; 
Kool et al., 1997; Kool et al., 1999; Bera et al., 2001; Hopper et al., 2001; Bera et al., 
2002a]. 
1.3.1.1 THE GLUTATIDONE TRANSFERASES 
The Phase II GST enzymes are a maJor component of cellular defence against 
xenobiotics in many species [Strange et al., 2000; Sheehan et al., 2001]. The GSTs can 
be divided into two superfainilies: the cytosolic or soluble GSTs and the microsomal 
GSTs. The microsomal GSTs, known as the Membrane Associated Protein in 
Eicosanoid and Glutathione 1netabolism (MAPEG) family, consist of six genes. These 
are pri1narily involved in detoxification of leukotriene ~, an epoxide product of 
arachidonic acid metabolism [Morgenstern et al., 1982; J akobsson et al., 1999]. The 
cytosolic GST superfamily are predominantly involved in the detoxification of a diverse 
range of toxic xenobiotics and endogenous toxins [Hayes & Pulford, 1995]. Using the 
reduced tripeptide GSH, the GSTs are able to catalyse nucleophilic aromatic 
substitutions, reversible Michael additions to a,P-unsaturated ketones and epoxide ring-
opening reactions, all of which result in the formation of thioether conjugates 
[ Armstrong, 1997]; catalyse the reduction of hydroperoxides which results in the 
fonnation of oxidised glutathione (GSSG) [Hayes & McLellan, 1999]; and catalyse 
isomerisations [Burgess et al., 1989]. In general, the reactions render the electrophiles 
less reactive by converting them to more hydrophilic compounds. In some instances 
however, the toxicity of some substrates is increased. Conjugation may render the 
co1npounds more reactive as occurs with halogenated alkanes or alkenes, which are 
nephrotoxic in either the conjugated or activated form, and therefore require further 
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detoxification [ Anders et al., 1988]. In some instances, the detoxification reaction is 
reversible and the original compound is regenerated [Atsmon et al., 1990b; Ploemen et 
al., 1994]. These toxifying properties can be exploited in cancer chemotherapy to treat 
tumours that over-express GS Ts [Hayes & Pulford, 1995]. 
The re1nainder of this introduction will focus exclusively on the cytosolic GST family 
of enzymes and the MAPEG family will not be discussed further. 
1.3.2 PROPERTIES OF THE GSTs 
1.3.2.1 MEMBERS OF THE GST SUPERFAMILY 
Eight hu1nan cytosolic/soluble classes of GST have been identified: Alpha (GSTA), 
Kappa (GSTK), Mu (GSTM), O1nega (GSTO), Pi (GSTP), Sigma (GSTS), Theta 
(GSTT) and Zeta (GSTZ) [Mannervik et al., 1985; Meyer et al., 1991; Hussey & 
Hayes, 1992; Pe1nble et al., 1996; Board et al., 1997; Kanaoka et al., 1997; Board et al., 
2000], each of which may include up to five separate isoforms. Although these are 
collectively known as the cytosolic GSTs, GSTA4 and the Kappa class GST are located 
in the mitochondria [Pe1nble et al., 1996; Gardner & Gallagher, 2001]. Classification of 
the GST classes is based on the relationship between primary structures with emphasis 
on the highly conserved N-terminal region, tertiary and quaternary structural properties, 
immunological properties and kinetic properties such as substrate and inhibitor 
specificities [Maimervik et al., 1985; Sheehan et al., 2001]. Members within a class 
generally have greater than 40% amino acid similarity and tend to cluster together at 
single loci [Hayes & Pulford, 1995; Webb et al., 1996], whereas between classes 
men1bers possess less than 30% .an1ino acid similarity [Hayes & Pulford, 1995]. It has 
been proposed that the Kappa GST gene may have been the evolutionary ancestor of the 
Theta GST gene [Pemble et al., 1996; Armstrong, 1997], from which the Alpha, Mu, 
O1nega, Pi, Sign1a and Zeta GST genes derived through gene duplication events hence 
allowing organisn1s to adapt to various toxic stresses during the course of evolution 
[Pemble & Taylor, 1992; Armstrong, 1997; Sheehan et al., 2001]. 
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The Alpha, Mu and Pi GSTs were originally identified in rat liver cytosol through their 
activity with aryl halides, especially the model GST substrate 1-chloro-2,4-
dinitrobenzene (CDNB) [Clark et al., 1973] and their ability to bind to GSH affinity 
matrices [Mannervik et al., 1985]. However, these methods failed to detect all of the 
presently known GSTs, either because they are not highly active with CDNB or because 
they do not bind to GSH affinity n1atrices. For example, the Theta class GSTs were 
discovered as a result of their capacity to utilise novel substrates such as 1,2-epoxy-3-
(p-nitrophenoxy)propane (EPNP), p-nitrophenethyl bromide (pNPB) and p-nitrobenzyl 
chloride (pNBC) [Meyer et al., 1991], and the Kappa class GST was originally isolated 
fro1n the rat mitochondrial matrix [Harris et al., 1991]. Database analysis, which 
identifies genes on the basis of sequence similarity rather than substrate specificity, has 
been responsible for the discovery of new GST families including the Omega and Zeta 
class GSTs [Pemble et al., 1996; Board et al., 1997; Board et al., 2000], and new 
isoenzyines in existing fa1nilies such as the GSTA 4 gene [Board, 1998]. With the 
continual expansion of sequence databases, there is a high likelihood that other novel 
GST fan1ilies and isoenzymes will be discovered. 
Of all the GST classes, the Alpha and Mu class GSTs appear to be the most diverse, 
with at least five distinct genes found in mammals. Five alpha class genes have been 
described in humans: GSTAJ [Rozen et al., 1992], GSTA2 [Klone et al., 1992; 
Rohrdanz et al., 1992], GSTA3 [Suzuki et al., 1993], GSTA4 [Desmots et al., 1998] and 
GSTA5 [Morel et al., 2002], and are clustered within a 300 Kb region on chromosome 
6p.12.lp12-2 [Board & Webb, 1987; Morel et al., 2002]. All but GSTA5 have been 
cloned [Tu & Qian, 1986; Board & Pierce, 1987; Board & Webb, 1987; Rhoads et al., 
1987; Board, 1998; Hubatsch et al., 1998; Liu et al., 1998; Johansson & Mannervik, 
2001 a]. Although the gene sequence for GSTA5 appears to contain a complete coding 
region sequence and no obvious defects have been observed to suggest it is non-
functional, cDNA sequences have not yet been detected in the EST database implying 
either very low expression levels, or specific tissue distribution [Morel et al., 2002]. 
GSTAJ, GSTA2 and GSTA3 are all similar with >90°/o sequence identity. GSTA4 
however, shares only 25% sequence identity with these three genes [Board, 1998]. 
Seven pseudo genes are also located in this cluster, which is ordered as follows: 5' -
GSTA4-GSTAP4-GSTA3-GSTAP2-GSTAP 3-GSTA5-GSTAP 1-GSTAJ-GSTAP 5-GSTA2-
GSTAP6-GSTAP7-3' [Morel et al., 2002]. The pseudo genes can be distinguished from 
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the functional genes by any combination of the following: deletion of single nucleotides 
or complete exons, cryptic stop codons and irregular splicing signals [Klone et al., 
1992; Suzuki et al., 1993; Lorper et al., 1996]. 
The Mu class is also made up of five closely linked isoforms, all of which have been 
cloned and characterised as recombinant proteins. These are GSTMJ [DeJ ong et al., 
1988; Seidegard et al., 1988], GSTM2 [Vorachek et al., 1991], GSTM3 [Campbell et al., 
1990], GSTM4 [Comstock et al., 1993; Ross & Board, 1993; Zhong et al., 1993a] and 
GSTM5 [Takahashi et al., 1993]. All five isoforms have been mapped to a 20 Kb 
cluster on chro1noso1ne lpl3.3 [Pearson et al., 1993; Ross et al., 1993]. With the 
exception of GSTM3, which is arranged tail-to-tail with GSTM5, the Mu class genes are 
oriented head-to-tail to each other as follows: 5' - GSTM4-GSTM2-GSTMJ-GSTM5-
GSTM3 - 3' [Xu et al., 1998b; Patskovsky et al., 1999a]. There have been reports of 
GST Mu-like sequences mapping to chromosomes 3 [Islam et al., 1989], 6 [DeJong et 
al., 1991; Ross et al., 1993] and 13 [DeJong et al., 1991], however these have not been 
further characterised and there is speculation as to whether these are related Mu class 
genes or pseudogenes [DeJong et al., 1991; Ross et al., 1993]. The five isoforms are 
highly similar, especially within the N-terminal region [Rowe et al., 1997], with 
GSTMJ, GSTM2, GSTM4 and GSTM5 sharing more than 84% sequence identity with 
each other. GSTM3 is the exception, sharing less than 75% sequence identity with the 
other Mu isoforms [Ross & Board, 1993; Patskovsky et al., 1999a], due to extensions 
found at either end of the protein. It possesses four extra amino acids at the acetylated 
N-terminus and an extra three at the C-terminus [Campbell et al., 1990; Rowe et al., 
1997]. In light of these differences, it has been suggested that the Mu class GS Ts can 
be divided into two groups: the Ml-like and the M3-like sequences [Patskovsky et al., 
1999a]. GSTMJ, GSTM2, GSTM4 and GSTM5 are believed to have originated from the 
Ml-like gene through reco1nbination and gene conversion events, whilst the GSTM3-
like gene, now the GSTM3 gene, re1nained unchanged [DeJong et al., 1991; Taylor et 
al., 1991; Vorachek et al., 1991]. 
The re1naining GST classes are less diverse. Database analysis has recently revealed 
the existence of two Omega class isoforms: GSTOJ and GST02 [Board et al., 2000; 
Morel et al., 2001; Whitbread et al., In Press], both of which have been cloned and are 
currently being characterised [Morel et al., 2001; Whitbread et al., In Press]. These two 
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isoforms share 64% sequence identity, and have been mapped to chromosome 10q24.3 
[Morel et al., 2001; Whitbread et al., In Press]. A third member of the GST O1nega 
class, GST03 , has been located on chromoso1ne 3 [Whitbread et al., In Press]. 
Although this shows 91 % sequence homology to GSTOJ, the lack of introns and 
different chromosomal location imply that this is a pseudogene. GSTOJ has also 
recently been identified as a 1nonomethylarsonic acid (MMA v) reductase [Zakharyan et 
al., 2001]. 
Two hu1nan Theta class GSTs sharing 55% amino acid identity have been cloned and 
characterised: GSTTJ [Meyer et al., 1991; Pemble et al., 1994] and GSTT2 [Hussey & 
Hayes, 1992; Tan et al., 1995; Coggan et al., 1998]. GSTTJ and GSTT2 are arranged in 
a tail-to-tail orientation on chromosome 22q 11-2 and are separated by a 50 Kb stretch of 
DNA [Tan et al., 1995; Webb et al., 1996; Coggan et al., 1998]. GSTT2 is found head-
to-head with the D-dopachrome tautomerase gene (DDCT). The two are believed to be 
divided by a bidirectional promoter [Coggan et al., 1998]. In addition, a duplication of 
the region encoding the DDCT gene and a GSTT2 ps-eudogene ( GSTT2P) is found 
upstream of the GSTTJ and GSTT2 genes [Coggan et al., 1998]. 
Unlike the GST families described above, only one isoenzyme has been isolated for the 
Pi, Zeta, Kappa and Sigina class GSTs. GSTP 1 has been cloned, extensively 
characterised [Kano et al., 1987; Cowell et al., 1988; Board et al., 1989; Morrow et al., 
1989] and 1napped to chro1noso1ne l lql3 [Moscow et al., 1988; Board et al., 1989]. A 
GSTP 1 reverse transcribed pseudogene has also been reported and mapped to 
chro1nosome 12ql3-14 [Board et al., 1989; Board et al., 1992]. GSTZJ was identified 
using EST sequence alignments and phylogenetic studies [Board et al., 1997] and has 
been mapped to chromosome 14q24.3 [Blackbum et al., 1998; Femandez-Cafi6n et al., 
1999]. This gene has also been identified as a maleylacetoacetate isomerase 
[Femandez-Cafi6n & Pefialva, 1998]. A human GSTKJ cDNA was identified through 
EST database analysis [Pemble et al., 1996], using the previously identified rat Kappa 
class GST [Ha1Tis et al., 1991; Pemble et al., 1996], however no reports on the further 
characterisation of human GSTKJ are available. The human GSTSJ , a class originally 
defined through sequence alignments of S-crystallin and GST cDNAs from molluscs 
[Buetler & Eaton, 1992], was identified as a homologue of the rat prostaglandin (PG) D 
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synthase (PGDS) and has been 1napped to chromosome 4q21-22 [Kanaoka et al., 1997; 
Kanaoka et al., 2000]. 
1.3.2.2 GST STRUCTURE AND SUBSTRATE SPECIFICITIES 
The GSTs are able to detoxify a vast number of xenobiotics and each class has distinct 
preferences for different substrates. A common substrate able to be utilised by every 
class of GST has not been identified. Although there is some overlap, even members 
within a class no n1atter how similar, can have distinct substrate specificities and 
catalytic efficiencies. This is possibly due to variations in the active site residues that 
exert slight structural differences [Chow et al., 1988]. For example, of the eleven 
an1ino acids that differ between the GSTA2-2 and GSTAl-1 proteins, four are located 
in the active site. It has been proposed that an accumulation of single amino acid 
residue replacements may be an important mechanism for generating diversity within a 
class for various substrates [Chow et al., 1988]. Despite these differences, all soluble 
GSTs appear to have a generally similar structure [Sheehan et al., 2001]. 
1.3.2.2.1 GST STRUCTURE 
The first three-dimensional structure of a human GST was solved in 1992 for the Pi 
class GST [Reinemer et al., 1992]. Subsequently, representative structures for the 
hun1an Alpha, Mu, Omega, Pi, Theta and Zeta GSTs, and a rodent Sigma class GST 
have been determined [Sinning et al., 1993; Raghunathan et al., 1994; Kanaoka et al., 
1997; Rossjohn et al., 1998; Bruns et al., 1999; Board et al., 2000; Polekhina et al., 
2001]. The structure for the Kappa class GST has not been determined. All GS Ts have 
the same fundamental structure, as the changes that distinguish each class are relatively 
conservative and do not dran1atically alter the structure [Dirr et al., 1994]. Each GST 
exists as a dimer with one catalytic site per subunit, each of which consists of two 
don1ains connected by short linker regions: the N-terminal domain I and the C-terminal 
domain II [Dirr et al., 1994]. The active site appears as a cleft along the domain 
interface. Although catalytically independent, a fully functional active site requires 
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both subunits [Danielson & Mannervik, 1985]. The N-terminal domain I, loosely 
referred to as the GSH binding site or G-site [Mannervik et al., 1978], is composed of 
the first 80 or so residues arranged in four ~-sheets flanked by three a-helices and 
provides the binding site for GSH [Armstrong, 1997; Sheehan et al., 2001]. It also 
contributes some of the contacts for substrate binding. This domain contains a 
catalytically essential tyrosine, serine or cysteine residue that interacts with the thiol 
group of GSH [Sheehan et al., 2001]. The C-terminal domain II, known as the 
hydrophobic substrate-binding site or H-site [Mannervik et al., 1978], is generally 
helical in structure, although the number of helices varies between GST classes 
[Sheehan et al., 2001]. Domain II is composed of the remaining amino acid residues 
and n1akes most of the contacts for the H-site mainly along the face of the a4 helix and 
the C-terminal tail and also contributes a highly conserved aspartic acid residue from 
the a4 helix to the G-site [Armstrong, 1997; Sheehan et al., 2001]. A small number of 
residue differences in this domain are responsible for the dramatic differences in 
substrate specificity observed between the GSTs, as these are able to regulate the 
hydrophobicity and steric limitations of the H-site [Danielson et al., 1987; Wilce & 
Parker, 1994]. Despite these changes, specificity for GSH is retained [Wilce & Parker, 
1994]. 
Many features of the subunit interface, which diverges to create a V-shaped crevice, are 
conserved between the GST classes [Sinning et al., 1993; Dirr et al., 1994; Armstrong, 
1997], but the differences that do exist among subunits of different classes, and even 
within classes, make their interfaces incon1patible, as these alter the electrostatic 
interactions contributing to the stability and function of the protein. These differences 
have been proposed to influence fonnation of heterodimers, which require highly 
si1nilar subunit interfaces. Only the GSTA1/A2 and GSTM1a/M2 heterodimers have 
been observed in vivo [Laisney et al., 1984; Stockman et al., 1985; Tsuchida et al., 
1990; Hussey et al., 1991]. GSTA1 /A4 and GSTM2/Pl heterodimers have been 
observed in vitro, however their existence in vivo is not possible due to subunit interface 
inco1npatibility [Pettigrew & Colman, 2001; Gustafsson et al., 2002]. The interface of 
the Alpha, Mu, Pi and Zeta class GSTs is characterised by a key and lock feature in 
which an aromatic residue (phenylalanine for Alpha, Mu and Pi; methionine for Zeta) 
acts as a key extending from the loop between the a2-helix and ~3 sheet of domain I on 
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one subunit, and fits into the hydrophobic lock provided by helices a4 and a5 in 
do1nain II of the other subunit [ Armstrong, 1997]. This particular interaction is not seen 
in the Theta and most Sigma class GSTs, hence these have a relatively flat and more 
hydrophilic interface [Ji et al., 1995; Armstrong, 1997; Stevens et al., 1998; Stevens et 
al., 2000]. One mammalian Sigma class GST however, the haematopoietic 
prostaglandin D synthase, does have a lock and key motif and a distinct active site cleft 
[Kanaoka et al., 1997]. 
Unique structural differences exist between the different GST classes in spite of similar 
overall topologies due to substitutions, deletions and insertions in the ~-sheets and a-
helices [Dirr et al., 1994]. The most notable are the Alpha class GS Ts, which are 
distinguished by the presence of an extra helix, the a9 helix (residues 210 to 220), in 
the C-terminal domain II, which forms a flexible cap over the H-site and is able to adopt 
different conformations depending on the substrate present [Sinning et al., 1993; 
Gustafsson et al., 1999]. This creates a smaller and more strongly hydrophobic site 
compared to the Mu and Pi classes [Sinning et al., 1993J. The Mu class GSTs possess 
what has been denoted a "mu loop" IJi et al., 1992], which is located between ~2 and 
a2 and results in a deeper active site cleft than that found in the Pi class [Ji et al., 1992; 
Raghunathan et al., 1994; Wilce & Parker, 1994]. GST Omega is distinguished by a 
19-residue praline rich N-terminal extension and seven a-helices in the C-terminal 
domain II. The active site is considerably more open than observed in other GSTs and 
the H-site is relatively large and polar [Board et al., 2000]. A consensus pattern of 
residues unique to the Theta class GSTs concentrated in the a2 helix has been observed 
[Rossjohn et al., 1996] and GSTT2-2 possesses a long C-terminal extension, which 
blocks both the H-site and most of the G-site [Rossjohn et al., 1998]. Zeta has a very 
small, almost buried polar, hydrophilic active site and lacks the V-shaped interface 
[Polekhina et al., 2001]. 
The most fundamental difference between the GST classes is the catalytically essential 
residue in domain I that interacts with the sulfur atom of GSH. The Alpha, Mu, Pi and 
Sigma class GSTs all possess a catalytically essential tyrosine [Wilce & Parker, 1994; 
Kanaoka et al., 1997; Polekhina et al., 2001]. In contrast, the Omega class GST uses a 
cysteine residue [Board et al., 2000], and the Theta and Zeta classes a serine residue 
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[Board et al., 1995; Wilce et al., 1995; Polekhina et al., 2001]. In addition, there is 
evidence for the involvement of residue Arg15 in the Alpha class [Stenberg et al., 
1991a; Bjomstedt et al., 1995], His108 in GSTMl-1, S108 in GSTM4-4 [Patskovsky et 
al., 1999b], R108 in GSTM2-2, Rl 12 in GSTM3-3 [Patskovsky et al., 2000], Rl00 in 
GSTT2-2 [Caccuri et al., 2001] and possibly Argl00 in GSTPl-1 [Patskovsky et al., 
2000] in the formation and stabilisation of the thiolate anion. 
1.3.2.2.2 GST SUBSTRATE SPECIFICITIES 
1.3.2.2.2.1 Detoxification Reactions 
Each class of GST is able to catalyse reactions with specific substrates due to their 
unique hydrophobic binding sites hence is able to provide protection against the toxic 
effects of a large number of cormnonly encountered and harmful substrates with various 
functional groups. These include a,~-unsaturated aldehydes produced endogenously by 
lipid peroxidation [Esterbauer et al., 1991] or environmentally through industrial waste, 
tobacco s1noke and fuel exhaust [Beauchamp et al., 1985]; the base propenals generated 
by oxidative damage to DNA [ Alarcon & Meienhofer, 1971; Alarcon, 197 6]; or the o-
quinones, the oxidation products of catecholamines such as aminochrome, dopachrome 
and noradrenochrome [Baez et al., 1997]. 
1.3.2.2.2.1.1 GST Alpha 
The Alpha class GSTs, particularly GSTAl-1 and GSTA2-2, possess high selenium-
independent glutathione peroxidase activity (GPx-II), which allows them to reduce 
cellular peroxides such as fatty acid hydroperoxides and phospholipid hydroperoxides 
to the corresponding alcohols [Awasthi et al., 1980; Singha! et al., 1992a]. Although 
several glutathione peroxidases (GPx) have been identified in the liver and the specific 
activity of GSTAl-1 and GST A2-2 is 1nuch lower than the selenium-dependent 
glutathione peroxidases (GPx-I), the total amount of GST protein in the liver is much 
higher than the other GPx proteins, suggesting that the GSTs play a major role in the 
protection mechanis1ns against lipid peroxidation [Hayes & McLellan, 1999; Zhao et 
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al., 1999]. Cholesterol A-oxide generated by oxidation of membranes is another 
potentially important epoxide detoxified by the Alpha class GSTs through combination 
with GSH [Meyer & Ketterer, 1982; Ansari & Smith, 1990; Hayes & McLellan, 1999]. 
The Alpha class GSTs, GSTA4-4 in particular, are also capable of conjugating a-~-
unsaturated aldehydes, the extremely reactive and genotoxic breakdown products of 
peroxidation reactions [Esterbauer et al., 1991; Board, 1998; Hubatsch et al., 1998]. 
These 1nay be derived endogenously and include 4-hydroxynon-2-enal ( 4HNE) 
[Esterbauer et al., 1991] and acrolein, the activated metabolic product of the cytostatic 
drug cyclophosphainide [Alarcon & Meienhofer, 1971]. They may also be exogenously 
derived and include chemicals such as crotonaldehyde and again, acrolein, that are 
found in industrial waste pollutants, tobacco smoke, gasoline and diesel exhaust 
[Beauchamp et al., 1985]. 
1.3.2.2.2.1.2 GST Mu 
The Mu class GSTs, particularly GSTMl-1, are distinguished by their ability to 
detoxify epoxide metabolites, which are generated by the breakdown of polycyclic 
aromatic hydrocarbons (P AH) and carcinogens such as Aflatoxin B1 by Phase I 
enzymes. These include the P AH metabolites styrene 7,8-oxide, trans stilbene-oxide, 
benzo[a]pyrene 4,5-oxide, benzo[a]pyrene-7,8-diol-9,10-epoxide, benz[a]anthracene, 7-
inethyl-benz[ a] anthracene, 7, 12-dimethylbenz[ a] anthracene and 3-methylcholenthrene, 
and the aflatoxin B1 1netabolite aflatoxin B1-8,9-exo-epoxide (AFB 1) [Warholm et al., 
1983; Hayes & Pulford, 1995; Johnson et al., 1997]. These compounds are considered 
highly n1utagenic and oncogenic and if allowed to bind to DNA, thereby forming P AH-
DNA adducts, they are able to 1nodify the structure and function of the DNA [Pelkonen 
et al., 1980]. These con1pounds are found in products of combustion such as cigarette 
smoke, car exhaust fu1nes and bun1t foods, or in the case of aflatoxins, mouldy foods. 
Peroxidation is not li1nited to fatty acid and phopholipid hydroperoxides, but also 
includes peroxidation of the cyclic o-qu1nones aminochrome, dopachrome, 
noradrenochrome and adrenochrome - oxidation products of the catecholamines 
dopainine, dopa, noradrenaline and adrenaline respectively [Baez et al., 1997]. 
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GSTMl-1, and GSTM2-2 in particular, possess 100 to 1000 times the activity of all the 
GSTs with the cyclic o-qu1nones. It has been proposed that the oxidation of 
catecholamines, which can produce excessive numbers of ROS, contributes to 
Parkinson's Disease (PD). This is believed to occur via the cyclic pro-oxidant pathway 
in which o-quinones are reduced and subsequently reoxidised. Excessive numbers of 
ROS are generated by this redox cycling, leading to oxidative stress, toxicity, apoptosis 
and ultimately neurodegeneration [Baez et al., 1995]. This is usually inhibited by the 
products of a competing reaction in which o-quinones are conjugated to GSH by GSTs 
[Segura-Aguilar et al., 1997]. More recently, it has been found that GSTM2-2 can 
actually catalyse the conjugation of dopamine and dopa to GSH, thereby preventing the 
formation of their respective cyclic o-quinones and subsequent redox cycling [Dagnino-
Subiabre et al., 2000]. 
1.3.2.2.2.1.3 GST Pi 
GSTPl-1 has relatively high activity with the diuretic ethacrynic acid (EA), but its 
characte1istic feature is high activity towards the a,~-unsaturated aldehydes acrolein 
and crotonaldehyde and against the base propenals [Berhane et al., 1994]. The latter are 
products of DNA degradation formed during oxygen-linked radical reactions in the 
presence of the chemotherapeutic drug bleomycin [Gilani et al., 1981; Grollman et al., 
1985] or y-irradiation [Janicek et al., 1985]. GSTPl-1 possesses high catalytic 
efficiency with the carcinogenic dial epoxides of P AHs such as such as anti-1,2-
dihydroxy-3 ,4-oxy-1,2,3 ,4-tetrahydrochrysene ( anti-CDE) formed from the 
environmental pollutant chrysene [Hu et al., 1997a] and (±)-7~,8a-dihydroxy-9a,10a-
oxy-7,8,9,10-tetrahydrobenzo(a)pyrene (±-anti-BPDE), the carcinogenic activated 
metabolite of benzo(a)pyrene, which is abundant in cigarette smoke [Robertson et al., 
1986; Hu et al., 1997b; Sundberg et al., 1998a; Sundberg et al., 1998b]. 
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1.3.2.2.2.1.4 GST Omega 
Due to the presence of the active site cysteine, GST Omega does not catalyse the GST 
reactions typical of many GSTs, which require an active site tyrosine or serine 
[Stenberg et al., 1991b; Board et al., 1995; Board et al., 2000]. As yet, a unique 
substrate has not been identified [Board et al., 2000], although weak thiol transferase 
and dehydroascorbate reductase activity characteristic of the glutaredoxins has been 
observed [Board et al., 2000]. GSTOl-1 has recently been ascribed a role in the 
pathway involved in the biotransformation of inorganic arsenic, a carcinogenic 
contaminant in drinking water in some regions of the world [Smedley & Kinniburgh, 
2001; Zakharyan et al., 2001]. In the penultimate step of this biotransformation 
pathway, also the rate-limiting step, GSTO 1-1 catalyses the GSH-dependent reduction 
of monomethylarsonic acid (MMA v) to monomethylarsonous acid (MMAm) 
[Zakharyan & Aposhian, 1999; Zakharyan et al., 2001]. 
1.3.2.2.2.1.5 GST Theta 
The Theta class GSTs catalyses the conjugation of several important small 
dihaloalkenes. GSTTl-1 in particular is unusual in that it is able to either toxicate or 
detoxicate substrates, depending on the nature of the substrate. It detoxifies 
monohaloalkanes and ethylene oxide, but toxifies dihalomethanes such as 
dichloromethane (DCM), dihaloethanes such as dibromoethane (DBE) and other 
bifunctional alkylating agents in GSH-dependent reactions [Ketterer & Christodoulides, 
1994; Thier et al., 1996; Sherratt et al., 1997]. DCM is found in paint strippers, aerosol 
preparations and is involved in the synthesis of plastics and pharmaceutical drugs. GSH 
conjugates of the dihalomethanes are believed to be mutagenic [Wheeler et al., 2001 b ], 
as studies have shown that mice, which express five-fold more GSTTl-1 in liver and 
lungs and have a much higher catalytic ability with DCM than humans, develop liver 
and lung tumours when exposed to DCM. Although the health risk in humans is 
unknown, it is believed to be relatively low when compared to the mouse due to the 
lower expression and lower capacity of GSTTl-1 to activate DCM [Wong et al., 1982; 
Burek et al., 1984; Sherratt et al., 2002]. DBE and 1,2,3,4-diepoxybutane are used in 
fmnigants, anti-knock mixtures and in the rubber industry. These compounds are 
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converted by GSTTl-1 to mutagenic half mustards and 2-haloacetaldehydes that are 
capable of interacting with DNA to fonn miscoding adducts [Barrio et al., 1972; Ozawa 
& Guengerich, 1983; Guengerich & Persmark, 1994; Thier et al., 1996; Hayes & 
Strange, 2000; Wheeler et al., 2001a]. 
In contrast, GSTT2-2 lacks activity with the alkyl halides. Its role is largely unknown, 
however it is reactive with secondary lipid peroxidation products such as the trans,alk-
2-enals and trans,trans,alka-2,4-dienals, implying a role against lipid peroxidation and 
ROS [Tan & Board, 1996]. GSTT2-2 is also specifically active with the sulfate ester 
menapthyl sulfate, suggesting that it may be active against other sulfate esters derived 
from carcinogenic aryln1ethanols [Tan & Board, 1996]. The rat orthologue of human 
GSTT2-2 has been shown to metabolise sulfate esters derived from 5-hydroxymethyl 
chrysene and 7,12-dihydroxymethylbenz[a]anthracene [Hiratsuka et al., 1990]. This 
activity could potentially provide protection against hepatocarcinoma development 
[Okuda et al., 1986; Watabe et al., 1986; Hiratsuka et al., 1990; Tan & Board, 1996]. 
1.3.2.2.2.1. 6 GST Zeta 
GST Zeta is unique in that it is able to catalyse the metabolism of cx-halopropionic acids 
and dihaloacetic acids [Tong et al., 1998a]. In particular, GSTZl-1 is responsible for 
catalysing the metabolism of the dihaloacetic acid dichloroacetate (DCA) to glyoxalate 
[Tong et al., 1998b]. DCA is a co1nmon contaminant in drinking water [Uden & Miller, 
1983] and has been shown to be hepatocarcinogenic in rodents [Bull et al., 1990; 
DeAngelo et al., 1996] in addition to exerting reproductive and embryotoxic effects 
[Linder et al., 1995; Hunter et al., 1996; Linder et al., 1997]. However, DCA is not 
believed to be carcinogenic in humans, and is used clinically in the management of 
lactic acidosis and its use as neuroprotective agent has been proposed [Stacpoole, 1989]. 
GSTZl-1 is irreversibly inactivated by DCA and other fluorine lacking dihaloacetic 
acids in rats, 1nice and humans by a mechanism in which the xenobiotic is 
biotransfo1med into a reactive metabolite that alkylates Cys 16, located in the active site, 
and Cys205, located near the active site. However, GSTZl-1 is not inactivated by cx-
1nonohaloacids and fluorine containing dihaloacetic acids [ Anderson et al., 1999; 
We1npe et al., 1999; Tzeng et al., 2000; Lantum et al., 2002]. Inactivation of GSTZl-1 
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by DCA has been shown to cause an accumulation of maleylacetone (MA), a byproduct 
of the tyrosine metabolism pathway [Cornett et al., 1999; Tzeng et al., 2000]. 
1.3.2.2.2.1. 7 GST Kappa and GST Sigma 
To date, unique electrophilic substrates have not yet been identified for either GSTKl-1 
or GSTS 1-1. However, the rat Kappa class GST has been found to possess relatively 
weak activity with CDNB and EA [Harris et al., 1991], and human GSTSl-1 has been 
found to possess some conjugating and peroxidase activities with some typical GST 
model substrates [Jowsey et al., 2001]. 
1.3.2.2.2.2 Non-detoxification Reactions 
In addition to their role as detoxification enzymes, some ·GST isoforms play important 
roles in different biological pathways. The predominant non-detoxification role of the 
GSTs is the ability to catalyse isomerisation reactions, the most common of which are 
those that convert cis double bonds to the trans configuration. GSTPl-1 acts as a 
retinoid iso1nerase, converting 13-cis-retinoic acid ( 13-cRA) to all-trans-retinoic acid ( t-
RA) in a GSH-independent reaction, hence may have a significant role in regulating the 
biological activities of 13-cRA. Isomerisation of 13-cRA has been proposed to be an 
activation mechanism for the potent therapeutic and teratogenic effects of 13-cRA 
[Chen & Juchau, 1998]. GSTZl-1, identified as a maleylacetoacetate isomerase, is 
responsible for catalysing the GSH-dependent cis-trans isomerisation of 
1naleylacetoacetate (MAA) to the alkylating agent fumarylacetoacetate (FAA). This is 
the penultin1ate step in the tyrosine and phenylalanine catabolic pathway [Blackbum et 
al., 1998; Femandez-Cafi6n & Pefialva, 1998]. Deficiencies in this pathway have led to 
diseases including alkaptonuria, phenylketonuria and several forms of tyrosinaemia, 
such as hereditary tyrosinaen1ia type I [Lindblad et al., 1977; Femandez-Cafi6n & 
Pefialva, 1998]. Deficiency in MAA isomerase, or the Zeta class GST, is believed to be 
toxic and although this has not yet been reported, cases in which GSTZ 1-1 activity is 
very low have resulted in severe tyrosinaemic disorder [Berger et al., 1988]. 
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GSTs are also capable of catalysing positional isomerisation of double bonds. The best 
characterised is that in which endogenous ~5-3-ketosteroids such as ~ 5-androstene-3 , 
17-dione and ~ 5-pregnane-3, 20-dione are converted by GSTA3-3 to ~4-androstene-3 , 
17-dione and ~ 4-pregnane-3, 20-dione, the immediate precursors of testosterone and 
progesterone, respectively [Johansson & Mannervik, 2001a]. The biosynthesis of 
prostaglandins represents yet another type of isomerisation reaction, in which an 
endoperoxide is converted to a 0-hydroxy ketone. GSTAl-1 and GST A2-2 catalyse the 
isomerisation of Prostaglandin H2 (PGH2) to PGD2, PGE2 and PGF2a [Burgess et al., 
1989]. PGD2 is also produced through isomerisation of PGH2 by GSTS 1-1, a 
haematopoietic or GSH-dependent PGDS [Kanaoka et al., 1997], and PGE2 is also 
generated by the isomerisation of PGH2 catalysed by the Prostaglandin E synthases 
GSTM2-2 and GSTM3-3 [Beuckmann et al., 2000]. PGD2 and PGE2 are unstable 
molecules that undergo hydration to fonn the PGJ2 series and PGA2 respectively, which 
inhibit cell proliferation [Kato et al., 1986; Atsmon et al., 1990a; Kim et al., 1993]. As 
these have an a,0-unsaturated keto group, they can be inactivated by members of the 
Alpha, Mu and Pi class GS Ts through conjugation with GSH [ Atsmon et al., 1990a; 
Ats1non et al., 1990b; Parker & Ankel, 1992; Ohno & Hirata, 1993; Bogaards et al., 
1997]. The PGJ 2 series function as activating ligands for the nuclear hormone receptor 
peroxison1e proliferator-activated receptor y (PP ARy), which regulates adipocyte 
differentiation [Forman et al., 1995; Kliewer et al., 1995], hence the ability of the GSTs 
to conjugate the PGJ2 series with GSH may block signalling to PP ARy. 
The GSTs also have a more direct role in the regulation of signalling pathways. 
GSTPl-1 has been shown to regulate signalling of the stress kinase Jun N-terminal 
kinase (JNK). Existing as the GSTPl /JNK complex, monomeric GSTPl acts as an 
inl1ibitor and thus protects cells against H20 2 induced death [Adler et al., 1999]. In 
addition, GSTMl-1 has been shown to act as an inhibitor of Apoptosis Signal-
regulating kinase 1 (ASKl) activity [Cho et al., 2001]. By forming a complex with 
ASKl , GSTMl-1 regulates the downstreain activation of the stress activated protein 
kinase p38. During heat shock, the ASKl /GSTMl-1 complex dissociates, allowing 
activation of p38 [Dorion et al., 2002]. 
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One of the more unusual non-detoxification roles has been attributed to the Omega class 
GSTs. Sequence si1nilarities have been found between GSTOl-1 and the chloride 
intracellular channel 1 (CLICl) nuclear channel. Further studies have revealed that 
whilst GSTO 1-1 does not form ion channels, it inhibits ryanodine receptor activity in 
cardiac muscle (RyR2) and potentiates ryanodine receptor activity in skeletal muscle 
(RyRl). Hence it has been suggested that GSTOl-1 has a role in protecting cells from 
apoptosis induced by Ca2+ mobilisation fro1n intracellular stores [Dulhunty et al., 2001]. 
1.3.2.2.2.3 Ligand Binding 
Some GSTs are able to noncovalently bind non-substrate ligands (neutral and anionic 
lipophilic che1nicals) such as bilirubin, bile acids, hormones and penicillin. Although 
the precise function of ligand binding is not known, it has been suggested that such 
binding is important for solubilisation of water insoluble ligands to allow intracellular 
transport, sequestration of metabolic precursors for storage or sequestration of toxic 
molecules as a defense 1nechanism [Litwack et al., 1971; Kamisaka et al., 1975; 
Wolkoff et al., 1979; Hayes et al., 1980; Simons & Jagt, 1980; Homma & Listowsky, 
1985; Listowsky et al., 1988; Ishigaki et al., 1989]. The Alpha class GSTs in particular 
are able to covalently bind a number of carcinogens such as 4-aminoazobenzene and 3-
methylcholanthrene, in order to prevent these from causing DNA damage [Ketterer et 
al., 1967; Jakoby, 1978]. These non-substrate ligands appear to bind to a unique site 
distinct fron1 the active site and whilst they act as allosteric inhibitors of enzyme 
catalysis, substrate binding is not inhibited [Boyer et al., 1984; Urade et al., 1987]. 
Recent work on GSTs fro1n various species proposes that there may be three ligand 
binding sites: one located in the intersubunit cleft [McTigue et al., 1995; Ji et al., 1996; 
Barycki & Colman, 1997; Le Trong et al., 2002; Sayed et al., 2002]; one located within 
the H-site [Oakley et al., 1999]; and one known as the buffer binding site, located near 
the H-site between P2 and al [Ji et al., 1997; Prade et al., 1997; Oakley et al., 1999]. 
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1.3.2.3 HUMAN GST TISSUE DISTRIBUTION 
GST activity is widespread throughout the hu1nan body, and has been detected in all 
human tissues tested (Table 1.1). The human GSTs are subject to differential 
expression and each tissue appears to have a characteristic GST profile in which the 
different isoenzymes have a unique cellular distribution and are expressed at different 
levels. For example, the liver contains high concentrations of GSTs, where they make 
up to 5%-10% of the total cytosolic protein content, consistent with its role as a major 
site of detoxification of xenobiotics and naturally occurring toxins [Whalen & Boyer, 
1998; Hayes & Strange, 2000]. The distribution of the GS Ts expressed in the human 
liver is further restricted with expression of GSTP 1-1 limited to epithelial cells, 
GSTMl-1 to hepatocytes [Strange et al., 1989], GSTTl-1 to bile duct epithelial cells 
and the nucleus of hepatocytes [Sherratt et al., 2002] and GSTA4-4 to bile duct cells, 
vessels and periportal hepatocytes of the liver [Desmots et al., 2001]. The cellular 
distribution of GST isoenzyme expression tends to reflect the role each plays in 
protecting against xenobiotics. For example, expression of GSTA4-4 in periportal cells 
as opposed to the centilobular cells is believed to be related to the high activity of 
GST A4-4 with products of lipid peroxidation, as the periportal zone is implicated in the 
initial breakdown of fatty acids, has a higher rate of fatty acid oxidation and therefore 
generates high levels of ROS [Gebhardt, 1992; Desmots et al., 2001]. 
Whilst patterns of GST expression tend to be conserved between individuals, they are 
subject to interindividual variation, as shown by studies on GST expression in the 
pancreas and the gastrointestinal tract (GI) [Coles et al., 2000; Coles et al., 2002]. The 
total GST content in the pancreas has been found to vary by seven-fold and the GST 
Al-1, GSTA2-2, GSTM2-2, GSTM3-3 and GSTPl-1 class isoenzymes have been 
found to vary six- to 30-fold between individuals. GSTA4-4 alone has been found to 
vary 50- to 100-fold from no expression through to very high expression in the pancreas 
[Coles et al., 2000]. A high degree of interindividual variation and consistent organ-
specific GST expression profiles have also been shown in the GI tract. Expression of 
GSTAl-1 in the ston1ach was found to vary two- to 160-fold between individuals. In 
addition, GSTAl-1 expression was consistently lower in the colon and stomach, with a 
20- to 800 fold decrease in the colon compared to the small intestine and a 1.4- to 140-
Table 1.1 - Distribution of glutathione transferases in hun1an adult tissues3 • 
Tissue AIQha Mu Omega Pi Sigma Theta Zeta Unknownb 
A 1-1 A2-2 A3-3 A4-4 Ml-1 M2-2 M3-3 M4-4 M5-5 01 -1 02-2 Pl-1 S 1-1 Tl-1 T2-2 Zl-1 
Adipocytcs + + 
Adrenal G land + + + + + + + + 
Appendix + 
Brc.1in + + + + + + + + + + + + 
erebrum + + + + + + 
Bone Marrow + + 
Breast + + 
arti !age + 
o lon + + + + + + + + + + 
rythrocytes + + + Basic 
al I bl add er + + Alpha 
Heart/ Aorta + + + + + + + + + + + + 
Kidney + + + + + + + + + + + + + 
Lens + + Basic 
Liver + + + + + + + + + + + + + Alpha 
Lung + + + + + + + + + + + + + + + Alpha, Mu 
L yn1p hocytes + + 
M an1n1ary + + + 
Gland 
Macrophage + 
Ovary + + + + + + Alpha, Mu 
Pancreas + + + + + + + + + + + + + Alpha 
PBMC + 
Pituitary gland + + + + + + 
Placenta 
Platelets 
Prostrate 
Retina 
Salivary Gland 
Skeletal Muscle 
Skin 
Small Intestine 
Spleen 
Stomach 
Synovium 
Testis 
Thymus 
Trachea 
Urinary bladder 
Uterus 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ Alpha 
· + Basic 
+ Alpha 
+ Basic 
+ Alpha 
. + Alpha 
+ Alpha 
+ Alpha 
+ Neutral 
a Based on Table 2 from Johansson & Mannervik, 2001b. Other data was compiled from the following references: Warhohn et al., 1980; 
Laisney et al., 1984; Stockman et al., 1985; Suzuki et al., 1987; Hayes et-al., 1989; Beckett et al., 1990; Can1pbell et al., 1990; Hussey & 
Hayes, 1992; Comstock et al., 1993; Takahashi et al., 1993; Tan et al., 1995; Juronen et al., 1996; Board et al., 1997; Rowe et al. , 1997; 
Sherratt et al., 1997; Desn1ots et al., 1998; de Bruin et al., 1999; Femandez-Cafi6n et al., 1999; Board et al., 2000; Coles et al., 2000; Jowsey 
et al., 2001; Coles et al., 2002; Morel et al., 2002. 
b Cam1ot be assigned conclusively as these were found prior to identification of all currently known isoenzymes. 
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fold decrease in the stomach compared to the duodenum [Coles et al. , 2002]. Such 
interindividual differences can be linked to age, gender and physiopathological and 
genetic factors [Desn1ots et al., 2001]. Induction of enzyme expression can also 
contribute to the observed differences between individuals, for example GSTP 1-1 is 
induced by insulin but suppressed by retinoic acid [Xia et al., 1993], whilst the Alpha 
class GSTs are induced by chemoprotective agents, such as the dithiolethione oltipraz 
[Morel et al., 1993], and isothiocyanates found in brussel sprouts [Bogaards et al., 
1994]. Despite the highly variable nature of GST expression between humans, the 
ability to detoxify xenobiotics is maintained although individuals with lower expression 
levels of a particular GST will become more susceptible to the effects of the particular 
xenobiotic the poorly expressed GST 1netabolises. Hence the differential expression of 
GSTs has been suggested to influence individual and organ specific variation in 
susceptibility to xenobiotic induced disease [Hayes & Pulford, 1995; Hayes & Strange, 
2000]. 
GST expression profiles and cellular distributions within a tissue vary during human 
development, with fetal tissues having a completely different GST profile when 
compared to their adult counterparts (Table 1.2) [Strange et al., 1984; Strange et al., 
"Developmental changes of GST expression profiles can greatly vary between the 
different GST classes, with changes in some GST classes restricted to a single tissue, 
whilst changes in other GST classes occurring in multiple tissues [Strange et al., 1985]." 
expression of the Alpha class GSTs increases during gestation, expression of the Mu 
class increases from 30 weeks gestation and that of the Pi class decreases in the liver 
from 30 weeks gestation [Strange et al., 1985]. During gestation the liver is a major site 
of haematopoiesis, therefore the observed changes in GST profiles may simply 
represent a change in cellular con1position rather than gene expression [Hiley et al., 
1988]. GSTPl-1 is the most highly expressed and ubiquitous GST in both fetal and 
adult tissues [Laisney et al., 1984; Cassar et al., 1990; Di Ilio et al., 1990]. Yet 
although it is the major GST in human fetal liver where it is expressed in the 
hepatocytes and bile duct epitheliu1n, it is either absent or detectable at very low levels 
in the epitheliu1n of adult liver [Awasthi et al., 1980; Warholm et al., 1981; Guthenberg 
et al., 1986; Pacifici et al., 1986; Faulder et al., 1987; Hiley et al., 1988; Strange et al., 
1989]. Expression of GSTS 1-1, which is believed to play a role in haematopoiesis and 
immune function, also decreases from relatively high levels in fetal liver to almost 
Table 1.2 - Distribution of the glutathione transferases in human fetal tissues3 • 
Tissue Alpha Mu Pi Sigma Zeta 
Al-I A2-2 Unknown Ml-I Unknown Pl-I S 1-1 Zl-1 
Alphab Mub 
Adrenal Gland + + + + 
Bladder + + + 
Bone Marrow + 
Brain + + 
Brainstem + + + 
Kidney + + + + + + 
Liver + + + + + + + 
Lung + + + + + 
Heart + + + 
Oesophagus + + + 
Skeletal muscle + 
Small Intestine + + + 
Spleen + + + 
Stomach + + + 
Testis + 
a Based on Table 1 in Raijmakers et al., 2002 and Table 3 in Johansson & Mannervik, 
2001b. Other data was compiled from the following references: Warholm et al., 1981; 
Guthenberg et al., 1986; Faulder et al., 1987; Strange et al., 1989; Beckett et al., 1990; 
Cassar et al., 1990; Board et al., 1997; Jowsey et al., 2001. 
b Cam1ot be assigned conclusively as these were found prior to identification of all 
currently known isoenzymes. 
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nothing in adult liver [Kanaoka et al., 2000; Jowsey et al., 2001]. In contrast, 
expression of GSTMl-1, which along with the Alpha class GSTs is the major GST 
found in adult liver [Rowe et al., 1997], increases significantly after birth from 
relatively low levels [Warholm et al., 1981; Strange et al., 1989]. Expression of 
GSTAl-1 and GSTA2-2 does not change during gestation in fetal liver, but increases 
during the perinatal period. It has been suggested that an increase in expression of these 
enzymes during this period may enable the fetus to survive the transition into the 
aerobic post-natal environment [Strange et al., 1989]. These developmental differences 
in GST expression in1ply that fetal tissues are sensitive to a different range of 
xenobiotics and therefore have very different detoxification requirements. 
Gender related differences in GST expression levels have also have been observed in 
some human tissues but not in others. For exainple, significantly higher concentrations 
of total GST Alpha have been observed in female livers [Mulder et al., 1999] and GST 
Alpha activity in the skin is 1.6-fold higher in females [Singhal et al., 1993], yet in the 
colon, activity is two-fold higher in males [Singhal et al. ,-1992b]. Also, higher plasma 
levels of GSTAl-1 have been observed in males, but the level in females was found to 
increase with age [Tiainen & Karhi, 1994; Mulder et al., 1997]. In contrast, a Mu 
isoform of pl 6.2 has only been found in the female colon [Singhal et al., 1992b]. 
Plasma samples of blood donors were also found to contain 1.5-fold higher levels of 
GSTPl-1 in males [Mulder et al., 1997]. It has been suggested that some gender 
specific differences in GST expression may in fact be linked with gender specific 
differences in so1ne cancers [Silverberg & Lubera, 1987]. 
1.3.2.4 GST OVER-EXPRESSION AND DRUG RESISTANCE 
The GSTs have been i1nplicated 1n resistance of cells and organisms to drugs, 
pesticides, herbicides and antibiotics [Mannervik & Danielson, 1988; Piccolomini et al., 
1989; Fournier et al., 1992; Dainelli et al., 2002]. Human GSTs in particular have been 
implicated in the growing resistance and subsequent failure of some tumour cells to 
respond to chemotherapeutic drugs, which ultimately results in patient relapse. There is 
now substantial evidence that tumour cells often have an altered GST expression profile 
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compared to their normal counterparts and that over-expression of both GSH and GS Ts 
is an important factor in the development of acquired anti-cancer drug resistance in 
preneoplastic lesions [Kitahara et al., 1984] and tumour cells [Tew, 1994]. GSTPl-1 is 
the predominant GST found overexpressed in the majority of human tumours [Shea et 
al., 1988; Sato, 1989; Castro et al., 1990] and frequently displays an increase in the 
concentration (up to 3% of the total protein content) seen in normal tissue [Shea et al., 
1988; Lewis et al., 1989; Kelley et al., 1994] and is therefore used as a putative tumour 
marker. Over-expression of GSTP 1-1 in a multidrug resistant human breast cancer cell 
line has been associated with a 45-fold increase in activity of GSTPl-1 [Batist et al., 
1986] and also increases the ability of cells to withstand insult by cytotoxic drugs 
[Nakagawa et al., 1990]. However, due to the large interindividual variation of GST 
expression observed between tissues, the drug resistance phenotypes of tumour cells is 
dependent upon and differs according to the GST expression profile in the tissue of 
interest [Castro et al., 1990; Tew, 1994]. Over-expression of the Alpha class GSTs is 
implicated in the development of tumour cell resistance to alkylating anti-neoplastic 
drugs, in particular the nitrogen mustard drugs such as chlorambucil and 
cyclophosphamide [Ciaccio et al., 1991; Meyer et al., 1992; Dirven et al., 1994; Tew, 
1994]. Usually, the Alpha class GSTs have a protective role in detoxifying these drugs. 
The Mu and Theta class GSTs have been implicated in resistance to the nitrosoureas. 
These GSTs, especially GSTTl-1 [Lien et al., 2002] have a high activity with 1,3-bis(2-
chloroethyl)-1 nitrosourea (BCNU). Over-expression of GSTM3-3 in human lung cells 
has been shown to catalyse the inactivation of this chemotherapeutic agent [Berhane et 
al., 1993] and it is possible that the same may be true for GSTTl-1 and GSTM2-2 [Lien 
et al., 2002]. As alkylating cancer drugs are also GST substrates, it is possible that the 
different side effects experienced by cancer patients is caused by variations in 
individual GST expression patterns [Johansson & Mannervik, 2001b]. By determining 
the GST isoenzyme profile of tumours, an appropriate treatment may be selected 
depending on the levels of expression and activity within the tumour [Kelley et al., 
1994]. GSTs are therefore a therapeutic target for rational drug design [Coles & 
Ketterer, 1990]. 
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1.3.2.5 POLYMORPIDSMS IN THE GSTS 
There is great interest in whether the failure to express GSTs, or differences in GST 
expression, influences susceptibility to disease due to their ability to metabolise a 
diverse range of exogenous and endogenously produced xenobiotics. It is widely 
accepted that exposure to exogenous environmental chen1icals in the form of 
carcinogenic P AHs and aro1natic amines in tobacco smoke, automotive exhaust, 
industrial by-products and cooked meats, fish and baked or fired grain derived dishes 
[Felton et al., 1994; Vineis, 1994] is associated with increased risk of cancer [Doll & 
Peto, 1981]. In addition, the accu1nulation of ROS in a wide range of tissues 
contributes to aging and many diseases associated with oxidative stress [Beckman & 
Aines, 1998]. The effects of genotoxic carcinogens can often be evaluated through 
measuring changes in the incidence of sister chromatid exchange, in the structure or 
number of chromosomes, micronuclei formation and altered enzyme activity [Norppa, 
1997; Strange et al., 2000]. Absent or dysfunctional members of the GST classes are 
therefore likely to alter individual tolerance to different xenobiotics and are candidates 
for increased disease susceptibility and altered drug responses. 
The existence of polyinorphism in the GSTs was first discovered when high GST Mu 
expression was observed in some, but not all, human livers. Electrophoretic analysis 
and activity assays identified this as the GSTMJ null (GSTMJ *O) allele [Warholm et al., 
1980; Board, 1981a; Strange et al., 1984]. Subsequent polymorphisms have been 
identified through electrophoretic methods [Board, 1981a; Laisney et al., 1984; Strange 
et al., 1984], analysis of metabolic differences [Peter et al., 1989; Bogaards et al., 1993; 
Hallier et al., 1993; Hallier et al., 1994; McLellan et al., 1997], differences in protein 
expression levels [Inskip et al, 1995; Wang et al., 2000; Coles et al., 2001a] and disease 
association studies [Latsoudis et al., 2000]. Other polymorphisms have been discovered 
as sequence discrepancies between published sequences [Board et al., 1989; Ali-Osman 
et al., 1997; Coggan et al., 1998; Johansson & Mannervik, 2001a]. More recently, 
analysis of the EST database has proved an effective tool for the discovery of 
polymorphism in the GSTs [Blackbum et al., 2000; Blackbum et al., 2001]. Coding 
region polymorphic variants in members of the Alpha, Mu, Pi, Theta and Zeta classes 
have been discovered and are listed in Table 1.3. Coding region polymorphisms in the 
Class Gene 
Alpha GSTA? 
GSTAJ 
GSTA2 
GSTA3 
GSTA4 
Mu GSTMJ 
GSTM3 
GSTJv/4 
Table 1.3 - Known poly111orphisms that affect the coding regions of the hu1nan GST genes. 
Nucleotide 
Altered a 
Gene deletion 
c.365G>A 
c.328C>T 
c.335G>C 
c.629A>C 
HgiAI site created 
c.1-87del 
c.88-87del 
c.21 lC>A 
SNP in exon 1 
c.487A>G 
Gene deletion 
c.519G>C 
Gene duplication c 
c.439T>G 
c.670G>A 
c.178-259del 
c.534T>C 
c.634G>A 
Ex8delinsVSCGIMX 
Consequenceb 
Protein Deleted 
p.K125K 
p.Pl l0S 
p.Sl 12T 
p.E210A 
Unknown 
Exons 1 and 2 deleted 
Exon 3 deleted 
p.L73I 
Unknown 
p.Tl63A 
Protein deleted 
p.K173N 
Protein duplicated 
p.G147W 
p.V224I 
Exon 4 deleted 
p.Fl 78F 
p.V212V 
Exon 8 deleted and 
replaced by 6 codons 
References 
Strange et al., 1984 
(Tetlow et al., 2000); Bredschneider et al., 2002 
Wang et al., 2000 
Hayes et al., 1989 
Rohrdanz et al., 1992 
Chen & Board, 1987 
Johansson & Mam1ervik, 2001 a 
Board, 1998; Johansson & Maimervik, 2001a 
Johansson & Ma1u1ervik, 2001 a 
Latsoudis et al., 2000 
Iida et al., 2001 
Board, 1981a; Strange et al., 1984; Seidegard et al., 1988 
Board, 1981a; Widersten et al., 1991; Seidegard et al., 1988 
McLellan et al., 1997 
Pearson et al., 1993; Ross & Board, 1993 
E1nahazion et al., 1999; Iida et al., 2001 
Ross & Board, 1993 
Con1stock et al., 1993; Pearson et al., 1993; Ross & Board, 1993; Zhong et al., 1993a 
Co1nstock et al., 1993; Ross & Board, 1993; Zhong et al., 1993a 
Ross & Board, 1993 
GSTM5 1-findlll site created 
Pi STPJ c.313A>G 
c.341C>T 
Theta GSTTJ Gene deletion 
c.310A>C 
GSTT2 c.417G>A 
Zeta GSTZJ N.D. 
c.94A>G 
c.124A>G 
c.245C>T 
Unknown 
p.I105V 
p.Al14V 
Protein de] eted 
p.T104P 
p.M139I 
p.I(32K 
p.K32E 
p.R42G 
p.T82M 
De Jong et al., 1991; Pearson et al., 1993 
Ali-Osman et al., 1997; Board et al., 1989 
Ali-Os1nan et al., 1997; Board et al., 1989 
Pemble et al., 1994 
Alexandrie et al., 2002 
Coggan et al., 1998 
Fen1andez-Cafi6n et al., 1999 
Board et al., 1997; Fernandez-Canon et al., 1999; Blackbun1 et al., 2000 
Board et al., 1997; Fernandez-Canon et al., 1999; Blackbun1 et al., 2000 
Fen1andez-Cafi6n et al., 1999; Blackbun1 et al., 2001 
a The nun1bering of nucleotides changed in the variant alleles is based on their position in the cDNA from the A in the initiation codon. 
b The nu1nbering of an1ino acids includes the initiator 1nethionine 
c The duplicated gene possesses an additional copy of either the GSTMJ *A or GSTMJ *B genes, or both. When the duplicated allele is defined, the 
tenns GSTMJ * IA and GSTMJ * JB should be used. 
N.D.: Not Described. 
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Kappa, Omega and Sigma class GSTs have not yet been reported. Some of the 
polymorphisms detected to date have been associated with altering susceptibility to 
carcinogens and toxins, hence influencing the efficacy and toxicity of drug treatment 
and development of disease [Hayes & Strange, 2000]. However, this will be discussed 
in more detail in the relevant results chapters. 
1.3.2.5.1 PHENOTYPE-GENOTYPE RELATIONSHIPS 
Many studies have attempted to link various GST variants with disease susceptibility 
and outcome, and have provided evidence that allelism in these genes does in fact 
mediate disease phenotype [Strange et al., 2001]. A number of groups have focussed 
on the effects of a single gene variant in small sample groups such as the GSTMJ *O 
allele and have reported conflicting evidence of its association with lung and bladder 
cancers. However, whilst the results generated are statistically significant, the odds 
ratios are generally low ( <2) and therefore provide weak evidence of 
genotype/phenotype associations [Rebbeck, 1997; Roulston, 1999; Hayes & Strange, 
2000; Johns & Roulston, 2000; Benhamou et al., 2002; Engel et al., 2002]. In addition 
to investigating the single effects of GST polymorphisms, many studies have also 
extensively investigated the compound effects of multiple GST polymorphisms, 
particularly the GSTMJ and GSTTJ null alleles, and found that the level of association 
to disease susceptibility was dep~ndent on interactions with other epistatic alleles or 
environmental factors [Brockmoller et al., 1994; Hietanen et al., 1997; Norppa, 1997; 
Rebbeck et al., 1997; Hirvonen, 1999]. However, most studies ·h~ve been unable to 
. . · 
demonstrate a significantly stronger association to disease susceptibility caused by these 
interactive genetic effects above those caused by a single variation [Strange et al., 
2000]. 
Allelic variants in the GST genes, either singly or in combination with other genes, have 
been shown to have a greater impact on disease outcome in phenotypically homogenous 
subgroups of patients [Hayes & Strange, 2000; Strange et al., 2001]. For example, 
cutaneous basal cell carcinoma patients cover a wide phenotypic spectrum but when 
patients were divided into subgroups dependent on further phenotypic classification, it 
was found that the frequency of the GSTTJ null (GSTTJ*O) allele and the CYP2D6 EM 
j 
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polymorphism increased in patients displaying multiple cluster multiple presentation 
phenotype (MPP) as opposed to single cluster MPP and the odds ratios were 
correspondingly high (7 .4 and 15 .5 respectively), i1nplying that these genes exert 
independent effects on susceptibility [Ramachandran et al., 1999; Ramachandran et al., 
2001; Strange et al., 2001]. 
Although many studies have investigated links between polymorphism in the xenobiotic 
metabolising enzyines with disease, the investigations have generally concentrated on 
one ethnic group rather than comparing the same association in several groups. 
However, wide ranging variations in allele frequency distribution among ethnic groups 
has also been observed, for instance the GSTMJ *O allele is found at 50% in the 
Caucasian population [Board, 1981a; Strange et al., 1984; Seidegard et al., 1988], but 
ranges from approximately 21 %-30 °/o in Chilean [Quinones et al., 1999] and some 
African groups [Zhao et al., 1994; Mukanganyama et al., 1997; Masimirembwa et al., 
1998; Johansson & Mannervik, 2001b] and 100% in the Micronesian population [Board 
et al., 1990]. In many instances the associations between a particular genetic risk factor 
and cancer appears to be dependent on race or ethnicity. This effect has been 
extensively studied in the Phase I enzyme CYPlAl, which has five polymorphisms, one 
of which, CYP JAJ *4, is specific to African individuals [Crofts et al., 1993]. This 
African-American specific polymorphism has been associated with increased risk of 
lung and breast cancer [Taioli et al., 1995a; Taioli et al., 1995b]. Another CYPlAl 
polyinorphis1n, CYP JAJ *2, has also only been associated with lung cancer in Japanese 
patients [Kawajiri et al., 1990], but has not been found by other studies in the Finnish 
[Hirvonen et al., 1992] and Norweigan populations [Tefre et al., 1991]. Such inter-
racial differences may possibly be due to differences in linkage disequilibrium patterns, 
gene regulation and function, and possibly the fact that different alleles may have 
diverse effects within different populations [Garte, 1998]. Thus within the human 
population, allele frequencies are generally influenced by ethnicity, race and geography 
[Garte, 1998]. 
Chapter 1 Literature Review 40 
1.3.3 DETECTION OF SNPs IN THE GSTs 
The GST superfamily provides a highly efficient line of defence against the toxic insults 
to which we are daily exposed. Polymorphisms within these proteins can greatly alter 
the efficiency of this defence therefore detection of novel SNPs in the GST genes is 
likely to help elucidate the mechanisms responsible for the observed variation in drug 
response and altered susceptibility to a nu1nber of diseases. This can now be easily 
achieved by utilising the new advances in SNP detection. Although a number of 
polymorphisms have previously been reported in human GST genes, they have 
generally been identified by chance. This study was aimed at applying a bioinformatic 
approach to identify the extent of genetic polymorphism in the human GST gene family. 
A large number of polymorphisms in the GST genes were detected in the current study, 
allele frequencies were determined in four ethnic populations and the functional effects 
of these polymorphisms were characterised. 
CHAPTER2 
MATERIALS. & METHODS 
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2.1 COMMONLY USED MATERIALS 
This chapter describes the materials and methods routinely used during this research. 
Specific procedures and resources will be described in the relevant chapters. 
Commonly used chemicals compounds are listed in Appendix Al, and are of analytical 
grade. Enzyines are listed in Appendix A2; buffers, solutions and culture media are 
listed in Appendix A3. 
2.2 LABORATORY PROCEDURES 
Solutions requ1nng sterilisation were either autoclaved at 121 °C/l00 kPa for 15 
1ninutes, or filter sterilised through 0.2 µM membranes. Disposable plastic labware was 
autoclaved before use and glassware was baked overnight at 180°C. Distilled deionised 
water ( ddH2O) was used for all solutions. All experiment_s were carried out under PC2 
laboratory conditions as stipulated by the Genetic Manipulation Committee. 
Radioactive substances were handled in accordance with the Australian National 
University Radiation Safety Handbook. 
2.3 DATABASE ANALYSIS 
2.3.1 SEQUENCE DATABASE ANALYSIS PROGRAMS 
Potential polyinorphisms were identified in the human EST database using the default 
settings of the advanced BLAST aligmnent tool [Altschul et al., 1997], which can be 
accessed through the NCBI web site http: //www.ncbi.nlm.nih.gov/. Aligned EST 
sequences were exan1ined for nucleotide variations using the "flat query-anchored with 
identities" fonnat. Potential polyinorphisms identified using this method were verified 
by ordering and sequencing I.M.A.G.E. (Integrated Molecular Analysis of Genomes and 
their Expression) Consortium (LLNL; Lawrence Livermore National Library) cDNA 
Clones [Lennon et al., 1996] (§2.5.5.1) through Genome Systems, Inc./Incyte Genomics 
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(Palo Alto, USA). The SNP Finder program, available at http: //lpg.nci.nih.gov/GAI/, 
was also used to identify potential variants in the GSTs using UniGene clusters that 
represented the gene of interest [Buetow et al., 1999]. This pro grain provides access to 
electropherograms hence potential polymorphisms could be verified through 
examination of existing trace data. 
2.3.2 SNP DATABASES 
Various SNP databases containing compilations of polymorphisms collated by SNP 
discovery programs were also searched for GST polymorphism entries by entering the 
gene name of interest. These included dbSNP, which was accessed through the 
LocusLink site at the URL http: //www.ncbi.nlm.nih.gov/LocusLink/; the CGAP-GAI 
candidate (CGAPC), validated (CGAPV) and confirmed (CGAPCo) SNP lists, 
available at http: //lpg.nci.nih.gov/; HGBASE (now HGVbase ), which was accessed at 
http ://hgvbase.cgb.ki.se/; ref seq, available at http ://lpgws.nci.nih.gov: 82/perl/snp2ref; 
the UUGC GeneSNPs database, at the URL http ://www.genome.utah.edu/genesnps/; 
and the UWGC EGPSNPs database, which 1s available at the URL 
http: //www.genome.washington.edu/projects/egpsnps/. The SNPper program, at 
http: //bio.chip.org/biotools, was also utilised to detect potential polymorphisms. 
Polymorphisms identified through the CGAP-GAI lists could be confirmed with 
existing trace data, those identified in the remaining lists were confirmed by small-scale 
population analysis (§2.5 .6.2). 
2.4 BACTERIAL STRAINS AND PLASMIDS 
Escherichia coli strains DH5a, M15(pRep4), TGl and XLl Blue (Table 2.1) were used 
to host recombinant proteins in the vectors pRB269, pKK261, pKK263 and pQE30 
(Qiagen). These were grown on LB plates and cultured in LB media overnight at 37°C. 
Media was supple1nented with 100 µg/mL ainpicillin, 34 µg/mL chloramphenicol or 20 
µg/mL kanamycin as required to select for cells containing plasmids. Important clones 
were stored at -70°C in 50% (v/v) glycerol. Individual colonies were isolated by 
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dilution streaking from bacterial stabs or glycerol stocks onto LB-agar plates 
supplemented with the appropriate antibiotic and an overnight incubation at 37°C. 
Table 2.1 - Strains of E. coli used for recombinant protein expression. 
Strain 
DH5a 
Genotype 
~80dlacZLiMl5, recAl, endAl, gyrA96, thi-l, hsdRl 7(rK-, mK+), 
supE44, relAl, deoR, Li(lacZYA-argF)Ul69 
Ml5(pRep4) NaI5, Str5, rif5, lac-, ara-, gar, mtr, F-, recA+, uvr+ 
TGl 
XLl Blue 
F', traD36, laclqZLiMl 5, proAB+/supE, Li(hsdM-mcrB)S, (rK-, 
mcrB-), thi, Li (lac-proAB) 
+ 
mK ' 
recAl, endAl, gyrA96, thi, hsdRl 7(rK-, mK+), supE44, relAl, lac, [F', 
proAB+, laclqZLiMl 5, :Tnl 0(Te{)] 
The ubiquitin fusion vector pRB269 was used to express the GSTA2-2 recombinant 
proteins [Baker et al., 1994], which were constructed from the GSTA2D variant created 
by Dr Dan Liu. The GSTM3-3 recon1binant proteins were expressed in pKK261, and 
were constn1cted from the GSTM3A variant created by Dr Veronica Ross. pKK26 l is a 
modification of the pKK223-3 vector generated by removing a BamHI-SalI fragment 
from the backbone of pKK223-3. The GSTA3-3 protein was cloned into pKK263, 
which is a modified version of pKK26 l. The GSTO 1-1 recombinant proteins were 
expressed in pQE30 (Qiagen), and were constructed from the GSTOl * A allelic isoform 
created by Professor Philip Board. 
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2.5 DNA MANIPULATIONS 
2.5.1 DNA PREPARATION 
2.5.1.1 PREPARATION OF LAMBDA DNA 
cDNA fro1n previously prepared la1nbda phage lysate originating from an LE392:Agtl 1 
human testis cDNA library (Clontech, Palo Alto, CA, USA) was extracted using the 
Wizard™ Lambda Preps DNA Purification System in accordance with the 
1nanufacturer' s protocols. 
2.5.1.2 PREPARATION OF PLASMID DNA 
Small-scale preparations of plasmid DNA was isolated from a 5 mL overnight culture of 
E. coli cells using the Promega Wizard Miniprep DNA Purification Kit, the Gene Works 
Bresaspin™ Plas1nid Minikit or the UltraClean™ Mini Plasmid Prep Kit (MoBio 
Laboratories Inc, USA). These kits were used in accordance with the manufacturer's 
protocols, although one addition was made when preparing DNA from plasmids 
propagated in TGl cells - 5 µL of alkaline protease solution (275 µg/µL) was added 
between the lysis and the neutralisation steps. Alkaline phosphatase non-specifically 
degrades proteins and is known to inactivate the endonuclease A present in TG 1 cells. 
After a five minute incubation at ambient temperature, the extraction process continued 
according to the manufacturer's protocols. 
2.5.2 ELECTROPHORESIS 
2.5.2.1 AGAROSE GEL ELECTROPHORESIS 
Polymerase Chain Reaction (PCR) products and plasmid DNA were routinely separated 
on O. 8 %-1. 5 % agarose gels in 1 Ox T AE running buff er at a constant vo 1 tage of 7 0 V ( or 
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10 V/cm of the distance between the electrodes). 1 Kb, 1 Kb plus (lµg/µL) and 
pUC19/HpaII (500 ng/µL) were used as DNA size markers. Gels were stained with 
ethidium bromide (5 µg/ml was added to the running buffer) and visualised under UV 
illumination (254 nm). DNA fragn1ents excised from agarose gels were extracted using 
the Geneclean® II kit (BIO 101, USA), the Qiagen Gel Extraction Kit or the 
UltraClean™ GelSpin DNA Purification Kit (MoBio Laboratories Inc, USA). 
2.5.2.2 ACRYLAMIDE GEL ELECTROPHORESIS 
Digested PCR product fragments for RFLP analysis were separated by 6%-12% 
polyacrylamide gel electrophoresis (PAGE) against the molecular size marker 
pUC19/HpaII using a Hoefer SE600 series Vertical Slab Gel Unit (Hoefer Scientific 
Instrument, San Francisco, CA; 160 x 180 x 1.5 mm). Electrophoresis was performed 
at room temperature in lx TBE ru1ming buffer at 30 mAmp for approximately 2 hours, 
or until the bromophenol blue dye front reached the bottom of the gel. Fractionated 
DNA was photographed using polaroid film under UV illumination after staining with 
ethidium bromide. 
2.5.2.3 RECOMBINANT PROTEIN EXPRESSION GELS 
Recombinant proteins were identified by separation on 12.5% SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) on either a PRAST System Separation and Control Unit 
(Pharmacia) or an Xcell II™ Mini-Cell apparatus (Novel Experimental Technology, 
USA), against the Rainbow™ coloured protein molecular weight marker. Gels were 
stained with Coomassie Brilliant Blue. GST Alpha and Mu recombinant protein 
concentrations were dete1mined using the Peterson Assay [Peterson, 1977]. GST 
Omega reco1nbinant protein concentrations were determined using the Lowry Assay 
[Lowry et al., 1951]. 
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2.5.3 DNA QUANTITATION 
Oligonucleotide concentrations were determined by measuring the optical density (OD) 
of the DNA at an absorbance of 260 nm using a Varian Cary 1 UV-Visible 
Spectrophoto1neter. Concentrations were calculated in pmol/µL based on the 
absorbance measure1nents, given that 1 OD260 unit for single stranded DNA was equal 
to 33 µg/inL. 
Concentrations of plasmid DNA were determined by comparison to the molecular 
weight marker A DNA!HindIII (500 µg/mL), after electrophoresis through a 0.8%-1.5 % 
agarose gel in 1 x T AE running buffer. 
2.5.4 RESTRICTION ENDONUCLEASE DIGESTIONS 
2.5.4.1 SUBCLONING 
Plasmid DNA ( approxi1nately 1 µg) was routinely digested with 10-20 units of the 
appropriate restriction endonuclease following the manufacturer's protocol. Double 
digests were either perfonned simultaneously in a buffer compatible with both enzymes, 
or as subsequent reactions. Reactions were terminated by heat inactivation (65 °C for 20 
minutes unless otherwise specified), phenol/chloroform extraction and ethanol 
precipitation, or by addition of a sucrose gel-loading dye. 
2.5.4.2 RFLP ASSAYS 
Genomic PCR products were tested for the presence of polymorphisms using RFLP 
assays. PCR products (2-5 µL) were digested in a 10 µL volume with 0.5-1 units of the 
appropriate restriction enzyine using the buffers and conditions as recommended by the 
manufacturer. Double digests were performed by selecting a buffer compatible with 
both enzymes. The reaction was terminated by addition of ficoll gel-loading dye. 
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2.5.5 DNA SEQUENCING 
2.5.5.1 CYCLE SEQUENCING 
I.M.A.G.E. Consortium (LLNL) cDNA Clones and GSTA2-2, GSTM3-3, GSTOl-1 
and GSTO2-2 reco1nbinant protein constructs were sequenced from double stranded 
DNA using the Thermosequenase cycle sequencing kit (Alnersham) with [cx-33P] dATP. 
Sequence information was resolved on 6% polyacrylamide glycerol tolerant gels 
containing 8.3 M urea using an IBI Base Runner™ Nucleic Acid Sequencer at a 
constant of 35 W in 0.8x glycerol tolerant rum1ing buffer. Gels were fixed in a 10% 
acetic acid (v/v)/10% methanol (v/v) solution, before being vacuu1n dried on a Model 
583 gel dryer (Bio-Rad Laboratories, USA) at 80°C for 1 hour. Autoradiography was 
performed at roo1n temperature for at least 24 hours on Fuji Medical X-ray film (RX). 
2.5.5.2 AUTOMATED SEQUENCING 
GSTA3-3 and GSTO2-2 reco1nbinant protein constructs were sequenced from double 
stranded DNA using the ABI PRISM™ Dye Terminator Cycle Sequencing Ready 
Reaction Kit using ABI Big Dye Ten11inator v.3 (Applied Biosystems, USA) and an 
ABI 3 77 DNA Sequencer at the Bio1nolecular Resource Facility at the John Curtin 
School of Medical Research. 
2.5.6 PCR CONDITIONS 
2.5.6.1 PREPARATION OF PRIMERS 
Oligonucleotides were synthesised on an Applied Biosystems 3 80B Oligonucleotide 
Synthesiser by the Bio1nolecular Resource Facility at the John Curtin School of Medical 
Research and were quantitated as described in §2.5.3. Alternatively, primers were 
purchased fro1n Geneset Pacific PTY. Ltd (Lismore, Australia). Primers were stored at 
-20°C and diluted as required. Alu1ealing temperatures (Tm) for each primer were 
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calculated using the following equation, which is based on the nucleotide composition 
of the primer: 
Tm= {[(#dCTPs + #dGTPs) x 4°C] + [(#dATPs + #dTTPs) x 2°C]} - 5°C 
where # refers to the number of nucleotides 
2.5.6.2 AMPLIFICATION OF DNA 
Amplification of DNA by PCR was conducted using a GeneWorks DNA Engine, a 
DNA Engine Tetrad (MJ Research PTC-225) or a Corbett Research FTS-1 thermal 
cycler. 
Exons of the vanous GST genes were specifically amplified from genomic DNA 
obtained from individuals with representing the three major global populations -
Africans, Chinese and Caucasians. The four populations chosen were: the Bantu 
Africans; the Madagascan Creole Africans - predominantly descended from the Bantu 
Africans but also an admixture of Caucasian and Asian/Oceania genetic influences 
[Hewitt et al., 1996]; the Australian Europeans; and the Southern Chinese. 25 samples 
from the Australian European, Creole African and Southern Chinese ethnic groups were 
a1nplified by PCR and genotyped by RFLP assays for small-scale population screens. If 
a variant was detected in this small sample set, up to 100 individuals from each of the 
three etlu1ic groups were amplified and genotyped. 7 4 sa1nples from the Bantu African 
population were genotyped at a later stage. Statistical comparisons between the four 
ethnic groups were perfonned using Chi-squared analysis. Results were defined as 
being statistically significant if p<0.05. 
In general, a 20 µL reaction mixture contained 6 pmol of the forward and reverse 
primers specific for each exon, 25 ng te1nplate DNA, lx Taq DNA polymerase reaction 
buffer, 1.5-2 mM MgCh (25 mM), 0.2 µM dNTPs, 0.5 units of Taq DNA polymerase 
and ddH2O. A negative control sample containing all components of the reaction 
except the template was included in each PCR to ensure the absence of contamination. 
PCR conditions involved an initial denaturation step at 95 °C for 2 minutes followed by 
35-40 cycles of a 95 °C denaturation step (20 sec) , 48-63 °C annealing step (18-20 sec), 
Chapter 2 Materials and Methods 49 
and 72°C extension step (30 sec), with a final 3 minute extension at 72°C. Agarose gel 
electrophoresis was used to confirm the absence of spurious bands and contamination, 
and the presence of PCR product (5 µL). 
Nested PCR reactions were performed using the fragment amplified during the first 
reaction as the template and two new PCR primers located within the first primer pair. 
Reactions were conducted as outlined above and allowed greater yields of PCR product 
to be obtained. Specific details for amplification of GST exons can be found in the 
relevant results chapters. 
2.6 RECOMBINANT DNA METHODS 
2.6.1 LIGATION 
Vectors and inserts were prepared for ligation by digestion with the appropriate 
restriction endonuclease as described in §2.5 .4.1. The digested insert DNA was isolated 
by agarose electrophoresis and the excised fragments purified using either the 
Geneclean® II kit (BIO 101, USA) or the UltraClean™ GelSpin DNA Purification Kit 
(MoBio Laboratories Inc, USA). Digested vector DNA was purified either as above or 
by standard phenol/chloroform extraction and ethanol precipitation. Vectors were 
resuspended in ddH20 and stored at -20°C. Inserts were ligated into 100 ng vector at 
4 °C overnight. A 10 µL ligation reaction contained either 2 µL 5x BRL buffer and 0.5 
µL of T4 DNA ligase (7500 Weiss units/mL) or 1 µL Ligase l0x buffer and 1 µL T4 
DNA ligase (3 Weiss units/µL). 
2.6.2 TRANSFORMATION 
Competent E. coli cells were prepared using the calcium, potassium and manganese 
chloride method. Aliquots were snap frozen on dry ice before storage at -70°C. 
Ligations (lµL) were transfonned into 100 µL of either cell type and incubated on ice 
for 30 minutes. Samples were heatshocked at 45 °C for 42 seconds, cooled on ice then 
Chapter 2 Materials and Methods 50 
incubated with 500 µL of LB at 37°C for 45 minutes. Transformed cells were plated 
onto LB-Amp, LB-Amp/Chlor or LB-Amp/Kan plates as required and incubated 
oven1ight at 37°C. 
2.6.3 SITE-DIRECTED MUTAGENESIS 
All polymorphic variants causing amino acid changes were created using the 
QuikChange™ Site-Directed Mutagenesis Kit (Stratagene). A 50 µL reaction contained 
5 µL of 1 Ox Reaction Buffer, 1.25 µL of the forward and reverse primers (10 pmol/µL) , 
2 µl of 10 mM dNTP mix, 5-10 ng dsDNA template and 1 µL Pfu Turbo DNA 
polyinerase. Cycling parameters were adjusted depending on the type of mutation 
required. Introduction of a point mutation involved an initial denaturation step of 95 °C 
(30 sec), followed by 12 cycles of 95 °C for 30 seconds, 55°C for 1 minute and 68°C for 
11 minutes. Introduction of a deletion involved an initial denaturation step of 95°C (30 
sec), followed by 18 cycles of 95 °C for 30 seconds, 55 °C for 1 minute and 68 °C for 11 
minutes. Products were digested with Dpnl and transformed into TGl, XLl-Blue or 
Ml 5Rep4 E. coli cells. All inutations and constructs were confirmed by DNA 
sequencing as described in §2.5.5. 
2.6.4 ENZYME CHARACTERISATION 
The specific activity of all recoinbinant proteins towards a range of substrates was 
determined spectrophotometrically at 37°C using previously described methods. These 
are described in Table 2.2. Statistical comparisons were performed using unpaired 
Student's t-test, and results were defined as being statistically significant if p<0.05. 
2.6.5 STRUCTURE ANALYSIS 
The structural effects of verified polymorphisms were determined by predictive 
modelling using the DeepView/Swiss-PdbViewer program (GlaxoSmithKline), which 
Table 2.2 - Substrates used for enzymatic characterisation of recombinant GST proteins. 
Substrate Final [substrate] Final [GSH] Buffer Anm Li£ Reference 
(mM) (mM) (mM-1cm-1) 
Li5-Androsten-3, 17-dione 0.1 1 0.025 M NaPi pH8.0 248 16.3 Johansson & Mam1ervik, 2001 a 
1-chloro-2,4-dinitrobenzene 1 1 0.1 M NaPi pH6.5 340 9.6 Habig & J akoby, 1981 
7 -chl oro-4-ni tro b enzo-2-o x a-1, 3-diax o 1 e 0.2 0.5 0.1 M NaOAc pH5.0 419 14.5 Ricci et al. , 1994 
Cumene hydroperoxide 1.5 1 0.1 M NaPi pH7.0a 340 6.2 Beutler, 197 5 
1,2-dichloro-nitrobenzene 1 5 0.1 M NaPi pH8.0 344 10 Habig & Jakoby, 1981 
l ,2-epoxy-3-(p-nitrophenoxy)propane 0.5 5 0.1 M NaPi pH6.5 360 0.5 Habig & Jakoby, 1981 
Ethacrynic acid 0.2 0.25 0.1 M NaPi pH6.5 270 5 Habig & J akoby, 1981 
2-hydroxyethyl disulfide 0.75 1 0.1 M Tris pH8, 340 6.2 Holmgren & Aslund, 1995 
2mMEDTAb 
p-nitrophenylacetate 0.2 0.1 0.1 M NaPi pH7.0 400 8.79 Habig & J akoby, 1981 
4-phenyl-but-3-en-2-one 0.05 0.25 0.1 M NaPi pH6.5 290 -24.8 Habig & J akoby, 1981 
tert-butyl-hydroperoxide 1.5 1 0.1 M NaPi pH7.0* 340 6.2 Beutler, 1975 
trans-non-2-enal 0.025 1 0.1 M NaPi pH6.5 __ 225 ___ -19.2 __ Brophy et al. , 1989 
a add 0.3 U/mL glutathione reductase and 0.2 mM NADPH 
b add 13.6 µg/mL glutathione reductase, 0.3 mM NADPH and 0.1 mg/mL BSA. This reaction was measured at 30°C. 
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can be accessed at http: //www.expasy.org/spdbv/. Protein Data Bank (PDB) files for 
the GSTAl (PDB code lGSE), GSTM3 (PDB code 3GTU) and GSTOl (PDB code 
lEEM) proteins were downloaded from the PDB (http://www.rcsb.org/pdb). To 
generate a model for GST A2, the 11 amino acids that differentiate GST A2 from 
GSTAl were introduced into the GSTAl model, and the new protein sequence was 
submitted to the First Approach Mode at the Swiss-Model website 
(http://www.expasy.org/swissmod/) [Guex & Peitsch, 1997]. Similarly, in order to 
generate a model for each of the variant proteins, the relevant residue was changed in 
the original protein sequence, and the newly altered sequence was submitted to the First 
Approach Mode at the Swiss-Model website. 
2.7 NOMENCLATURE 
Genes, mRNA, cDNA, proteins and polymorphisms were all described according to the 
agreed nomenclature guidelines [den Dunnen & Antonarakis, 2001; Wain et al., 2002]. 
2.8 COMPUTER SOFTWARE ANALYSIS 
Various co1nputer software programs were used 1n this study. DNA sequence 
translations and restriction maps were generated using DNA Strider version 1.2 
(Commissariat a l'Energie Atomique, France). Oligonucleotides were designed using 
Atnplify 1.2 (University of Wisconsin, USA) [Engels, 1993]. MacCurve Fit version 
1.1.2 (Kevin Raner Software, Australia) was used to fit enzyme kinetic data. Student's 
t-tests were calculated using GraphPad Prism v. 3.02. 
CHAPTER3 
THE ALPHA CLASS GS Ts 
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3.1 INTRODUCTION 
The Alpha class GSTs can be described as one of the more versatile GST families. 
With four expressed isoforms, this family is able to fulfill a variety of functions and has 
a correspondingly wide range of substrate specificities. Formerly known as ligandins, 
some Alpha class GSTs are able to bind non-substrate co1npounds such as bilirubin, bile 
acids, heme, thyroid and steroid hormones and penicillin in a non-covalent fashion, thus 
allowing solubilisation and storage of these compounds in the liver [Litwack et al., 
1971; Wolkoff et al., 1979; Hayes et al., 1980; Simons & Jagt, 1980; Homma & 
Listowsky, 1985; Ishigaki et al., 1989]. The ligandins are also capable of covalently 
binding strong alkyl a ting agents, providing protection against their damaging effects 
[Ketterer et al., 1967; Jakoby, 1978]. Alpha class GSTs have been shown to catalyse 
the detoxification of the nitrogen mustard group of alkylating anticancer drugs [Ciaccio 
et al., 1991; Meyer et al., 1992; Dirven et al., 1994; Tew, 1994], a,~-unsaturated 
aldehydes [Board, 1998; Hubatsch et al., 1998] and some heterocyclic amines (HCAs) 
[Lin et al., 1994; Coles et al., 2001b]. In addition to their ability to function as typical 
GSTs, they all possess some degree of keto-steroid isomerase activity [Benson et al., 
1977; Johansson & Mannervik, 2001 a] and prostaglandin synthase activity [Burgess et 
al., 1989]. However, it is their selenium-independent peroxidase (GPx-II) activity that 
distinguishes the Alpha class GS Ts from the other GST families [ Awasthi et al., 1980; 
Zhao et al., 1999]. Given the diverse nature of the Alpha class GSTs, polymorphism in 
these genes may have far-reaching i1nplications, both in terms of drug metabolism and 
disease aetiology. 
The existence of polymorphism in the Alpha class GSTs has been previously 
recognised, notably in the GSTA2 gene, which is predominantly expressed in the liver 
[Rowe et al., 1997] and subject to interindividual variation in its level of expression 
[Hayes et al., 1989]. Considering the Alpha class GS Ts are believed to represent a 
1najor line of defence against oxidative stress induced by phospholipid hydroperoxides 
and fatty acid hydroperoxides, GSTA2 polymorphism studies may prove to be of clinical 
interest. Through its GPx-II activity, GSTA2, and to a lesser extent GSTAJ [Stockman 
et al., 1987; Chow et al., 1988; Zhao et al., 1999], can catalyse the reduction of these 
organic hydroperoxides to the co1Tesponding alcohols [Awasthi et al., 1980; Singhal et 
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al., 1992a]. This activity is of particular importance to the liver, which being the major 
site for drug and xenobiotic detoxification, is at an increased risk of suffering oxidative 
stress due to the large nu1nber of ROS generated during detoxification and lipid 
peroxidation [Zhao et al., 1999]. The first GSTA2 polymorphism was described in 1989 
[Hayes et al. , 1989], and differed fro1n the original cDNA sequence at residue 112 
[Rhoads et al., 1987], with a serine replacing the threonine at this position. A later 
study, in which the full GSTA2 gene sequence was determined, revealed a second 
polymorphism at residue 210, with an alanine replacing glutamic acid [Rohrdanz et al., 
1992]. A subsequent study found that the p.Tl 12 variant was never seen in combination 
with the p .A210 variant, yet the p. S 112 variant was associated with either the p .E210 or 
p.A210 variants [Coles et al., 2000]. More recently, a polymorphism in which a serine 
replaces a praline at residue 110 was described [Wang et al., 2000]. Whilst there is 
speculation as to the functional consequences of these three polymorphisms, there has 
been no further investigation into any of these variants. Alterations in the GPx-II 
activity of GSTA2-2 introduced by polymorphisms could ultimately be responsible for 
diseases associated with oxidative damage. 
Another important component in the defence against oxidative stress is provided by the 
ubiquitously expressed GSTA4-4. This isofonn has a uniquely high catalytic efficiency 
for the 4-hydroxyalkenals, particularly 4HNE [Board, 1998; Hubatsch et al., 1998], one 
of the 1najor byproducts of lipid peroxidation [Esterbauer et al. , 1991], and it has been 
suggested that this enzyine provides significant protection against oxidative damage 
[Desn1ots et al., 1998; Hubatsch et al., 1998]. 4HNE is a genotoxic cx,~-unsaturated 
aldehyde and has been i1nplicated in oxidative damage associated with aging [Stadtman, 
1992], atherosclerosis [Palinski et al., 1989], cataract formation [Ansari et al., 1996] , 
cancer [Eckl et al., 1993] and neurodegenerative disease such as Parkinson's Disease 
[Y oritaka et al., 1996] and Alzheimer's Disease [Mark et al., 1997]. Recent localisation 
of GSTA4-4 to the mitochondria suggested that GST A4-4 might help maintain 
mitochondrial redox status during cellular respiration, with disruption potentially 
resulting in oxidative stress [Gardner & Gallagher, 2001]. In addition, it has been 
suggested that the level of GSTA4-4 expression and any polymorphic variants of this 
gene may act as susceptibility factors towards degenerative disorders and diseases 
characterised by a loss of mitochondrial function [Gardner & Gallagher, 2001]. 
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Recently, two coding region polymorphisms have been identified in the GSTA4 gene. A 
preliminary report has described the presence of an uncharacterised SNP in exon 1 
[Latsoudis et al., 2000], and a threonine to alanine substitution at residue 163 
( c.487 A>G) was identified through a large-scale genome screening effort [Iida et al., 
2001], yet remains uncharacterised. 
Polymorphisms in the Alpha class GSTs are also implicated in diseases other than those 
associated with oxidative stress. Recently, polyinorphism in the promoter region of 
GSTAJ, consisting of two alleles GSTAJ *A and GSTAJ *B, has been shown to not only 
affect both the absolute levels of GSTAl-1 expression and the ratio of GSTAl-1 to 
GSTA2-2 expression in the liver [Coles et al., 2001a] and potentially other tissues 
[Morel et al., 2002], but has also been linked to an increased susceptibility to colorectal 
cancer (CRC) [Coles et al., 2001b]. CRC susceptibility has been associated with a high 
dietary intake of cooked meats, which are laden with heterocyclic amines (HCA) and 
their activated products, particularly N-acetoxy-2-amino-1-methyl-6-
phenylimidazo( 4,5-b )pyridine (N-acetoxy PhIP) [Layton et al., 1995], implying that 
HCAs may be involved in CRC aetiology. It is believed that low, or altered, expression 
of GSTAl-1 may influence its unique ability to catalyse N-acetoxy PhIP, thereby 
increasing the risk of CRC [Lin et al., 1994; Coles et al., 2001 b]. Another three 
pro1noter region polymorphisms have since been identified, however these do not 
appear to have any significant effects on GSTAl-1 function [Bredschneider et al., 
2002]. Although polymorphis1ns have not yet been identified in the coding region of 
GSTAJ, it can be postulated that these too could alter an individual's susceptibility to 
CRC. 
In addition to the role GSTs play in detoxification, some have been shown to have a 
purely biological role. GSTA3-3 has a uniquely high activity as an isomerase in steroid 
hormone biosynthesis. GSTA3-3 specifically catalyses the double bond isomerisation 
of Li5-androstene-3, 17-dione and Li5-pregnane-3, 20-dione to Li4-androstene-3, 17-dione 
and Li 4-pregnane-3, 20-dione, which are immediate precursors of testosterone and 
progesterone, respectively [Johansson & Mannervik, 2001a]. During the recent cloning 
of the full-length GSTA3 cDNA, two novel GSTA3 alternative transcripts were also 
identified along with a possible p.L71I polymorphism [Johansson & Mannervik, 
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2001 a]. One transcript is characterised by the deletion of exon 3 which would, if 
translated, result in a + 1 frameshift and give rise to a truncated protein of 32 amino 
acids [Johansson & Mannervik, 2001 a]. In the second transcript both exons 1 and 2 are 
missing and 26 nonsensical nucleotides are attached to the 5' end of exon 3 [Board, 
1998; Johansson & Mam1ervik, 2001a]. All three GSTA3-3 transcripts are expressed in 
steroidogenic tissues: the testis, ovary, adrenal gland and placenta, so it could be 
expected the alternative transcripts and any polymorphic variants may alter expression 
levels and protein function and hence the role of GSTA3-3 in steroidogenesis. 
This chapter describes the use of various database mining techniques to facilitate the 
discovery of novel Alpha class polymorphisms. The distribution of the confirmed 
polymorphisms was determined in four ethnic populations and the recombinant proteins 
were characterised enzymatically and by predictive modelling to determine whether the 
function or the structure of the protein was altered by the introduction of the 
polymorphism. 
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3.2 MATERIALS AND METHODS 
Database analysis and standard PCR and recombinant methods used in this chapter are 
described in Chapter 2. Techniques unique to this chapter are outlined below. 
3.2.1 DATABASE SCREENING 
Potential polyn1orphisms in the four Alpha class GSTs were identified and verified 
using the database mining methods described in §2.3, and are listed in Tables 3.1 and 
3.2. 
3.2.2 PCR/RFLP ANALYSIS 
Potentially polyinorphic exons of the GSTAJ, GSTA2 and GSTA3 genes were 
specifically amplified from genomic DNA using PCR as described in §2.5.6.2. For 
variants detected in the GSTAJ and GSTA2 genes using the BLAST alignment tool and 
the SNP Finder program, 200 Australian Europeans, and up to 100 Creole Africans and 
Southern Chinese san1ples were ainplified. Small-scale population screens, as described 
in §2.5 .6.2, were performed to confirm the presence of variants detected in the SNP 
databases. The oligonucleotide sequences and the specific conditions for each PCR are 
listed in Table 3 .3. The presence of variation in the PCR products was determined by 
RFLP analysis (§2.5.4.2) using the appropriate restriction enzymes (Table 3.4). Eight 
of the 15 verified sequence alterations changed restriction endonuclease sites. For the 
remaining seven, primers were designed containing a partial restriction endonuclease 
site, which was con1pleted by either the absence or the presence of the polymorphic 
base [Kangsadalampai et al., 1998]. Up to 200 samples from the Australian European, 
and 100 samples from the Bantu African, Creole African and Southern Chinese groups 
were amplified by PCR, to allow allele and haplotype frequency determination for any 
polyn1orphisn1s identified. 
Table 3.1 - GST Alpha variants detected in the EST database by the BLAST alig1unent tool and in the UniGene database by the 
SNP Finder pro gran1. 
Gene Nucleotide Residue Exon Program ESTs with Libraries Sequence Confirmed in 
Alteration represented Confirmeda,b population studies 
GSTAJC c.115G>T p.E39X 3 BLAST 3 1 Yes-H73011 No 
SNP Finder 4 1 Yes-1.0 No 
c.159G>T p.Q53H 4 SNP Finder 1 1 Yes-0.83 No 
c.365G>A p.K125K 5 BLAST 29 7 Yes-T81799 Yes 
c.365A>G p.1(1251( 5 SNP Finder 14 10 Yes-0.17 Yes 
c.598G>C p.Ql99H 7 BLAST 4 2 No-T81799 N.S. 
SNP Finder 1 1 No-0.01 N.S. 
c.669A>C p.X223Y 7 BLAST 2 2 No-AI08445 N.S. 
GSTA2 c.322C>T p.L108F 5 BLAST 2 2 No-AI357144 N.S. 
c.335C>G p.Tl 12S 5 BLAST 9 3 Yes-AI357144 Yes 
c.384A>C p.T128T 5 SNP Finder 2 2 No-0.05 N.S. 
c.389A>T p.N130I 5 BLAST 4 3 No-AI357144 N.S. 
c.517A>G p.Sl 73G 6 BLAST 3 2 No-H71630 N.S. 
c.588G>T p.Kl96N 7 BLAST 2 2 Yes-AI023858 No 
SNP Finder 2 2 Yes-0.96 No 
c.629A>C p.E210A 7 BLAST 8 2 Yes-AI023858 Yes 
c.629C>A p.A210E 7 SNP Finder 8 6 Yes-1.0 Yes 
a The accession number of the I.M.A.G.E. Consortium (LLNL) cDNA clones sequenced to confirm the presence of potential polymorphisms 
identified using the BLAST alignment tool is provided. 
b Polyinorphis1ns detected using the SNP Finder program are allocated a likelihood score. As the number approaches 1.0, there is a greater 
likelihood that this polymorphism will be real. Sequences were confirmed by viewing the electopherogram data n1ade available at the site. 
c GSTAJ was not represented in the UniGene clusters, hence was not able to be analysed using the SNP Finder prograin. Polyinorphisms 
discovered in GSTAJ were identified through the search performed for GSTA2, which downloaded several different contigs. Contig 4 
corresponded to GSTA2, and Contig 5 to GSTAJ. 
N.S.: Not Studied 
Table 3.2 - GST Alpha polymorphisms detected in the SNP databases. 
Gene Nucleotide Residue Exon Database Able to Confirmed in 
confirma population studies 
GSTAJ c.115G>T p.E39Xb 3 HGBASE Unable No 
c.159G>T p.Q53Hb 4 refseq, HGBASE Unable No 
c.331G>T p.Vl 1 lL 5 dbSNP, ref seq, GeneSNPs Unable No 
c.335G>C p.Cl 12S 5 dbSNP, ref seq, GeneSNPs Unable N.S. 
c.382A>C p.I128L 5 dbSNP, ref seq, GeneSNPs Unable No 
GSTA2 c.183T>C p.D61D 4 EGPSNPs Unable N.S. 
c.269C>T p.A90V 4 GeneSNPs Unable No 
c.306G>A p.L102L 5 refseq, GeneSNPs Unable N.S. 
c.328C>T p.Pll0S 5 EGPSNPs Unable Yes 
c.335G>C p.S 112Tb 5 refseq (0.99t Yes Yes 
c.446T>C p.V149A 6 refseq, EGPSNPs, GeneSNPs Unable No 
c.588G>T p.K196Nb 7 dbSNP, refseq, GeneSNPs (0.96) \ HGBASE Yes No 
c.629A>C p.E210Ab 7 dbSNP, refseq (0.99) C, EGPSNPs, GeneSNPs (1.0) C, HGBASE Yes Yes 
GSTA3 c.21 lC>A p.L71I 4 refseq, GeneSNPs Unable Yes 
GSTA4 c.351 G>A p.Ql 17Q 5 dbSNP, ref seq Unable N.S. 
a Son1e sequences were unable to be confirmed directly through the databases, therefore small-scale population screens were used to confirm these polyn1orphisn1s. 6 These polymorphisn1s were also detected by the BLAST alignn1ent tool and the SNP Finder program. 
c If the SNP was subnutted by the GAI to different databases, links to the SNP Finder program were provided, allowing access to electropherograms. 
Tab le 3.3 - Oligonucleotides used for GSTAJ, GSTA2 and GSTA3 exon ainplification. 
Primer 
Name 
GSTAJ 
A1Ex3F 
A1Ex3R 
A1Ex4A 
A1Ex4B 
A1Ex4F2a 
A1Ex4R2 
A1Ex5F 
A1Ex5R 
A1Ex5F2 
A1Ex5Hphlb 
A1Ex5Stuf 
A1Ex5Ddelct 
GSTA2 
A2Ex4F 
A2Ex4Mwore 
A2Ex5F 
A2Ex5R 
A2Ex5Mwot 
A2Ex6F 
A2Ex6R 
A2Ex7F 
A2Ex7R 
A2E7Sphig 
GSTA3 
A3Ex4F 
A3Ex4R 
Exon Primer sequence Annealing Product 
5' to 3' Conditions Length 
3 GAATGAACTAACAAGAACGT 50°C, 20 sec 124 bp 
3 TCATCAGAGGAACTTAGAGA 
4 CACAACCATTTGTTCATCCCA 58°C, 18sec 312bp 
4 ATCCTGCTGCTGGTCATGATG 
4 TGGATATTTGATGATGCA 60°C, 18 sec 139 bp 
4 TACCGTACAGGGCTC 
5 GTTGTTTCTTGTCTTTCAGG 50°C, 18 sec 174 bp 
5 CATCTTCACTTACTTTTTCA 
5 CCCGTATGTCCACCTG 49°C, 18 sec 68 bp 
5 TAGCGATTTTTTATTTTCAC 
5 AAATGATCCTCCTTCAGGCC 51 °C, 18 sec 93 bp 
- -
5 CAGGGAAGTAGCGATTTCTTA 
4 TTTCAAGTGAACTCTTACAGG 61°C,18sec 29lbp 
4 AAGAACAGAAAATATAGCGTACAGG 
5 GTTGTTTTTTGTCTTTCAGG 55°C, 18 sec 174 bp 
5 CAGCTTCACTTACTTTTTCA 
ATTTGGGTGAAATGATGCTT 53°C,16sec 126bp 
6 TCTCCAGGTCTTAAAGAGCCAC 56°C, 18sec 115bp 
6 AAGGCTAGAGTCAAGCTCTTCC 
7 TGTGCTTTGTGGATTACAGG 58°C, 20 sec 302 bp 
7 CTAAGTGGGTGAATAGGAGT 
7 AAGGAAGCCTCCCATGCATG 55°C, 18 sec 221 bp 
4 CATTTTATAACCTCAGTCATTTCAACCATC 57°c 18 sec 327 bp 
CCTGGTCATGATGCCCTGTCATGGTCT 
a A 1nodification of ttc • atg (underlined) was introduced to create an Nsil site in 
amplified DNA containing the p.Q53H variation. This primer was used in combination 
with A1Ex4R2 on PCR products produced by A1Ex4A and A1Ex4B. 
b A modification of etc • cac (underlined) was introduced to create an Hphl site in 
amplified DNA containing the c.365G>A silent variation. This primer was used in 
co1nbination with A1Ex5F2 on PCR products produced by A1Ex5F and A1Ex5R. 
c A modification of tgc • agg (underlined) was introduced to create a Stul site in 
amplified DNA containing the p.Vl 1 lL variation. This primer was used in combination 
with A1Ex5Ddel. 
ct A modification oft • c (underlined) was introduced to create a Ddel site in amplified 
DNA containing the p.Cl 12S variation. This pri1ner was used in combination with 
A1Ex5Stul. 
e A modification of c • g (underlined) was introduced to create an Mwol site 111 
amplified DNA containing the p.A90V variation. 
f A 1nodification of c • g (underlined) was introduced to create an Mwol site in 
amplified DNA containing the p.Pl lOS variation. This primer was used in conjunction 
with A2Ex5R. 
8 A modification of g • c (underlined) was introduced to create an Sphl site in 
amplified DNA containing the p.E21 OA variation. This primer was used in combination 
with A2Ex7R. 
Table 3.4 - Restriction Endonuclease Sites used to detect polymorphisms in the 
GSTAJ, GSTA2 and GSTA3 genes. 
Variation 
GSTAJ 
p.E39X 
p.Q53H 
p.Vl 1 lL 
p.K125K 
p.I128L 
GSTA2 
p.A90V 
p.Pl 10S 
p.Tl 12S 
p.Vl94A 
p.K196N 
p.E210A 
GSTA3 
p.L71I 
Exon Endonuclease 
Site 
3 PstI 
4 Nsil 
5 StuI 
5 HphI 
5 DdeI 
4 MwoI 
5 MwoI 
5 Mbo II/ HincII 
6 Cac8I 
7 ApoI 
7 SphI 
4 Bspl286I 
Fragment Size (bp) 
Wild-type Heterozygous Variant 
68,55 123,68, 55 123 
139 139, 121, 18 121, 18 
92 18, 75,92 18, 75 
68 68,60,8 60,8 
31,62 18,61,44,62 18,31,44 
20,271 20,271,291 291 
20,37,69 20,37,57,69 57,69 
114,60 114,90,60,24 90,60,24 
114 40, 74,114 40, 74 
302 302,244,58 244,58 
221 221,201,20 201,20 
60,99, 168 60,99, 168,228 99,228 
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3.2.3 RECOMBINANT PROTEIN WORK 
3.2.3.1 GSTA2-2 
3.2.3.1.1 SITE-DIRECTED MUTAGENESIS 
The GSTA2-2 protein encoded by the I.M.A.G.E. Consortium (LLNL) cDNA Clone 
T96198 was expressed in E. coli as an ubiquitin fusion in the plas1nid pRB269 [Baker et 
al., 1994]. The T96198 cDNA was a1nplified by PCR using the forward primer 5'-
GACCGCGGTGGTATGGCAGAGAAGCCCAAGC-3' and the reverse primer 5'-
ACGTCGACTCATTAAAACCTGAAAATCTTCC-3' to create a SacII restriction site 
upstream of the GSTA2-2 initiation codon, and a Sall site downstream of the GSTA2-2 
stop codon. The 692 bp amplified product was digested with SacII and Sall and the 
resulting fragment ligated into the SacII and Sall sites of pRB269. This construct was 
confirmed by sequencing as being the GSTA2D protein (Table 3.5) and was created by 
Dr Dan Liu. Using the QuikChange Site-Directed Mutagenesis Kit (§2.6.3), the 
GSTA2B protein (containing the p.A210 variation) was created from GSTA2D using 
the primer pair A27KN1 and A27KN2 (Table 3.6). 
The GSTA2A protein was constructed (using cloning and ligation techniques outlined 
in §2.5.4.1 and §2.6.1) by replacing the 210 bp DraIII-Sphl fragment in the GSTA2D 
protein with the 215 bp DraIII-Nspl fraginent from the I.M.A.G.E. Consortium (LLNL) 
cDNA Clone AI357144. The GSTA2C and GSTA2E proteins (containing the p.Tl 12 
and p.S 110 variations respectively) were created from the GSTA2A protein using the 
QuikChange Site-Directed Mutagenesis Kit (§2.6.3) and the primer pairs A25ST1 and 
A25ST2, and GSTA2Pl 10SA and GSTA2Pl 10SB respectively (Table 3.6). All 
1nutations and constructs were confirmed by DNA cycle sequencing (§2.5.5.1). 
3.2.3.1.2 PROTEIN EXPRESSION AND PURIFICATION 
Plasmids encoding the GST A2A, GSTA2B and GST A2C variants were transfected into 
E. coli strains XLl-Blue or TGl (§2.6.2) containing the plasmid pRBl 73 [Baker et al., 
Table 3.5 - Nucleotide and amino acid variations in GSTA2. 
Haplotype Nucleotide 
c.328 c.335 c.588 c.629 
GSTA2A C g g a 
GSTA2B C g g C 
GSTA2C C C g a 
GSTA2D C g t C 
GSTA2E t g g a 
Residue 
p.110 p.112 p.196 p.210 
GSTA2A Pro Ser Lys Glu 
GSTA2B Pro Ser Lys Ala 
GSTA2C Pro Thr Lys Glu 
GSTA2D Pro Ser Asn Ala 
GSTA2E Ser Ser Lys Glu 
Table 3.6 - Mutagenesis primers used to create GSTA2-2 recombinant protein variants. 
GSTA2 Primer Name Mutagenesis Primer Sequences 
Haplotype 5' to 3' 
GSTA2B A27KN1 CCCACAGTGAAGAAGTTTCTACAGCCTGGC 
A27KN2 GCCAGGCTGTAGAAACTTCTTCACTGTGGG 
GSTA2C A25ST1 CTTCTGCCCTTTACTCAACCTGAGGAAC 
GSTA2E 
A25ST2 GTTCCTCAGGTTGAGTAAAGGGCAGAAG 
GST A2P 11 OSA GGTGAAA TGATCCTTCTTCTGTCCTTT AGTCAACCTGAGGAAC 
GSTA2Pl 1 OSB GTTCCTCAGGTTGACT AAAGGACAGAAGAAGGATCATTTCACC 
Chapter 3 Materials and Methods 58 
1994], a source of the ubiquitin-specific protease Ubp2 [Baker et al., 1992]. This 
ubiquitin specific protease co-translationally removes the N-terminal ubiquitin moiety 
fro1n the fusion proteins. 4 mL of an overnight culture was diluted 1: 100 into LB 
supplemented with 100 µg/ml ampicillin and 34 µg/ml chloramphenicol. The 400 mL 
cultures were incubated at 37°C with vigorous shaking to an OD6oo of 0.6 and protein 
expression was induced with 0.5 mM IPTG for 3 hours. The cells were harvested by 
centrifugation at 5 I( for 10 minutes at 4°C (GSA-1500 rotor), resuspended in 15 mL of 
20 mM NaPi, pH 7.0 and lysed by sonication (5 x 15 second bursts). Cellular debris 
was removed by centrifugation at 12 K for 20 minutes at 4°C (SS-34 rotor). 
All proteins were purified at 4 °C by affinity chromatography. Cleared lysates were 
diluted with a further 10 mL of 20 mM NaPi, pH7.0 and incubated with GSH agarose at 
4 °C for 1 hour on a rotary mixer. The agarose was collected by centrifugation at 1000 
rp1n for 5 1ninutes and washed twice with 40 mL of 20 mM NaPi, pH 7.0. The agarose 
was washed with 200 mL of 20 mM NaPi, pH 7.0 on a scintered funnel, then transferred 
to a column and washed with a further 50 mL of 50 mM Tris-HCl, pH 7.2. The pure 
protein was eluted from the GSH-agarose with 50 mM GSH in 200 mM Tris-HCl, pH 
9.6. Fractions containing recombinant GSTA2 protein were identified by 12.5% SDS-
p AGE and stored in 10% glycerol at -20°C. Protein concentrations were determined as 
described in §2.5.2.3. 
3.2.3.2 GSTA3-3 
3.2.3.2.1 AMPLIFICATION AND ISOLATION OF THE GSTA3 cDNA 
cDNA was extracted from existing lambda phage lysate prepared from an LE392:Agtl 1 
human testis cDNA library as described in §2.5.1.1. The GSTA3 cDNA was amplified 
from this cDNA using the pnmer pair GSTA3EcoRIF2 5 ' -
AATAATGAATTCATGGCAGGGAAGCCCAAGCTT and GSTA3NCBamHIR 5' -
AATAATGGATCCTTCTTAGCCTCCATGGCTGCT [Johansson & Mannervik, 
2001a], which have an EcoRl and BamHI restriction site respectively incorporated. A 
20 µL reaction volume contained lx cloned Pfu l Ox reaction buffer, 0.2 mM dNTPs, 
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1.5 mM MgCh, 6 pmol of the forward and reverse primers and 0.5 unit of Pfu Turbo 
DNA polymerase. A negative control sample containing all components of the reaction 
except the ten1plate was included in each PCR to ensure the absence of contamination. 
PCR conditions involved an initial denaturation step at 95°C for 5 minutes followed by 
35 cycles of a 95°C denaturation step (2 min), 54°C annealing step (1 min), and 72°C 
extension step (1 min), with a final 7 minute extension at 72°C [Johansson & 
Mannervik, 2001 a]. Agarose gel electrophoresis was used to confirm the absence of 
spurious bands and contamination and the presence of PCR product (5 µL). 
3.2.3.2.2 SUBCLONING 
The 667 bp and 719 bp GSTA3 PCR products were digested with the restriction 
enzymes EcoRI and BamHI and cloned into the BamHI and EcoRI sites of the pKK.263 
vector as described in §2.5 .4.1 and §2.6.1. The constructs were confirmed by 
automated sequencing as described in §2.5.5.2. 
3.2.4 GSTA2-2 ENZYME CHARACTERISATION 
3.2.4.1 STRUCTURAL ANALYSIS 
The GSTA2A [p.Pl 10;S112;E210], GSTA2B [p.Pl 10;Tl 12;E210], GSTA2C 
[p.Pl 10;S112;A210] and GSTA2E [p.S110;S112;E210] variants were built into a 
homology n1odel of GSTA2-2 based on the co-ordinates of GSTAl-1 (PDB code 
lGSE) as described in §2.6.5. 
3.2.4.2 ENZYMATIC ANALYSIS 
Glutathione S-transferase activity towards a range of typical Alpha class substrates was 
measured as described in §2.6.4. Three separate preparations of the GST A2A, 
GST A2B and GSTA2C isoforms were prepared. Two separate preparations of the 
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GSTA2A and GSTA2E isoforms were prepared at a later stage. No changes in the yield 
or expression levels of these variants were observed. 
3.2.4.3 STEADY STATE KINETIC ANALYSIS 
Steady state kinetics for the recombinant proteins GSTA2A and GST A2E against the 
substrate CDNB were determined using a 5x5 experiment. Kinetic parameters for the 
CDNB reaction were determined by measuring the kinetics for five concentrations of 
CDNB (1000, 800, 600, 400 and 200 µM) against five concentrations of GSH (1000, 
500, 200, 100 and 50 µM GSH). Similarly, kinetic parameters for the p-
nitrophenylacetate (pNP A) assay were determined by measuring the kinetics for five 
concentrations of pNP A (1000, 7 50, 400, 200 and 100 µM) against five concentrations 
of GSH (1000, 500, 200, 100 and 50 µM GSH). The steady state kinetic parameters 
were determined by fitting the Michaelis Menten equation to the data points using the 
MacCurve Fit progra1n. Hyperbolae were fitted to bring R2 closest to 1 (<1), and SSE 
closest to 0.0001 (>0.0001). 
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3.3 RESULTS 
3.3.1 DETECTION OF ALPHA CLASS GST POLYMORPHISMS 
3.3.1.1 DETECTION USING DATABASE ANALYSIS PROGRAMS 
The BLAST alignment tool and the SNP Finder program were used to detect 
polymorphisms in the Alpha class GST cDNA sequences located in the human EST 
database and UniGene clusters respectively. The EST database contained 136 GSTAJ, 
46 GSTA2, 20 GSTA3 and 95 GSTA4 cDNAs. The UniGene clusters contained 132 
GSTA2 (of which 99 were subsequently verified as GSTAJ and 33 GSTA2), eight 
GSTA3 and one GSTA4 cDNA and mRNA sequences. From these sequence databases, 
eleven variants were detected in the GSTAJ and GSTA2 genes (Table 3.1). Of these, 
only six variants were confirmed upon resequencing a representative I.M.A.G.E. 
Consortium (LLNL) cDNA clone or viewing existing electropherographic data. 
3.3.1.2 DETECTION USING SNP DATABASES 
A nu1nber of SNP databases were also analysed for GST Alpha class submissions. 
Multiple variants were listed in these databases, however when limited to those that 
altered ainino acid residues in the coding region, seven novel variants were found: the 
p.Vl 1 lL, p.Cl 12S and p.I128L substitutions in GSTAJ; the p.A90V, p.Pl l0S and 
p.Vl49A substitutions in GSTA2; and the p.L71I substitution in the GSTA3 gene (Table 
3.2). Although son1e GSTA2 variants could be confirmed through analysis of 
electropherograms and available frequency data, small-scale population analysis was 
undertaken for confinnation on all polyinorphisms identified. Four variants that had 
been detected using the BLAST alignment tool and SNP Finder programs were also 
detected in these databases. 
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3.3.1.3 DETERMINATION AND DISTRIBUTION OF ALLELE FREQUENCIES 
Amplification of the variant exons followed by digestion with the appropriate restriction 
enzyme allowed simple determination of the nucleotide present at each of the 13 
potential variant sites. For the six variants detected using the BLAST alignment tool 
and SNP Finder programs, 200 Australian Europeans, 87 Creole Africans and 97 
Southern Chinese samples were initially screened. Only three polymorphisms were 
identified and confirmed in these populations: the silent p.Kl25K (c.365G>A) GSTAJ 
variant, and the p.Tl 12S (Figure 3.1) and p.E210A (Figure 3.2) GSTA2 variants (Table 
3.7). 74 Bantu African samples were subsequently screened for the two GSTA2 
variants. In GSTAJ, the silent polymorphism was commonly found in all populations 
studied, but the c.G365 allele was rarer in the Creole African and Southern Chinese 
populations. Chi-square analysis provided support for a difference in genotypic 
distribution between the three races (x24 = 54.74, p<0.05). In GSTA2, the p.Tl 12 
variant of the p.Tl 12S polymorphism was only ever detected in the heterozygous state. 
This variant was found to be extremely rare in all but the Bantu African population, in 
which the frequency for this allele increased significantly from the 0%-0.5% observed 
in the Australian European, Creole African and Southern Chinese groups to 15°/o. Chi-
square analysis provided support for a difference in genotypic distribution between 
these populations (x2 6 = 102.48, p<0.05), specifically between the Bantu Africans and 
the remaining three populations (Australian European/Bantu African: x2 2 = 56.62, 
p<0.05; Creole African/Bantu African: x\ = 27.10, p<0.05; Southern Chinese/Bantu 
African: x\ = 33.58, p<0.05). In contrast, the p.A210 variant of the p.E210A 
polymorphism occurred quite frequently, ranging from an extremely high allele 
frequency of 42% in the Bantu African population to a mere 8% in the Australian 
European population. Chi-square analysis provided support for a difference in 
genotypic distribution between the four populations (x2 6 = 124.54, p<0.05). Further 
analysis demonstrated no difference in genotypic distribution between the Creole 
1 ~ ?. 
5.47, p>0.05). Of note, this polymorphism was not in accordance with the Hardy-
Weinberg in the Bantu African population. It is possible that this locus is in linkage 
disequilibrium with other loci." 
3.4) polymorphis1ns. Screening additional samples from each of the three populations, 
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Figure 3.1 - PCR/RFLP analysis of the GSTA2 p.Tl 12S variant. A 174 hp PCR 
product spanning exon 5 of the GSTA2 gene was digested with Hincll and Mboll for 
nucleotide 335 determination. Lane 1 - pUC/HpaII marker; Lanes 2, 4-6, 8 - GIG 
homozygotes; Lanes 3, 7 - C/G heterozygotes. 
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Figure 3.2 - PCR/RFLP analysis of the GSTA2 p.E2 l 0A variant. A 221 bp PCR 
product spanning exon 7 of the GSTA2 gene was digested with Sphl for nucleotide 629 
determination. Lanes 1, 2, 8 - A/C heterozygotes; Lanes 4, 5, 7 - CIC homozygotes; 
Lanes 6, 9 - A/A heterozygotes; Lane 3 - pUC/HpaII marker. 
Table 3.7 - GST Alpha allele and haplotype frequencies in three etlu1ic groups. 
Gene Polymorphism Population 11 Genotype Allele Freguency 
GSTAJ p.K 125K Australian 200 G/G=40 G/A=86 A/A=74 c.G365=0.42 c.A365=0.58 
Creo le African 87 G/G=4 G/A=38 A/A=45 c.G365=0.26 c.A365=0.74 
hinese 96 G/G=2 G/A= 19 A/A=75 c.G365=0.12 c.A365=0.88 
GSTA2 p.Pll0S Austra lian 192 C/C= l 73 C/T= 19 T/T=0 p.Pl 10=0.95 p.S 110=0.05 
Bantu African 65 C/C=63 C/T=2 T/T=0 p.P 110=0.98 p .S 110=0.2 1 
Creole African 80 C/C=61 C/T= l 7 T/T=2 p .P 110=0.87 p .S ll0=0.13 
Chinese 100 C/C=78 C/T=20 T/T=2 p .Pl 10=0.88 p.Sll0=0.12 
p.T l 12S Australian 200 CIC=0 C/G=2 G/G= 198 p .T l 12=0.005 p.S 112=0.995 
Bantu Afr ican 73 CIC=0 C/G=22 G/G=51 p .T l 12=0.15 p.S 11 2=0.85 
Creo le African 87 C/C=0 C/G= l G/G=86 p .T l 12=0.006 p .S l 12=0.994 
Chinese 97 CIC=0 C/G=0 G/G=97 p .Tl 12=0 p .S112= 1 
p.E2 10A Aush·alian 200 A/A= 169 AIC=30 C/C= l p.E210=0.92 p.A210=0.08 
Bantu African 7 1 A/A= 12 A/C=59 C/C=0 p.E210=0.58 p .A2 10=0.42 
Creo le African 87 A/A=43 AIC=39 C/C=5 p .E2 10=0.72 p.A210=0.28 
hinese 97 A/A=61 A/C=35 C/C= l p .E2 10=0.81 p .A2 10=0.19 
GSTA3 p.L 7 11 Aush·alian 100 C/C=0 CIA =0 A/A= l00 p .L7 1=0 p.I71 =1 
Bantu African 73 C/C= l C/A=20 A/A=52 p.L 71 =0.15 p.!71 =0.85 
reole African 85 C/C= l C/A=6 A/A=78 p .L71 =0.05 p.!71 =0.95 
hinese 97 CIC=0 C/A=0 A/A=97 £.L71 =0 p.I7 1 = l 
Gene 
GSTA2 
PoJ:!ulation n 
Australian 192 
GSTA2A 
[_2.Pl 10;S112;E210] 
0.86 
Haplotype 
GSTA2B GSTA2C 
[p.Pl 10;S112;A210] [J?.P_l 1 O;Tl 12;E21 OJ 
0.08 0.0052 
GSTA2E 
[p.S110;S l 12;E2 10] 
0.049 
Bantu African 64 0.40 0.43 0.16 0.02 
Creole African 80 0.60 0.27 
- 0.13 
Chinese 89 0.70 0.19 
- 0.11 Note: All polymorphisms are in agreement with the Hardy-Weinberg equilibrium, with the exception of the p.E21 OA polymorphism in the Bantu African population. 
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Figure 3.3 - PCR/RFLP analysis of the GSTA2 p.Pl 10S variant. A 126 bp PCR 
product spanning exon 5 of the GSTA2 gene was digested with Mwol for nucleotide 328 
determination. Lanes 1, 7 - TIT homozygotes; Lanes 3, 8 - CIC homozygotes; Lanes 4-
6, 9, 10 - CIT heterozygotes; Lane 2 - pUCIHpall marker. The 38 bp fragment is not 
associated with the Mwol digestion, but is primer dimer associated with the PCR 
product. 
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Figure 3.4 - PCRIRFLP analysis of the GSTA3 p.L 711 variant. A 327 bp PCR product 
spanning exon 4 of the GSTA3 gene was digested with Esp 12861 for nucleotide 211 
determination. Lanes 2, 4-8, 10, 12 - A/A homozygotes; Lane 3 - CIC homozygote; 
Lanes 9, 11 - C/A heterozygotes; Lane 1 - pUC/Hpall marker. 
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plus 74 samples from the Bantu African population, to determine allele frequencies for 
these polymorphisms revealed that the GSTA2 p.S 110 variant was relatively uncommon, 
especially in the Australian European and Bantu African populations. The p.S 110 allele 
frequency was higher in the Creole African and Southern Chinese populations at 
approxi1nately 11 %-12 %, due to the identification of four homozygous individuals. 
Chi-square analysis provided support for a genotypic difference between the four 
populations (x2 6 = 22.73, p<0.05). Further analysis demonstrated that there was no 
genotypic difference between the Australian European and Bantu population (x2 2 = 
3.01, p<0.05). The GSTA3 p.L71 variant was found to be even more uncommon, 
appearing only in the two African populations where only one individual from each 
group was homozygous for the allele. Again, Chi-square analysis provided support for 
a genotypic difference between the four populations (x2 6 = 61.90, p<0.05). 
The occurrence of alternate alleles at different nucleotide positions in GSTA2-2 results 
in the generation of 16 possible haplotype combinations, although evidence for only 
five of these was obtained in this study. These five haplotypes have been defined in 
Table 3.5. Four of these were observed in the Australian European and Bantu African 
populations, and only three in the Creole African and Chinese populations, based on the 
assumption that the combination of p.S 110 with the p.A210 residue is never observed 
(Table 3. 7). This assumption was based on the observation that the four p.S 110 
homozygotes detected were also homozygous for the p.E210 variant, as were 47 of the 
5 8 p. S 110 heterozygotes. The ren1aining 11 p. S 110 heterozygotes were heterozygous 
for the p.E210/A210 variant, hence it was therefore assumed that the p.Sl 10 residue 
was associated with the p.E210 residue. The haplotype defined as GSTA2D (Table 3.5) 
was identified in the I.M.A.G.E. Consortiu1n (LLNL) cDNA clone T96198, but was not 
observed in the three populations studied here. 
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3.3.2 ENZYME CHARACTERISATION 
3.3.2.1 GSTA2-2 
3.3.2.1.1 STRUCTURAL ANALYSIS 
To evaluate the potential effects of the p.Pl lOS, p.Tl 12S and p.E210A variants of 
GSTA2-2, the substitutions were 1nodelled into the 3-D structure of GSTAl-1 (Figure 
3.5). The GSTAl-1 p.K125K polyinorphism was not analysed further. Being a silent 
polymorphism, p.K125K is not expected to have any effects upon the function of the 
protein. Residue 110 is located in the H-site of the GSTA2-2 protein (Figure 3.6) at the 
C-terminus of the a4 helix (Figure 3 .5), and although the p.P 11 OS change is non-
conservative - praline is a nonpolar residue and serine an uncharged polar residue, 
predictive modelling demonstrates that this substitution only introduces minor changes 
to the overall protein structure (Figure 3. 7 A). However, _the substitution of p.S 110 for 
p.Pl 10 introduces one new H-bond between p.L106 and p.L108 (Figure 3.7B). Neither 
residue 112, located in the loop between the a4 and a5 helices, nor residue 210, which 
is located at the beginning of the C-terminal a9 helix, interacts with the active site. 
Predictive modelling indicates that these two residues do not alter the protein structure 
(Figures 3.8A and 3.9A). Although the p.Tl 12S change is conservative, both serine and 
threonine are polar non-charged residues, the substitution of p.Tl 12 for p.S 112 
introduces one new H-bond between p.Tl 12 and p.L108 (Figure 3.8B). The p.E210A 
substitution is non-conservative, with alanine, a small polar residue being replaced by 
glutamic acid, a larger, acidic residue. Despite being a non-conservative substitution, 
only one H-bond, between p.D209 and p.E210, is lost upon the replacement ofp.E210 
with p.A210 (Figure 3.9B). 
3.3.2.1.2 ENZYMATIC ANALYSIS 
Despite the structural modelling indicating that the p.Tl 12 and p.A210 variants were 
unlikely to have significant functional effects, the activities of these variants were 
examined with typical Alpha class substrates (Table 3.8). As predicted, there were no 
( 
Figure 3.5 - Ribbon diagram of GSTA2 depicting the position of the polymorphic 
p.Pl l0S, p.Tl 12S and p.E210A substitutions. The most common amino acids, p.Pl 10, 
p.Sl 12 and p.E210, are shown in black. The least common residues, p.Sl 10, p.Tl 12 
and p.A210 are coloured red. Glutathione, shown in gold, is bound in the active site. 
The catalytically essential p.Y9 residue is coloured green. 
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Figure 3.6 - Protein sequence aligmnent of human GSTAI-1, GSTA2-2, GSTA3-3 and 
GST A4-4. Identity with the corresponding residue in GSTAl-1 is indicated with a dot. 
Residues highlighted in blue are situated in the G-site, and those highlighted in red in the 
H-site, according to the crystal structure of GSTAI-1 [Sinning et al., 1993]. Adapted 
fro1n Figure 2 in Morel et al., 2002. 
Figure 3.7 - Carbon backbone of the GSTA2 monomer encoding p.Pl 10 overlaid with 
the protein encoding p.S 110. GSTA2 encoding the more common an1ino acid p.Pl 10 
( depicted in black) is coloured grey; GSTA2 encoding the less common amino acid 
p.S 110 ( depicted in red) is coloured blue. Glutathione, shown in gold, is bound in the 
active site. The catalytically essential p.Y9 residue is coloured green. (A). Substitution 
of the labelled p.S 110 residue for the p.Pl 10 residue introduces 1ninor changes to the 
overall structure of the GSTA2 protein. (B). Magnification of residue 110 and 
neighbouring residues showing the different H-bond patterns. H-bonds cormnon to both 
variants are coloured dark blue; those introduced by the substitution of p.S 110 for 
p .P 110 are shown in pink. 
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Figure 3.8 - Carbon backbone of the GSTA2 n1onomer encoding p.S 112 overlaid with 
the protein encoding p.Tl 12. GSTA2 encoding the more common amino acid p.S112 
( depicted in black) is coloured grey; GST A2 encoding the less common amino acid 
p.Tl 12 (depicted in red) is coloured blue. Glutathione, shown in gold, is bound in the 
active site. The catalytically essential p.Y9 residue is coloured green. (A). Substitution 
of the p.S 112 residue for the labelled p.Tl 12 residue does not alter the overall stn1cture 
of the GSTA2 protein. (B). Magnification of residue 112 and neighbouring residues 
showing the different H-bond patterns. H-bonds common to both variants are coloured 
dark blue; those introduced by the substitution of p.Tl 12 for p.S112 are shown in pink. 
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Figure 3.9 - Carbon backbone of the GSTA2 n1ono1ner encoding p.E210 overlaid with 
the protein encoding p.A210. GST A2 encoding the more common amino acid p.E210 
( depicted in black) is coloured grey; GST A2 encoding the less common amino acid 
p.S 110 ( depicted in red) is coloured blue. Glutathione, shown in gold, is bound in the 
active site. The catalytically essential p.Y9 residue is coloured green. (A). Substitution 
of the labelled p.A210 residue for the p.E210 residue does not alter the overall structure 
of the GSTA2 protein. (B). Magnification of residue 210 and neighbouring residues 
showing the different H-bond patterns. H-bonds comn1on to both variants are coloured 
dark blue; the H-bond lost with the substitution of p.A210 for p.E210 is shown in pink. 
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Table 3.8 - Specific activities of recombinant GST A2-2 variants towards various substrates. 
Substrate GSTA2A GSTA2B 
[p.Pl 1 0;S112;E210] [p.Pl 1 0;S112;A21 0] 
µmo I/min/mg 
~
5
-Androsten-3,17-dionea 0.22 ± 0.0075 0.21 ± 0.063 
1-chloro-2,4-dinitrobenzeneb 21.47 ± 2.32 23.00 ± 3.48 
7-chloro-4-nitrobenz-2-oxa-1,3-diazoleb 33.00 ± 2.40 35.36 ± 3.96 
Cumene hydroperoxideb 17.21 ± 1.86 21.72 ± 3.03 
a Results for CDNB, NBD-Cl and Cu OOH are the n1ean ± S .E. for nine determinations. 
b Results for ~5-AD are the mean± S.D. for three determinations. 
GSTA2C 
[p.Pl 10;Tl 12;E210] 
0.16 ± 0.048 
26.69 ± 3.45 
37.73 ± 3.66 
22.76±2.18 
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significant differences in activity for the p.Tl 12 (GSTA2C) and p.A210 (GSTA2B) 
variants as compared to the GST A2A protein. Large, significant differences were seen 
between the p.Sl 10 variant and the GSTA2A protein (Table 3.9) with a ten-fold 
decrease in activity with ~5 -AD (p=0.04), a two-fold decrease with CDNB (p=0.004), 
and a four-fold decrease with CuOOH (p<0.0001). A 6.2-fold increase was observed 
with pNP A (p<0.0001). No significant differences in activity between GSTA2A and 
GST A2E were observed with the substrates DCNB, EA or NBD-Cl. No changes in 
expression levels were observed. 
One point to note is the difference in specific activities measured for GSTA2A shown in 
Tables 3.8 and 3.9. This is due to the fact that the experiment presented in Table 3.8 
was performed at a different ti1ne to that presented in Table 3.9 hence different 
preparations of enzyme and reagents were used. This emphasises that if enzyme 
activities are to be validly compared, the enzymatic assays must be performed at the 
same time and under the same conditions. 
3.3.2.1.3 KINETIC STUDIES 
Due to the large effect the p.Pl l0S polymorphism has on the structure and function of 
the GSTA2A protein, kinetic studies were carried out to determine how this variant 
altered the catalytic efficiency of the GSTA2-2 protein. Kinetic parameters for CDNB 
were 1neasured and Table 3 .10 shows that the catalytic efficiency (KcatlKm) of the 
GST A2E variant is only around 50% of the GSTA2A protein. This difference appears 
to be largely due to the difference in Keat. Unfortunately, although kinetic analyses were 
undertaken using pNP A as a substrate, the kinetic parameters could not be measured 
due to inconsistencies in the assay. 
3.3.2.2 GSTA3-3 
The p.L71I polymorphisn1 in GSTA3-3 is a conservative change - both leucine and 
isoleucine are nonpolar residues of a similar size. It is unlikely that this change will 
Table 3.9 - Specific activities of recombinant GST A2-2 variants towards various substrates. 
Substrate 
Li5-Androsten-3,17-dione 
1-chloro-2,4-dinitrobenzene 
7-chloro-4-nitrobenz-2-oxa-1,3-diazole 
Cumene hydroperoxide 
1,2-dichloro-nitrobenzene 
Ethacrynic Acid 
p-ni trophen ylacetate 
GSTA2A 
[p.Pl 1 O;S112;E21 O] 
µmol/min/mg 
0.20 ± 0.094 
35.14 ± 2.71 
93.27 ± 4.50 
14.72 ± 0.71 
0.14 ± 0.01 
0.048 ± 0.024 
0.14 ± 0.032 
The data represented are the mean± S.D. for three determinations. 
GSTA2E 
[p.S11 O;S112;E21 O] 
0.015 ± 0.0072 
16.82 ± 4.45 
91.17 ± 1.48 
3.61 ± 0.41 
0.15 ± 0.009 
0.065 ± 0.029 
0.87 ± 0.017 
Table 3.10 -Kinetic parameters of recombinant GSTA2-2 proteins with the substrate CDNB. 
Protein Km CDNB KmGSH Keat Kea/Km CDNB Kea/Km GSH 
(mM) (mM) (sec-1) (s-lmM-1) (s-lmM-1) 
GSTA2A 0.65 ± 0.035 0.19 ± 0.040 34.15 ± 2.15 52.34 178.68 
[p.Pl 10;Sl 12;E210] 
GSTA2E 0.45 ± 0.11 0.23 ± 0.064 14.62 ± 1.06 32.43 64.89 
[p.S 11 O;S 112;E21 OJ 
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affect the structure or the function of the GSTA3-3 protein, as it is not situated in either 
the G-site or H-site of the protein (Figure 3.6). This alteration was unable to be 
characterised enzymatically, as the transcript of GSTA3-3 missing exon 3 ( 667 bp ), a 
known alternative transcript, was initially cloned, and the full-length transcript (719 bp) 
that was subsequently cloned could not be expressed. Difficulties expressing GSTA3-3, 
especially at high levels, has been previously reported [Johansson & Mannervik, 2002]. 
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3.4 DISCUSSION 
The Alpha class GSTs are involved in a diverse range of roles including steroid 
biosynthesis and providing protection against alkylating agents and the products of lipid 
peroxidation. Functional polymorphisms in the GST Alpha class genes can therefore be 
expected to have wide-ranging physiological consequences, altering susceptibility to 
disease and drug response. Discovery of novel polymorphisms in these genes will 
expand our understanding of the underlying mechanisms governing the roles these 
genes play. 
The use of database-mining programs such as the BLAST alignment tool to search the 
EST database and the SNP Finder program to search UniGene clusters enabled 
detection of polymorphisms in the GSTAJ and GSTA2 genes (Table 3.1). Lack of 
variation detected in the GSTA3 and GSTA4 genes may reflect a true absence of 
polymorphisn1, or be due to poor representation of cDNA sequences encoding these 
genes in the two respective databases. This was particularly relevant to the GSTA3 
gene, which was represented by a mere 20 cDNAs in the EST database and eight in the 
UniGene cluster, as opposed to the 136 (EST) and 99 (UniGene) cDNAs for GSTAJ, 
and 46 (EST) and 33 (UniGene) cDNAs for GSTA2. Low representation is generally 
attributed to genes that are neither highly expressed nor found in multiple tissues. This 
is likely to explain the low representation of GSTA3 in the EST database since it is only 
expressed in a limited number of tissues ( adrenal gland, ovary, placenta and testis) 
[Johansson & Mannervik, 2001a]. In contrast, GSTAl-1 and GSTA2-2 are highly 
expressed in the liver, and at lower levels in a series of other tissues [Strange et al., 
1984; Rowe et al., 1997]. Si1nilarly, although GSTA4-4 was represented by 95 cDNAs 
in the EST database and is widely expressed [Desmots et al., 2001; Morel et al., 2002], 
only eight to 16 partial cDNAs covered a particular section of the coding region, and 
only one cDNA was found in the UniGene cluster. The likelihood of detecting 
polyn1orphisn1s in these sequence databases increases if the gene of interest is 
represented by a greater nun1ber of full-length cDNA sequences from different cDNA 
libraries generated from a diverse pool of sources. The continual expansion of these 
sequence databases will enable the detection of more polymorphic variants in genes that 
are not currently well represented. 
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Databases dedicated to the collection of SNPs spanning the entire gene sequence from 
the 5' UTR through to the 3' UTR and derived from numerous sources were also 
analysed for GST Alpha gene submissions. Again, there was a distinct lack of coding 
region variants detected in the GSTA3 and GSTA4 genes (Table 3.2). GSTA3 was not 
well represented in these databases, although non-coding region polymorphisms were 
present in all but EGPSNPs, the CGAP lists and HGBASE (data not presented). GSTA4 
was better represented and was found in all but the EGPSNPs database, although again, 
1nost of the submitted information pertained to the non-coding regions ( data not 
presented). This implies that perhaps these two genes are not highly polymorphic. 
However, this is not entirely true as two polymorphisms in the GSTA 4 gene, not 
detected by any method used in this study, were detected by independent groups 
[Latsoudis et al., 2000; Iida et al., 2001]. It is likely that as more sequencing 
information is gathered, a greater number of polymorphisms will be detected in these 
genes. 
Unlike the BLAST alignment tool and the SNP Finder programs that were used to 
search different sequence databases, whereby it was possible to verify polymorphisms 
by resequencing cDNA clones or by accessing the available sequence trace data, the 
polyinorphisms submitted to the SNP databases cannot be easily confirmed, as the 
information is generally obtained through sequencing genomic DNA from anonymous 
groups of individuals. In some instances, such as when viewing CGAP submissions and 
some refseq data, access to electropherograms is provided through the SNP Finder 
program. Other databases, such as the GeneSNPs and EGPSNPs, have determined 
frequency data for so1ne polymorphisms. Although the SNP databases generally try to 
confirm the validity of the polymorphisms in multiple individuals and/or multiple 
reactions through resequencing efforts, the simplest way to determine the validity of 
these listings for the purpose of this thesis was to perform small-scale population 
screens, although this probably limits the number of polymorphisms confirmed to those 
that are common. To counter the possibility that some polymorphisms may occur 
specifically in particular ethnic groups, the small-scale screening included 
representatives from the world's major ethnic subgroups. 
A particular proble1n encountered when searching these databases, and when using 
UniGene clusters, is that sequence data from multiple isoforms is often confused and 
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therefore submitted as one gene, giving incorrect estimations of the number of 
polymorphis1ns present in that particular gene. This was highlighted by the fact that 
GSTAJ, one of the major liver detoxification enzymes, was only found in the GeneSNPs 
database. Further investigation revealed that GSTAJ sequences had in fact been 
submitted to various databases however, these had been catalogued as GSTA2 
sequences. Hence the alignment of these apparently homogenous GSTA2 submissions 
with the GSTA2 cDNA sequence gave the impression that there were many GSTA2 
polymorphisms, when in reality these "polymorphisms" represented the nucleotide 
differences distinguishing GSTAJ from GSTA2. This confusion of genes is common, 
and as the incorrect information is presented, the need to be aware of sequence 
similarity within members of multi-gene families must be emphasised. 
Despite the problems inherent with SNP detection methods, as discussed above, each 
was able to detect variants not identified by the other methods. Five variants that 
altered amino acid residues were identified and verified by re-sequencing in the GSTAJ 
and GSTA2 genes using the BLAST alignment tool and SNP Finder programs (Table 
3.1), and seven novel coding region variants were detected in all four GST Alpha genes 
in the SNP databases (Table 3.2). Of these, only five out of the 12 possible variants 
were verified and found in the Australian European, Bantu African, Creole African and 
Southern Chinese populations. With regard to the Kl 96N GSTA2 variant however, the 
alteration was found at the end of a repetitive string of bases, implying it is probably a 
sequencing e1Tor. Usually, this would have been filtered out, but analysis was continued 
as this variation was identified in two I.M.A.G.E. Consortium (LLNL) cDNA clones. It 
is possible that the remaining seven variants represent rare alleles. Alternatively, as the 
ethnic origin of the cDNA in the EST and UniGene databases is unknown, there is a 
possibility that these variants may be associated with particular ethnic groups. The 
latter option provides the most likely explanation as to why the p.A90V and p.Vl49A 
GSTA2 variants were not confirmed in the population studies presented here. These 
polymorphisms were found in the GeneSNPs ( associated with UUGC) and EGPSNPs 
( associated with UWGC) databases, both of which contribute to the Environmental 
Gene Project. It is highly probable that SNPs detected by both centres are real, as these 
are initially discovered whilst resequencing genes of relevance to the project. Any 
SNJ>s so identified are further confirmed in a PDR cohort, which contains European 
American, African American, Mexican-American, Native American and Asian 
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American samples. GeneSNPs calculated a heterozygote frequency of 0.01 % for the 
p.A90V variant, and EGPSNPs found that the p.V149A variant was quite conunon 
(T=Sl.91 %, C=18.09%; T/T=30, C/T=l 7). It is possible that the p.A90V and p.V149A 
GSTA2 variants have evolved in the Americas, which is why they were not observed in 
the ethnic groups studied here. 
Of the four n1issense polymorphis1ns that were identified and confirmed in this study, 
both the GSTA2 p.Tl 12S and p.E210A polymorphisms have previously been noted as 
sequence discrepancies [Hayes et al., 1989; Rohrdanz et al., 1992], however allele 
frequencies and functional characteristics of these polymorphisms had not been 
investigated. The p.Tl 12 variant of the p.Tl 12S polymorphism was found to be 
relatively rare and only found in the heterozygous state in the Australian European and 
two African populations, although this allele was noticeably more frequent in the Bantu 
African population. In contrast, the p.E21 0A polymorphism was quite common. The 
p.A210 allele was represented in all ethnic groups studied, ranging from a modest 8% in 
the Australian European population to 42% in the Bantu African population. Allele 
distributions calculated by EGPSNPS found a similar distribution in their American 
populations (E=70.51%, A=29.49%; A/A=19, A/C=17, C/C=3) to that found in the 
Creole African population studied here (Table 3.7). Despite the good representation of 
the p.A210 variant in all populations studied here, this was never seen in combination 
with the p.Tl 12 variant, consistent with observations reported by Coles and colleagues 
[2000]. 
The GST A2 p.P 11 OS polymorphisn1, previously identified by mass spectrometry, was 
also not subjected to further investigations [Wang et al., 2000]. This was originally 
found in six out of 63 pancreas samples [Wang et al., 2000], and in keeping with this 
reasonably rare occurrence in the pancreas, the p.S 110 variant was found to be 
relatively uncormnon in the four populations studied here, especially in the Bantu 
African population in which only two heterozygous individuals were identified, a 
finding similar to that calculated by EGPSNPs in the American populations (C=97.83 %, 
T=2.17%; C/C=44, C/T=2) . The p.S 110 allele was better represented in the Creole 
African and Southern Chinese populations, in which a total of four homozygous 
ind_ividuals were detected. It appears that this relatively rare p.S 110 variant is only 
observed in con1bination with the collli11on p.Sl 12 and p.E210 variants. 
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Genotyping results for the fourth missense polymorphism discovered in this study, the 
novel GSTA3-3 p.L71I polymorphism, revealed that the p.L71 variant was absent in all 
populations tested except the two African populations, in which it is found at a modest 
frequency of 5%-15%. This polymorphism was also discovered during the recent 
characterisation of the GSTA3 gene, along with two alternative transcripts [Johansson & 
Mannervik, 2001 a]. The alternative transcript missing exon 3 was cloned during the 
present study, preventing characterisation and comparison of each variant. In light of 
the role GSTA3-3 plays in progesterone and testosterone biosynthesis pathway 
[Johansson & Mannervik, 2001a], cloning of the full-length cDNA is being continued in 
order to determine the effect this polymorphism has on the GSTA3-3 protein and hence 
how it may affect steroid biosynthesis. However, as both isoleucine and leucine have 
similar properties, and residue 71 is located in neither of the active sites of the protein, it 
is unlikely that this will have any functional consequences. 
Recombinant proteins encoding the three GSTA2 missense polymorphisms detected in 
this study were subsequently tested for evidence of functional and structural alterations. 
In keeping with the predictions based on 3-D modelling, which demonstrated a lack of 
local and global conformational changes, no significant alteration in activity towards 
four typical alpha class substrates was observed when the recombinant GST A2A 
[p.Pl lO;Sl 12;E210], GSTA2B [p.Pl lO;Sl 12;A210] and GSTA2C [p.Pl lO;Tl 12;E210] 
proteins were tested. Although residue 210 is located at the beginning of the flexible C-
tern1inal a-9 helix (residues 210 to 220) that forms a cap over the active site [Sinning et 
al., 1993] (Figure 3.5), the external orientation of the residues in this position suggest 
that they may have little influence upon function. Hence at this stage there is little 
evidence that the observed differences in allele and haplotype frequencies regarding 
these three alleles are directly due to functional effects. 
In contrast, significant alterations in the specific activity of the GSTA2E variant 
[p.S 11 O;S l 12;E2 l OJ towards several substrates were measured. The specific activity of 
the GST A2E isoform was generally lower than that of the GST A2A enzyme, yet an 
increase in specific activity was seen towards pNP A (Table 3 .9). Significant changes 
can be expected, considering that p.Pl 10 is located at the C-terminus of the a4 helix 
(Figure 3.5), which along with the N-tenninal loop and a9 helix contributes to the 
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Alpha active site [Sinning et al. , 1993]. Praline residues, which are hydrophobic, 
contribute to the structural rigidity of a protein. Hence substitution of a praline in the 
active site by a hydrophilic serine residue can be expected to both reduce the rigidity of, 
and alter the topography of the active site. In support of the observed enzymatic 
changes, predictive 1nodelling demonstrated that this polymorphism caused minor 
changes to the overall protein structure. In addition, one new H-bond to residues 
neighbouring those involved in GSH or substrate binding were created upon the 
substitution of p.S110 for p.Pl 10 (Figure 3.7B). It can be envisaged that these 
combined effects could increase the flexibility of the active site, and through the ability 
of serine to form H-bonds with surrounding residues and incoming substrates, also 
increase the hydrophilicity of the active site. These effects could lower the affinity of 
the GSTA2E protein for hydrophobic substrates, alter the progress of substrates into the 
active site or even alter the optimal fit of a substrate in the active site through 
differences in electrostatic interactions or steric hindrance, all of which could potentially 
alter the enzyines catalytic abilities. 
The reduced affinity of the GSTA2E protein for hydrophobic substrates was 
den1onstrated not only by the decreased specific activities seen for the hydrophobic 
substrates CDNB, /15-AD and CuOOH, but further shown by the decreased catalytic 
efficiency (Kcat!Krn) of GSTA2E for CDNB and GSH, largely brought about by a 2.3-
fold reduction in Keat compared to GST A2A. This may reflect perturbations in product 
release, or in the ability of the molecule to allow substrates in and products out. Kinetic 
data measured for GST A2A was comparable to that measured by Zhao and colleagues 
[ 1999]. Although kinetic parameters were not measured for /15 -AD and Cu OOH due to 
time constraints, it is likely that the decreased specific activities observed are also due to 
inefficient binding. In contrast, the introduction of a serine residue enhanced the 
activity of GST A2-2 for pNP A, possibly due to the greater flexibility of the active site 
allowing the substrate better and faster access, or the ability of serine to act as a strong 
nucleophile upon this polar substrate. Unfortunately the mechanism behind the 
increased specific activity of the GST A2E enzyn1e for the pNP A substrate could not be 
tested accurately in this study, for although kinetic experiments were undertaken, the 
results obtained were inconsistent. No change in specific activity was observed with the 
hydrophilic substrates EA or NBD-Cl. 
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Considering the high peroxidase activity possessed by the GSTA2-2 family [Stockman 
et al., 1987; Chow et al. , 1988; Zhao et al., 1999] and the five-fold reduction in specific 
activity observed here with the GST A2E variant towards CuOOH, it is possible that an 
increased susceptibility to disease associated with oxidative stress may be observed in 
individuals expressing this isoform, perhaps even at a younger age. Disease is most 
likely to be manifested in tissues in which the variant GST A2-2 is expressed, namely 
the liver. The liver is a prime target, both because GST A2-2 is one of the major liver 
proteins [Strange et al., 1984; Rowe et al., 1997] and it is at an increased risk, in 
comparison to other organs, of suffering oxidative stress due to the large number of 
ROS generated during drug and xenobiotic metabolism [Zhao et al., 1999]. 
Approximately one fifth of each population studied, except the Bantu African 
population, was heterozygous for the p.S 110 variant. So, although the effect of this 
polymorphism in these individuals would be dampened by the high activity p.Pl 10 
allele, increased susceptibility to the products of oxidative stress could still be observed. 
It is unlikely that this polymorphism will have a direct causal link to any particular 
disease, especially as disease caused by oxidative stress is complex, involves 
interactions between many genes, and may also be influenced by an individual's 
environment and lifestyle. In addition, polymorphisms already characterised in the GST 
genes have been shown to exert only a relatively weak influence on phenotype [Hayes 
& Strange, 2000; Strange et al., 2000]. In order to better determine the exact role this 
polymorphis1n n1ay have on diseases related to oxidative stress, particularly hepatic 
diseases, patient groups representing these different diseases should be screened. Ten of 
the 19 Australian European individuals heterozygous for the p.S 110 allele did not 
express the GSTMJ gene ( data not presented), another major liver protein [Rowe et al. , 
1997]. As the Alpha class GSTs are by default the major liver GSTs in GSTMJ *0 
individuals, it may be of interest to determine whether any associations can be made 
between the GSTA2-2 p.S110 variant and the GSTMJ *0 allele. 
The decreased peroxidase activity exhibited by the GST A2E protein may also extend to 
the prostaglandin endoperoxidase conversion pathway, in which GSTA2-2 uses its GPx-
II activity to catalyse the reduction and isomerisation of the prostaglandin PGH2 to 
PGD2 and to a lesser extent, PGF2a [Burgess et al., 1989]. A decrease in peroxidase 
Chapter 3 Discussion 74 
activity could potentially interfere with PGD2 and PGF2a synthesis and function . PGD2, 
a major prostaglandin in the central nervous system [Ogorochi et al. , 1984] , is believed 
to have neuromodulator or neurotransmitter properties with involvement in the 
induction of hypothermia [Ueno et al. , 1982] and sleep [Hayaishi, 1988]. PGF2a blocks 
adipogenesis through the activation of mitogen activated protein kinase hence is 
believed to play a role in the prevention of obesity and diabetes [Reginato et al. , 1998]. 
Yet as other pathways exist for the synthesis of these prostaglandins [Burgess et al. , 
1989; Kanaoka et al., 1997] , the p.S110 variant is not likely to have a profound effect 
on PGD2 or PGF2a related functions. 
The Alpha class GSTs have a protective role in detoxification of alkylating anti-
neoplastic drugs, in particular the nitrogen mustard drugs. However, there is growing 
evidence that over-expression of the Alpha class GSTs is involved in the development 
of resistance to these drugs in tumour cells [Lewis et al., 1988; Hayes & Wolf, 1990; 
Tsuchida & Sato, 1992; Tew, 1994]. GSTA2-2 has been implicated in resistance to 
chlorambucil [Lewis et al. , 1988; Ciaccio et al., 1991; Meyer et al., 1992], the 
alkylating agent used in treating Hodgkin's and non-Hodgkin's lymphoma, chronic 
lymphocytic leukemia and ovarian cancer [Meyer et al. , 1992]. It is possible that the 
p.S 110 variant may alter resistance to these hydrophobic drugs, as point mutations are 
one of many ways known to alter drug resistance [Hayes & Wolf, 1990]. 
When considering the multitude of effects polymorphisms may have on protein 
function, it is extremely important to take interindividual variation of protein expression 
into account. Various studies have demonstrated marked interindividual and gender 
variation of GSTAl-1 and GST A2-2 expression, both within tissues and between 
tissues [Hayes et al. , 1989, Singhal et al. 1993, Mulder et al., 1999; Coles et al. , 2000; 
Coles et al. , 2002]. It has been suggested that the variation in enzyme activity caused 
by this variation 1nay in fact be greater than that caused by genetic polymorphisms 
[Coles et al. , 2000]. The recent discovery that GSTA2-2 expression is regulated by 
allelism in the GSTAJ promoter [Coles et al., 2001a] should also be considered, as it is 
possible that the effect of the p.S 110 variant may be modulated to some degree by the 
GSTAJ genotype. 
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Using a combination of database-mining methods, a moderate level of genetic 
polymorphism was identified in the human Alpha class GST genes. Although each 
method yielded results, this study has shown that identification of polymorphism should 
not be limited to one method or technique, especially since some genes are not as well 
represented as others in the various databases. Of the four missense polymorphisms 
verified in three ethnic populations: the p.Pl l0S, p.Tl 12S and p.E210A GSTA2 
polymorphisms and the p.L 711 GSTA3 polymorphism, functional and structural 
differences were observed in only one, the GSTA2 p.Pl l0S variant. Further 
characterisation is required to determine the physiological effects. 
CHAPTER4 
THE Mu CLASS GSTs 
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4.1 INTRODUCTION 
The Mu class GSTs represents another diverse family of GSTs, possessing five isoforms 
with wide ranging functions . The Mu class GSTs are involved in the detoxification of 
epoxides, as well as prostaglandin synthesis and peroxidation of the oxidation products 
of the catecholamines cyclic o-quinones. Polymorphism ~ · ·_ · .. _; :' ·-: , .. __ t ""·, -' was 
first suggestedin the Mu class genes when it was noticed that GSTµ (now known as 
GSTMJ), which is highly expressed in the hu1nan liver, was not detected in some 
individuals [Warhohn et al., 1980]. Further studies showed that this absence of 
expression was due to a null allele (GSTMJ *0) [Board, 1981a; Strange et al. , 1984] , 
caused by deletion of the GSTMJ gene [Seidegard et al., 1988; Xu et al., 1998b]. This 
finding prompted interest in the detection and identification of other GST Mu class 
polymorphisms that may impact upon the detoxification abilities of these proteins. 
Of the five GST Mu enzyines, GSTMl-1 shows the highest affinity for detoxifying 
epoxide 1netabolites such as styrene 7,8-oxide, trans stilbene-oxide and AFB 1 exo-8 ,9-
epoxide [Warholm et al., 1983; Hayes & Pulford, 1995; Johnson et al., 1997], which are 
generated by the breakdown of P AHs and aflatoxin B 1 by Phase I enzymes. These 
mutagenic and oncogenic compounds are found in products of combustion, such as 
cigarette smoke, car exhaust fu1nes and burnt or mouldy foods. As mentioned above, 
the first Mu class polyinorphis1n identified was the GSTMJ *0 allele. The frequency of 
this null allele varies considerably between populations, ranging from 21 %-30% in 
Chilean and son1e African populations [Zhao et al., 1994; Mukanganyama et al., 1997; 
Masimiren1bwa et al. , 1998; Quinones et al., 1999; Johansson & Mannervik, 2001b] , to 
50% in the Caucasian population [Board, 1981a; Strange et al., 1984; Seidegard et al. , 
1988] and 100% of the Micronesian population [Board et al., 1990]. In 1986 the 
proposal that GSTMJ *0 individuals were unable to metabolise epoxides [Board, 1981 b; 
Warholn1 et al, 1983] was confirmed when an association between smokers 
homozygous for the GSTMJ *0 allele and an increased risk for lung cancer due to higher 
levels of P AH-adducts was repo1ied [Seidegard et al. , 1986; Shields et al., 1993]. A 
large nun1ber of studies have since tried to link the GSTMJ *0 allele, either singly or in 
co1nbination with other alleles such as the GSTP 1 V105 and CYP JAJ alleles [Hayashi et 
al., 1992; Ryberg et al. , 1997] , to a significant increase in susceptibility to disease 
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caused by epoxide exposure. Studies have concentrated especially on smoking related 
cancers such as lung and bladder cancers [Bell et al., 1992; Ryberg et al., 1994; Tang et 
al., 1998; Salagovic et al., 1999; Johns & Roulston, 2000; Aktas et al., 2001; Engel et 
al., 2002] in addition to stomach and colon cancers [Strange et al., 1991; Zhong et al., 
1993b], with conflicting conclusions [Seidegard et al., 1990; Zhong et al., 1991; Daly et 
al., 1993; Hirvonen et al., 1993; Brockmoller et al., 1998; Ge1iig et al., 1998; Roulston, 
1999; Welfare et al., 1999; Benhamou et al., 2002]. 
Paradoxically, the GSTMJ *0 allele has also been shown to confer protective effects. A 
two- to three-fold increase in relapse-free survival has been observed in children 
diagnosed with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) 
carrying the GSTMJ *0 allele [Hall et al., 1994; Chen et al., 1997; Davies et al., 2000; 
Stanulla et al., 2000]. However, a direct association between GSTMJ and other 
prognostic features of ALL has not been demonstrated [Chen et al., 1997; Anderer et 
al., 2000]. Also, protection against colorectal adenomas in GSTMJ *0 individuals by 
anti-carcinogenic isothiocyanates found in cruciferous vegetables has been recorded 
[Lin et al., 1998]. 
In contrast to those individuals lacking a functional GSTMJ gene, two Saudi Arabians 
have been discovered with a duplication of the GSTMJ gene, which possesses ultra-
rapid enzyme activity and thus enables rapid xenobiotic detoxification [McLellan et al., 
1997]. In addition, two functionally identical GSTMJ alleles have been described: 
GSTMJ *A and GSTMJ *B. Although these differ by one amino acid, with GSTMJ *A 
encoding a lysine at residue 173 [DeJong et al., 1988] and GSTMJ *B an asparagine 
[Seidegard et al., 1988] and there is a charge change, they are functionally identical and 
are able to form active heterodimers with each other [Widersten et al., 1991]. 
In addition to epoxide metabolism, GSTMJ and GSTM2 possess highly efficient 
peroxidase activity towards the cyclic o-quinones: aminochrome, dopachrome, 
noradrenochrome (GSTM2) and adrenochrome (GSTMJ) [Baez et al., 1997]. These 
GST Mu substrates are fanned during the oxidation of the catecholamines dopamine, 
dopa, noradrenaline, and adrenaline respectively in a process that generates excessive 
numbers of ROS through redox cycling. This can lead to oxidative stress, toxicity, 
apoptosis and ultimately neurodegeneration and is believed to be involved in the 
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aetiology of Parkinson's Disease (PD) [Baez et al., 1995]. This neurological disorder is 
characterised by the degeneration of dopaminergic neurons in the pars compacta of the 
substantia nigra of the human brain, a region found to express both GSTMl-1 and 
GSTM2-2 [Baez et al., 1997; Ahmadi et al., 2000]. Conjugation of dopamine and dopa 
to GSH, catalysed by GSTM2-2, has been shown to prevent the formation of their 
respective cyclic o-quinones and subsequent redox cycling [Dagnino-Subiabre et al., 
2000]. It has therefore been suggested that GSTMl-1 and GSTM2-2 may possess a 
neuroprotective role [Baez et al., 1997]. Although no association has been made 
between PD and the GSTMJ *0 allele [Stroombergen & Waring, 1999; Ahmadi et al., 
2000; Harada et al., 2001], the onset of PD was prolonged in patients with a viable 
GSTMJ gene [Ahmadi et al., 2000] and males with the GSTMJ *0 allele who had been 
exposed to various toxins were discovered to be more susceptible to PD [Stroombergen 
& Waring, 1999]. To date, the only GSTM2 polymorphism known is a silent mutation 
involving asparagine at residue 74 [Vorachek et al., 1991; Ross & Board, 1993]. 
Considering that GSTM2-2 is one of the more highly expressed Mu class GS Ts in the 
brain [Rowe et al., 1997], it can be postulated that other GSTM2 polymorphisms 
resulting in functional change could influence the aetiology of PD. 
GSTM3-3 and GSTM2-2 have been shown to possess cytosolic prostaglandin E 
synthase activity [Ogorochi et al., 1987; Beuckmann et al., 2000]. Employing this 
activity both enzymes are believed to be involved in the GSH-dependent isomerisation 
of PGH2 to PGE2 in the brain. PGE2 is responsible for mediating several 
neurophysiological roles in the central and peripheral nervous systems. As both 
GSTM2-2 and GSTM3-3 are the most highly expressed Mu class GSTs in the brain 
[Rowe et al., 1997], polymorphis1n in the GSTM3 or GSTM2 genes may disrupt these 
functions. Three polymorphisms have been identified in the GSTM3 gene, however two 
ren1ain uncharacterised: the glycine to tryptophan substitution at residue 147, believed 
to have no functional effect [Pearson et al., 1993; Ross & Board, 1993], and the valine 
to isoleucine substitution at residue 224 [Emahazion et al., 1999; Iida et al., 2001]. A 
third polyinorphism consisting of two alleles, GSTM3 *A and GSTM3 *B, 1s 
distinguished by a three base pair deletion in intron 6 [Inskip et al., 1995]. GSTM3*B 
has been associated with altered expression levels of GSTM3-3 due to the presence of a 
negative transcription factor YYl (yin yang 1) recognition motif in GSTM3 * B created 
by the deletion of these three bases. YYl is able to intragenically regulate gene 
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expression through activation or repression of transcription [Hariharan et al., 1991; Shi 
et al., 1991]. A significant association has been found between the GSTM3*B and 
GSTMJ *A alleles, and it is believed that susceptibility to different diseases may be 
determined by the combined epistatic effects of the different GSTM 1 and GSTM3 alleles 
[Inskip et al., 199 5; Y engi et al., 1996]. Various studies have since tried to associate 
interactions between GSTMJ alleles and expression of GSTM3-3 with different cancers 
and have generally found that the GSTM3*B*B genotype in combination with the 
GSTMJ gene has a protective effect. A decreased risk to multiple basal cell carcinoma 
[Yengi et al., 1996], laryngeal squamous cell carcinoma and other upper aerodigestive 
tract cancers has been observed in Caucasians expressing the GSTMJ *A or GSTMJ *B 
and GSTM3 *B alleles [Jahnke et al., 1996; Matthias et al., 1998]. However, there is 
conflicting evidence of the role the GSTM3 alleles play in oral cancers [Jourenkova-
Mironova et al., 1999a; J ourenkova-Mironova et al., 1999b] and ethnic differences have 
been observed [Worrall et al., 1998; Park et al., 2000]. 
Polymorphis1n has also been recorded in the GSTM4 and .GSTM5 genes. The GSTM4-4 
isoenzyine has extre1nely low activity with the typical range of GST Mu substrates and 
a specific substrate has not been found, although a weak correlation between GSTM4-4 
and PGF synthase has been 1nade [Beuckmann et al., 2000]. A silent polymorphism 
involving phenylalanine at residue 178 has been recognised [Comstock et al., 1993; 
Pearson et al., 1993; Ross & Board, 1993; Zhong et al., 1993a] and analysis of the 
literature has revealed the presence of an unrecognised and uncharacterised V212M 
polyinorphism [Comstock et al., 1993; Ross & Board, 1993; Zhong et al., 1993a]. In 
addition, two alternatively spliced GSTM4-4 transcripts have been identified, and both 
are believed to encode catalytically non-functional proteins [Ross & Board, 1993]. One 
transcript is distinguished by an 82 bp deletion, which abolishes exon 4 and leads to a 
pre1nature stop codon 36 amino acids downstream. In the second transcript exon 8 is 
1nissing. Instead, intronic sequence is read through from the end of exon 7, creating an 
additional six codons and an inframe stop codon. Relatively little has been reported 
about GSTM5, although an uncharacterised HindIII polymorphism has been detected 
[DeJong et al., 1991; Pearson et al., 1993]. 
This chapter describes the use of various database mining techniques to facilitate the 
discovery of novel Mu class polymorphisms. The distribution of the confirmed 
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polymorphisms was determined in three ethnic populations and the recombinant 
proteins were characterised enzymatically to determine whether the function or the 
structure of the protein was altered by the introduction of the polymorphism. 
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4.2 MATERIALS AND METHODS 
Database analysis and standard PCR and recombinant methods used in this chapter are 
described in Chapter 2. Techniques unique to this chapter are outlined below. 
4.2.1 DATABASE SCREENING 
Potential polyinorphisn1s in the five Mu class GSTs were identified and verified using 
the database mining n1ethods described in §2.3, and are listed in Tables 4.1 and 4.2. 
4.2.2 PCR/RFLP ANALYSIS 
Small-scale population studies were performed by specifically amplifying potentially 
polymorphic exons of the GSTMJ-GSTM5 genes from genomic DNA using PCR as 
described in §2.5.6.2. Oligonucleotides and conditions specific for each PCR are 
detailed in Table 4.3. The presence of candidate polymorphisms in the PCR products 
was determined by RFLP analysis (§2.5.4.2) using the appropriate restriction enzymes 
(Table 4.4). Two of the variants tested altered restriction endonuclease sites. For the 
re1naining variants, primers were designed containing a partial restriction endonuclease 
site, which was co1npleted by either the absence or the presence of the variant base 
[Kangsadalan1pai et al., 1998]. Up to 100 samples from the Australian European, Bantu 
African, Creole African and Southern Chinese population groups were amplified by 
PCR, to allow allele and haplotype frequency determination for polymorphisms 
confinned by the small-scale population screens. 
Table 4.1 - GST Mu variants detected in the EST database by the BLAST aligmnent tool and in the Uni Gene database by the 
SNP Finder program. 
Gene Nucleotide Residue Exon Program ESTs with cDNA libraries Sequence Confirmed in 
alterations represented Confirmeda,b population studies 
GSTMJ c.518C>G p.Nl 73Kc 7 BLAST 8 5 Yes-AA227608 Yes 
c.527C>T p.D176D 7 BLAST 7 4 Yes-AA227608 Yes 
GSTM2 c.222T>C p.N74Nd 4 BLAST 6 5 N.S. N.S. 
c.226A>G p.E89G 5 SNP Finder 1 1 Yes-0.05 No 
( 
c.614C>A p.P205Q 7 SNP Finder 2 2 No-0.01 N.S. 
c.628A>T p.T210S 8 SNP Finder 7 5 Yes-0.44 N.S. 
GSTM3 c.371A>C p.H124P 5 SNP Finder 3 3 No-0.02 N.S. 
c.384G>C p.K128N 6 SNP Finder 1 1 Yes-0.44 No 
c.439T>G p.W147Gd 6 BLAST 40 21 N.S. Yes 
c.549A>G p.Pl83P 7 SNP Finder 2 1 Yes-0.66 N.S. 
c.572G>T p.R191L 7 SNP Finder 1 1 Yes-0.83 No 
c.670G>A p.V224I 8 BLAST 13 8 Yes-AI870867 Yes 
c.670A>G p.I224V 8 SNP Finder 18 13 Yes-1.0 
GSTM4 c.165A>G p.L55Ld 3 BLAST 7 5 N.S. N.S. 
GSTM5 c.103A>C p.M35Ld 2 BLAST 7 5 N.S. No 
a The cDNA clones sequenced to confirm the presence of potential polymorphisms identified using the BLAST alignment are identified. 
b Polymorphisms detected using the SNPfinder program are allocated a likelihood score. As the number approaches 1.0, there is a greater 
likelihood that this polyinorphism will be real. Sequences were confinned by viewing the electopherogra1ns made available at the site. 
c This is the known GSTMJ *A to GSTMJ *B polymorphism [De Jong et al., 1988; Seidegard et al., 1988]. 
ct These polyinorphisms were detected as sequence discrepancies i.e. the BLAST query sequence was the only sequence with the original 
residue. However, evidence of the GSTM2 p.N74N and GSTM3 p.Wl47G polymorphisms are present in the literature: the GSTM2 clone of 
Ross & Board [1993] had the c.222C variation, and that of Vorachek et al. [1991] the c.222T variation; the GSTM3 clone of Pearson et al. 
[1993] had the c.439G variation and that of Cainpbell et al. [1990] the c.439T variation. The GSTM5 p.M35L polymorphis1n was later studied 
in sn1all-scale population studies. 
N.S.: Not studied 
G e n e  N u c l e o t i d e  R e s i d u e  
G S T M J  
c . 8 4 T > C  p . Y 2 8 Y  
c . 3 0 6 C > T  p . N l 0 2 N  
c . 5 1 9 C > G  p . N l  7 3 K
6  
c . 5 2 8 C > T  
p . D l  7 6 D
6  
c . 5 6 2 T > A  p . F l  8 8 1  
c . 6 2 8 T > A  
p . S 2 1 0 T c  
G S T M 2  
c . 1 2 0 T > C  p . D 4 0 D  
c . 2 2 3 T > C  
p . N 7 4 N
6  
c . 3 5 7 T > A  
p . D l  1 9 E  
c . 3 7 2 A > G  
p . K l 2 4 K  
c . 3 8 2 T > C  
p . L l 2 8 L  
c . 3 8 5 C > G  
p . Q l 2 9 E  
c . 3 8 9 C > A  
p . A l 3 0 E  
c . 4 0 1  T > A  
p . M l 3 4 K  
c . 4 0 5 G > A  
p . L l 3 5 L  
c . 5 5 9 C > G  
p . R l 8 7 G  
c . 6 2 8 A > T  
p . T 2 1 0 S b , c  
G S T M 3  c . 2 2 2 C > A  p . I 7 4 I  
c . 3 7 1 A > C  p . H l 2 4 P
6  
T a b l e  4 . 2  - G S T  M u  p o l y i n o r p h i s n 1 s  d e t e c t e d  i n  t h e  S N P  d a t a b a s e s .  
E x o n  
D a t a b a s e  
2  d b S N P ,  r e f  s e q ,  G e n e S N P s ,  S N P p e r  
5  
r e f s e q  
7  
f  
C G A P V  ( 0 . 3 8 ) ,  d b S N P ,  S N P p e r  
7  
f  
C G A P V  ( 0 . 9 9 ) ,  d b S N P ,  G e n e S N P s ,  S N P p e r  
7  
f C G A P V  ( 0 . 1 1 )  
8  
f  
C G A P V  ( 0 . 9 9 ) ,  d b S N P ,  r e f s e q ,  G e n e S N P s ,  H G B A S E  
3  d b S N P ,  r e f  s e q ,  S N P p e r  
4  
d b S N P ,  r e f  s e q ,  G e n e S N P s ,  E G P S N P s ,  S N P p e r  
5  r e f s e q  
6  r e f s e q  
6  
r e f s e q ,  G e n e S N P s  
6  r e f s e q ,  G e n e S N P s  
6  d b S N P ,  r e f  s e q ,  G e n e S N P s  
6  
d b S N P ,  r e f  s e q ,  G e n e S N P s  
6  
d b S N P ,  r e f  s e q ,  G e n e S N P s  
7  
r e f s e q  
8  
d b S N P ,  r e f s e q ,  G e n e S N P s ,  E G P S N P s ,  H G B A S E  
4  H G B A S E  
5  C G A P V  ( 0 . 0 2 )  
A b l e  t o  
C o n f i r m a  
U n a b l e  
U n a b l e  
Y e s  
Y e s  
Y e s  
Y e s  
U n a b l e  
U n a b l e  
U n a b l e  
U n a b l e  
U n a b l e  
U n a b l e  
U n a b l e  
U n a b l e  
U n a b l e  
U n a b l e  
U n a b l e  
U n a b l e  
U n a b l e  
C o n f i r m e d  i n  
p o p u l a t i o n  s t u d i e s  
N . S .  
N . S .  
Y e s  
Y e s  
N o  
N . S .  
N . S .  
N . S .  
N o  
N . S .  
N . S .  
N o  
N o  
N o  
N . S .  
N o  
N . S .  
N . S .  
N . S .  
c.384G>C p.K128Nb 6 CGAPV (0.44), refseq, HGBASE Yes No 
c.384G>T p.K128N 6 CGAPV (0.44) No N.S. 
c.549A>G p.P183Pb 7 CGAPV (0.66), dbSNP, HGBASE Yes N.S. 
c.572G>T p.R191Lb 7 CGAPV (0.83), refseq, HGBASE Yes No 
c.670G>A p.V224Ib 8 CGAPV (1.0), dbSNP, refseq, GeneSNPs, HGBASE Yes Yes 
GSTM4 c.534T>C p.Fl 78Fd 7 dbSNP, ref seq, GeneSNPs, SNPper Unable N.S. 
c.634G>A p.V212Me 8 dbSNP, ref seq, GeneSNPs, SNPper Unable No 
c.657A>G p.X219X 8 dbSNP, GeneSNPs, SNPper Unable N.S. 
GSTMS c.103C>C p.M35Lb 2 refseq Unable No 
a Son1e sequences were unable to be confirn1ed directly through the databases used therefore sn1all-scale population screens were used to confinn these polyn1orphisn1s. 
Those detected through the validated CGAP lists could be confirn1ed through viewing existing electropherogran1s using the SNP Finder progran1. 
6 These polymorphisms were also detected by the BLAST alignn1ent tool and the SNP Finder program. 
c This polymorphisn1 was detected in both GSTMJ and GSTM2. It is unlikely to be a real polymorphism, rather represents both genes. 
d This silent GSTM4 polyn1orphism has been noted. Comstock et al. [1993], Ross & Board [1993] and Zhong et al. [1993a] detected the c.534C variant; Pearson et al. [1993] 
detected the c.534T variant. 
e Analysis of the literature has revealed the presence of this poly1norphis1n. Comstock et al. [1993] and Ross & Board [1993] isolated the p.V212 variant; Zhong et al. 
[1993a] isolated the p.M212 variant. 
r These polymorphisn1s were detected in sequences sub1nitted as GSTM4 in the validated CGAP lists although the sequences represent GSTMJ, due to the fact that the 
GSTMJ *B sequence template X08020 was used as the query sequence. The sequences that were subnutted under GSTMJ in the candidate CGAP lists were of unknown 
identity and are listed as being located on chron1osome X or chron1osome 19 (AK001936) in the SNP index. The GSTMJ sequences subnutted into the CGAP validated lists 
(CGAPV) were also of unknown identity and W95015, which is 100% identical to AK001936, was used as the query te1nplate. 
Table 4.3 - Oligonucleotides used for GSTMJ-5 exon amplification. 
Primer Exon Primer sequence Annealing Product 
5' to 3' Conditions Length 
GSTMJ 
M1Ex71F 7 GATCACTTTTGTAGATTTTCTCGT 54°C, 18 sec 228 bp 
M1Ex7R GAAACCAGTACTCAATACATGCG 
M1Ex7F 7 CTCCACCGTATATTTGACACCAA 61 °C, 18 sec 72 bp 
M1Ex7R2 CTCAAAGCGGGAGATGAAGTCC 
GSTM2 
M2Ex5F 5 GCTGAGAGTGAATCTGCTTTAGCA 128 bp 
M2Ex5R ATCTGGGTCATAGCAGAGTTTGGC 57°C, 20 sec 
M2Ex5R2 GACACAAACTCTGCAGGGAAAGG 54°C, 18 sec 205 bp 
M2Ex6F 6 CTGGGGCCATGCACAAAAC 57°C, 18 sec 227 bp 
M2Ex6R TAGGAAGTATGACAAATCTGTG 
M2Ex7F 7 TTTGTCATACTTCCTATATTATG 53°C, 16 sec 202 bp 
M2Ex7R AGACATAAAGAGAAAGGAGGC 
Ml/2Ex8F 8 TCCCCTTACTAGGTATTTA 51 °C, 18 sec 635 bp 
Ml/2Ex8R GAGTGAAGAGGGACAATG 
GSTM3 
M3Ex6F 6 CCTGTGCCCTGATTAACT 53 °C, 18 sec 226 bp 
M3Ex6R CTTAGGTCTGAGGAGTAG 
aM3Ex6AflII CCTCTCAGGAAAAACTTAA 51 °C, 18 sec 
M3Ex7F 7 CACCTATGATATCTTGGATCAG 58°C, 18 sec 205 bp 
M3Ex7R CAACCATTGATCCCATTAGGC 
bM3Ex8NlaIII 8 CCAGTGGGGCAACAAGCAT 55 °C, 18 sec 133 bp 
M3Ex8R GGACACCAGTAACATAAGTG 
GSTM4 
M4Ex8F 8 CCCCCTTAGTAGCTATTTG 55°C, 18 sec 667 bp 
M4EX8A GAGACAGAACCAGTCTACG 
GSTM5 
M5Ex2F 2 ACTCAAGCTATGTGGAAAAGCAGTAC 61 °C, 18 sec 343 bp 
M5Ex2R TCCCACATCCCAGGGTTCAGGGAG 
a A modification of g• t (underlined) was introduced to create an AflII site in the 
M3Exon 6 amplified DNA. This primer was used with the M3Ex6R primer. 
b A _modification of gee• gca (underlined) was introduced to created an NlaIII site in the 
M3Exon8 amplified DNA. 
Table 4.4 - Restriction Endonucleases used to detect polymorphisms in GSTM J-5. 
Variation Exon Endonuclease 
Site 
GSTMJ 
p.Dl 76D 
p.Fl 881 
GSTM2 
p.E89G 
p.D199E 
p.Q129E 
p.A130E 
p.M134K 
p.R187G 
GSTM3 
p.K128N 
p .W147G 
p.R191L 
p.V224I 
GSTM4 
p.V212M 
GSTMS 
p.M35L 
7 Fok! 
7 Msll 
5 Sau3AI 
5 Apo! 
6 HpyCH4V 
6 Cac8I 
6 Alu! 
7 HpaIT 
6 AjlII 
6 BstXl 
7 EcoNI 
8 NlaIII 
8 FokI/MscI 
2 Mwol 
Wild-type 
119,109 
228 
128 
205 
120,70,26,11 
118,109 
96,64,44,23 
202 
155 , 15 
226 
205 
113 ,20 
323 ,249,95 
Fragment Size (bp) 
Heterozygous 
119,109,83 ,26 
228,118,110 
128,92,36 
205 , 126,79 
190,120,70,26,11 
227,118,109 
96,64,5 8,44,23 ,6 
202,159,43 
170, 155 , 15 
226,125 ,101 
205 ,119,86 
133 ,113 ,20 
Polymorphic 
119,83 ,26 
118,110 
92,36 
126,79 
190,26,11 
227 
96,5 8,44,23 ,6 
159,43 
170 
125 , 101 
119,86 
133 
323 ,249,171 ,95 ,78 323 ,171 ,95 ,78 
199,57,39,26,13 ,9 199,83 ,57,39,26,13 ,9 199,83,39,13 ,9 
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4.2.3 GSTM3-3 RECOMBINANT PROTEIN WORK 
4.2.3.1 SITE-DIRECTED MUTAGENESIS 
The GSTM3-3 protein was expressed in E. coli in the plasmid pKK261 and was 
confirmed by cycle sequencing to be the GSTM3A protein (Table 4.5). Using the 
QuikChange Site-Directed Mutagenesis Kit (§2.6.3), the GSTM3B protein 
[p.G 147;!224] was created from GSTM3A using the primer pair M3V224IA and 
M3V224IB (Table 4.6). The GSTM3C [p.W147;V224] and GSTM3D [p.W147;I224] 
proteins were created from the GSTM3A and GSTM3B proteins respectively using the 
primer pair GSTM3G147WA and GSTM3G147WB (Table 4.6). All mutations were 
confirmed by cycle sequencing (§2.5.5.1). 
4.2.3.2 PROTEIN EXPRESSION AND PURIFICATION 
Plasmids encoding the GSTM3A, GSTM3B, GSTM3C and GSTM3D recombinant 
proteins were transfected into E.coli strains XLl-Blue or TGl (§2.6.2). To express 
these, 4 mL of an overnight culture was diluted 1: 100 into LB supplemented with 100 
µg/ml ampicillin. The 400 mL cultures were grown at 37°C to an OD600 of 0.6 and 
protein expression was induced with 0.2 1nM IPTG overnight. The cells were harvested 
by centrifugation at 5 K for 10 minutes at 4 °C (GSA-1500 rotor), resuspended in 30 mL 
resuspension buffer (50 1nM Tris-HCl, pH 7.2, 50 mM EDTA, 15% glucose) and lysed 
by sonication (5 x 15 second bursts). Cellular debris was removed by centrifugation at 
12 K for 20 minutes at 4°C (SS-34 rotor). 
The proteins were all purified at 4 °C by affinity chromatography. Cleared lysates were 
incubated for one hour on a rotary mixer with hexyl-glutathione agarose. The agarose 
was collected by centrifugation at 1000 rpm for 5 minutes and washed twice with 40 
mL of 50 mM Tris-HCl, pH 7.2. The agarose was washed with a further 500 mL of 50 
mM Tris-HCl, pH 7.2 on a scintered funnel, then transferred to a column and washed 
with a further 100 111L of 50 mM Tris-HCl, pH 7.2. The proteins were eluted from the 
hexyl-glutathione agarose with 5 mM pentyl glutathione in 50 mM Tris-HCl, pH 9.6. 
Table 4.5 - Nucleotide and an1ino acid variations in GSTM3-3. 
Haplotype Nucleotide 
c.439 c.670 
GSTM3A G G 
GSTM3B G A 
GSTM3C T G 
GSTM3D T A 
Residue 
p.147 p.224 
GSTM3A Gly Val 
GSTM3B Gly Iso 
GSTM3C Trp Val 
GSTM3D Trp Iso 
Table 4.6 - Mutagenesis primers used to create GSTM3-3 recon1binant protein variants. 
GSTM3 
Haplotype 
GSTM3B 
Primer 
Name 
M3V224IA 
M3V224IB 
Mutagenesis Primer Sequences 
5' to 3' 
CCCACAGTGAAGAAGTTTCTACAGCCTGGC 
GCCAGGCTGTAGAAACTTCTTCACTGTGGG 
GSTM3C/D GSTM3G 14 7W A CAA TTCTCCATGTTTCTGTGGAAA TTCTCATGGTTTG 
GSTM3G 14 7WB CAAACCATGAGAA TTTCCACAGAAACATGGAGAA TTG 
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Fractions containing recombinant GSTM3 were identified by 12.5°/o SDS-PAGE 
(§2.5.2.3). The strongest fractions were pooled and dialysed in 50 mM Tris-HCl, pH 
7.2, 1 mM EDTA and 0.2 mM DTT. After an initial 4-5 hours of dialysis, the protein 
was transferred to fresh dialysis buffer and left overnight. Protein concentrations were 
determined using the Peterson 1nethod (§2.5.2.3). 
4.2.4 GSTM3-3 ENZYME CHARACTERISATION 
4.2.4.1 STRUCTURAL ANALYSIS 
The GSTM3A [p.G147;V224], GSTM3B [p.G147;I224], GSTM3C [p.W147;V224] and 
GSTM3D [p.W147;I224] variants were built into the GSTM3 chain of the 3-D structure 
of GSTM2-3 (PDB file 1 GTU) as described in §2.6.5 . 
4.2.4.2 ENZYMATIC ANALYSIS 
Glutathione S-transferase activity assays towards a range of GST substrates were 
measured as described in §2.6.4. Three separate preparations of GSTM3A and 
GSTM3B, and two separate preparations of GSTM3C and GSTM3D were prepared. 
4.2.4.3 STEADY STATE KINETIC ANALYSIS 
Steady state kinetics for the recombinant proteins GSTM3A, GSTM3B, GSTM3C and 
GSTM3D against the substrate CDNB were determined using a 5x5 experiment. 
Kinetic parameters for the CDNB reaction were determined by measuring the kinetics 
for five concentrations of CDNB (1000, 800, 600, 400 and 200 µM) against five 
concentrations of GSH (1000, 500, 200, 100 and 50 µM GSH). The steady state kinetic 
parameters were determined by fitting the data points to the Michaelis Menten equation 
using the MacCurve fit program. Hyperbolae were fitted to bring R2 closest to 1 (<1) 
and to minimise the SSE (>0.0001). 
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4.3 RESULTS 
4.3.1 DETECTION OF Mu CLASS POLYMORPHISMS 
4.3.1.1 DETECTION USING DATABASE ANALYSIS PROGRAMS 
The BLAST alignment tool and the SNP Finder program were used to detect 
polyinorphisms in the Mu class GST cDNA sequences located in the human EST 
database and Uni Gene clusters respectively. The EST database contained 86 GSTMJ, 
88 GSTM2, 100 GSTM3, 64 GSTM4 and 80 GSTM5 cDNAs. However, when searching 
dbEST with the GSTMJ and GSTM2 cDNA sequences, 65 of the 86 and 88 GSTMJ and 
GSTM2 ESTs respectively were identical, indicating that only 21 cDNAs were unique 
to GSTMJ and 23 unique to GSTM2. The UniGene clusters contained 65 GSTM2, 69 
GSTM3, five GSTM4 and 13 GSTM5 cDNA and mRNA sequences. From these two 
sequence databases, ten variants that altered amino acid residues were detected in the 
GSTMJ, GSTM2, GSTM3 and GSTM5 genes (Table 4.1). Of these, six variants were 
confirmed upon resequencing a representative I.M.A.G.E. Consortium (LLNL) cDNA 
clone or viewing existing electropherograms: the p.Nl 73K variant in GSTMJ, the 
p.E89G and p.T210S variants in GSTM2 and the p.Kl28N, p.Rl91L and p.V224I 
variants in GSTM3. Two of the variants, the GSTM3 p.Wl47G and the GSTM5 p.M35L 
variants, were not initially sequenced as these were believed to be sequence 
discrepancies, that is, the query sequence used to search the EST database was the only 
sequence encoding the original residue: p.Wl47 in the case of the GSTM3 sequence, 
and p.M35 in the case of the GSTM5 sequence. The p.Wl47G variant was later 
detected during simultaneous screening for the known GSTM3 intronic polymorphism 
IVS6+22-24delAGG. The GSTM5 p.M35L variant was later studied in small-scale 
population studies as it had also been submitted to the public access SNP databases 
(Table 4.2). 
4.3.1.2 DETECTION USING SNP DATABASE ANALYSIS 
A number of SNP databases were also analysed for GST Mu class submissions. 
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Multiple variants were found in these databases, however when limited to those that 
altered amino acid residues in the coding region, nine potentially novel variants were 
found: p.Fl88I and p.S210T in GSTMJ, p.Dl 19E, p.Ql29E, p.Al30E, p.Ml34K and 
p.Rl97G in GSTM2, p.Kl28N in GSTM3 and p.V212M in GSTM4 (Table 4.2). 
Although some variants could be confirmed by analysing electropherograms and 
available frequency data, small-scale population analysis was undertaken for 
confirmation on all variants identified. Seven variants that had been detected using the 
BLAST alignment tool and SNP Finder programs were also detected in these databases. 
4.3.1.3 VARIANTS DISCARDED FROM FURTHER ANALYSIS 
Three of the polymorphisms identified were not investigated further: the p.Nl 73K and 
p.T210S GSTMJ variants and the p.S210T GSTM2 variant. The GSTMJ p.Nl 73K 
polymorphis1n has already been described and characterised [DeJong et al., 1988; 
Seidegard et al., 1988] , however cDNA clones for this and a novel silent p.Dl 76D 
polymorphism were further analysed as these two polymorphisms appeared to be linked. 
The two polymorphisms were confirmed by resequencing and found to occur in the 
Australian European population, but a link between the two polymorphisms was not 
found ( data not shown). These results have not been presented as the true frequency of 
these alleles is confounded by the possibility that these samples are heterozygous for the 
GSTMJ *O allele. The variation at residue 210 in GSTMl-1 and GSTM2-2 was not 
investigated further as it was assumed that this represented a database error. The 
nucleotide sequences of GSTMJ and GSTM2 are highly similar throughout intron 7, 
exon 8 and the 5' untranslated region. The substitution of c.628T (GSTMJ) for c.628A 
(GSTM2), which changes p.S210 in GSTMl-1 to p.T210 in GSTM2-2, is the only 
difference observed in this region. It is likely that GSTMJ submissions contain both 
GSTMJ and GSTM2 sequences. The same is true for GSTM2 submissions. 
Chapter 4 Results 86 
4.3.1.4 DETERMINATION AND DISTRIBUTION OF ALLELE FREQUENCIES 
25 samples from three ethnic groups were tested for the presence of the 14 variants 
utilising PCR/RFLP assays to determine the nucleotide present at the potentially 
polymorphic site. Only two variants were ultimately identified and confirmed in the 
three populations: the GSTM3 p.W147G (Figure 4.1) and GSTM3 p.V224I (Figure 4.2) 
polymorphisms. Allele frequencies for these two polymorphisms were subsequently 
determined in up to 100 samples for the Australian European, Bantu African, Creole 
African and Southern Chinese populations (Table 4.7). The p.W147 variant of GSTM3-
3 was found to be extremely rare, with only three heterozygous individuals detected in 
the Chinese population. No evidence for genotypic differences between the four 
populations was detected (x2 6 = 2.59, p>0.05). The BstXI restriction endonuclease used 
to genotype this polymorphism simultaneously genotyped the four populations for the 
known IVS6+22-24delAGG polymorphism (Figure 4.3). The GSTM3*B allele was 
found at a very high frequency of 80% in the Bantu African population compared with 
the 19% and 36% found in the Australian European and Creole African groups 
respectively. The GSTM3*B allele was absent in the Southern Chinese population. 
Significant genotypic differences were found between these four populations (x2 6 = 
231.08, p<0.05). The p.V224 variant, considered the common residue in GSTM3-3 , 
was more frequent than the p.1224 variant in the Australian European (66%) and two 
African populations (67% and 89%). This situation was reversed in the Chinese 
population, where at 74%, the p.1224 variant was more common. Again, a significant 
genotypic difference was found between the four races (x2 6 = 134.66, p<0.05). Further 
analysis den1onstrated no evidence for genotypic differences between the Australian 
European and Creole African populations (x22 = 0.25, p>0.05). 
The p.W147G and p.V224I allelic variants of GSTM3-3 can be combined into four 
potential haplotypes as defined in Table 4.5. Only two of these were observed in the 
Australian European and two African populations, and three in the Chinese population 
(Table 4.7). This is based on the assu1nption that the combination of p.Wl47 with 
p.V224 is never observed in the Chinese population, an assumption based on the 
observation that two p.W147 heterozygotes were homozygous for the p.1224 variation, 
and a third p.W147 was heterozygous for the [p.V224;I224] polymorphism (Table 4.7). 
242 bp-
190 bp-
147 bp-
110 bp-
67 hp-
1 2 3 
Fragment (bp) 
226 
125 
101 and/or98 
4 5 · 6 
TIT TIG GIG 
226 bp 
• 101 bp 
• 98bp 
Figure 4.1 - PCR/RFLP analysis of the GSTM3 p.W147G variant. A 266 bp PCR 
product spanning exon 6 and part of intron 6 of the GSTM3 gene was digested with 
BstXI for nucleotide 439 determination. Lane 1 - pUC/Hpall marker; Lanes 2-4, 6 -
GIG homo zygotes; Lane 5 - T /G heterozygote. 
242 hp -
190 hp -
147 hp -
110 hp -
1 2 3 4 5 6 7 8 9 10 
Fragment (hp) 
133 
113 
20 
GIG GIA A/A 
• 133 hp 
• 113 hp 
Figure 4.2 - PCR/RFLP analysis of the GSTM3 p.V224I polymorphism. A 133 hp PCR 
product spanning exon 8 of the GSTM3 gene was digested with N/alll for nucleotide 
670 determination. Lane 1 - pUCIHpall marker; Lanes 2, 3, 5, 8, 10 - GIA 
heterozygotes; Lanes 4, 6, 7 - GIG homozygotes; Lane 9 - A/ A heterozygote. 
Table 4. 7 - GSTM3 allele frequencies in three ethnic groups. 
Gene Polymorphism 
GSTM3 p.W147G 
IVS6+22-24delAGG 
p.V224I 
Gene 
GSTM3 
Population n 
Australian 100 
Bantu African 74 
Creole African 74 
Chinese 111 
Australian 100 
Bantu African 61 
Creole African 74 
Chinese 111 
Australian 100 
Bantu African 70 
Creole African 69 
Chinese 93 
Population n 
Australian 100 
Bantu African 57 
Creole African 68 
Genotype 
T/T=0 T/G=0 
T/T=0 T/G=0 
T/T=0 T/G=0 
T/T=0 T/G=3 
A*/A*=68 A*/B*=26 
A*/A*=2 A*/B*=20 
A*/A*=29 A*/B*=36 
A*/A*=l 11 A*/B*=0 
G/G=43 G/A=46 
G/G=54 G/A=16 
G/G=30 G/A=33 
G/G=4 G/A=40 
GSTM3A 
[p.G147;V224] 
0.66 
0.89 
0.68 
Chinese 92 0.255 
Note: All polyinorphisms are in agree1nent with the Hardy-Weinberg equilibrium 
Allele Frequency 
G/G=l00 p.W147=0 p.G147=1 
G/G=74 p.W147=0 p.Gl47=1 
G/G=74 p.W147=0 p.G147=1 
G/G=108 p.W147=0.01 p.G147=0.99 
B*/B*=6 * A=0.81 B*=0.19 
B*/B*=39 *A=0.20 B*=0.80 
B*/B*=9 *A=0.64 B*=0.36 
B*/B*=0 *A=l B*=0 
A/A=l 1 p.V224=0.66 p.I224=0.34 
A/A=0 p.V224=0.89 p.I224=0.11 
A/A=6 p.V224=0.67 p.I224=0.33 
A/A=94 p.V22_4=0.26 p .I224=0. 7 4 
Haplotype 
GSTM3B 
[p.G 147;1224] 
GSTM3D 
[p.W147;I224] 
0.34 
0.11 
0.32 
0.728 0.016 
190 bp-
147 bp-
110 bp- -· 
1 2 3 4 
Fragment (bp) 
125 
101 
98 
5 6 7 8 · 9 10 11 
* Al* A * Al*B *B/*B 
• 125 bp 
• 115 bp 
• 112 bp 
• 101 bp 
• 98bp 
Figure 4.3 - PCR/RFLP analysis of the known GSTM3 IVS6+22-24delAGG 
polymorphism. A 266 bp PCR product spanning exon 6 and part of intron 6 of the 
GSTM3 gene was digested with BstXI to determine GSTM3*A and GSTM3*B allele 
frequencies. Lane 1 - pUC/Hpall marker; Lanes 2, 5, 7, 8 - GSTM3*A*B 
heterozygotes; Lanes 3, 4, 9, 11 - GSTM3*A *A homozygotes; Lanes 6, 10 -
GSTM3*B*B homozygotes. It is likely that the bands appearing at approximately 112 
and 115 bp in the GSTM3*A *B heterozygotes caused by the formation of 
heteroduplexes [Inskip et al. , 1995]. 
Chapter 4 Results 87 
4.3.2 ENZYME CHARACTERISATION 
4.3.2.1 STRUCTURAL ANALYSIS 
To evaluate the potential effects of the p.W147G, and p.V224I variants of GSTM3-3 , 
the substitutions were modelled into the GSTM3 chain of the 3-D structure of GSTM2-
3 (Figure 4.4). Neither residues 147, located at the N-terminal end of the loop between 
the a5 and a6 helices, nor 224, located in the C-terminal extension unique to GSTM3-3 , 
are located in the active site. However, predictive modelling demonstrates that both the 
p.W147G and p.V224I substitutions alone, and in combination, introduce varying 
degrees of conformational changes into the overall protein structure (Figures 4.5A, 4.6A 
and 4.7 A). The p.Wl47G change is non-conservative, in which glycine, a small, 
uncharged polar residue is replaced with tryptophan, a bulky residue with a non-polar 
ring structure side chain. Although there is no evidence for altered H-bonding to 
residues immediately surrounding residue 147 (Figure 4.5B), alteration of the backbone 
surrounding the catalytically essential p.Yl 1 residue due to p.W147 creates one new H-
bond between p.Rl5 and p.A18 (Figure 4.5C). In contrast, the p.V224I change is 
conservative - both valine and isoleucine are non-polar residues of similar size. 
Although this substitution would appear to have no effect on protein structure, backbone 
alterations in the in1mediate vicinity of residue 224 were observed, although H-bonding 
was not affected (Figure 4.6B). More importantly however, this substitution created a 
1najor change in the conformation of the catalytically essential p.Yl 1 residue, creating 
two new H-bonds: one from p.Yl 1 to p.Ll 7, the other between p.Rl5 and p.A18 
(Figure 4.6C). When seen in combination with the p.Wl47 variant, p.1224 adopted a 
different conformation to that observed with the p.G147 variant (Figures 4.6B and 
4.7B). The conformation of p.W147 and p.Yl 1 residues as seen in Figures 4.5B and 
4.5C, were not affected by the presence of the p.1224 variant. 
4.3.2.2 ENZYMATIC ANALYSIS 
The activity of each of the four variants with a range of typical GST substrates was also 
examined, however activity was only observed with CDNB, CuOOH and t-nonenal 
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Figure 4.4 - Ribbon diagram of GSTM3 depicting the position of the polymorphic 
p.W147G and p.V224I substitutions. The most common amino acids, p.0147 and 
p.V224I, are shown in black. The least common amino acids, p.W147 and p.1224, are 
coloured red. The catalytically essential p.Yl 1 residue is coloured green. 
Figure 4.5 - Carbon backbone of the GSTM3 n1ono1ner encoding p.G147 overlaid with 
the protein encoding p.W147. GSTM3 encoding the more common amino acid p.G147 
( depicted in black) is coloured grey; GSTM3 encoding the less common amino acid 
p.W147 (depicted in red) is coloured blue. The catalytically essential p.Yl 1 residue is 
coloured green. (A). Substitution of the p.W147 residue for the p.G147 residue 
introduces minor changes to the overall structure of the GSTM3 protein. (B). 
Magnification of residue 14 7 and neighbouring residues. (C). Magnification of residue 
11 and neighbouring residues. The H-bond introduced by the substitution of p.W147 
for p.G147 is shown in pink. 
A. 
/ 
{ __..• 
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Figure 4.6 - Carbon backbone of the GSTM3 n1ono1ner encoding p.V224 overlaid with 
the protein encoding p.1224. GSTM3 encoding the more cormnon amino acid p.V224 
( depicted in black) is coloured grey; GSTM3 encoding the less con1mon amino acid 
p.1224 ( depicted in red) is coloured blue. The catalytically essential p.Yl 1 residue is 
coloured green. (A). Substitution of the p.1224 residue for the p.V224 residue causes 
substantial changes to the overall structure of the GSTM3 protein. (B). Magnification 
of residue 224 and neighbouring residues. (C). Magnification of residue 11 and 
neighbouring residues. The H-bonds introduced by the substitution of p.1224 for 
p. V224 are shown in pink. 
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Figure 4.7 - Carbon backbone of the GSTM3 monomer encoding [p.G147;V224] 
overlaid with the protein encoding [p.W147;I224]. GSTM3 encoding the more 
common amino acids [p.G147;V224] (depicted in black) is coloured grey; GSTM3 
encoding the less common amino acids [p.W147;I224] (depicted in red) is coloured 
blue. The catalytically essential p.Yl 1 residue is coloured green. (A). Introduction of 
both the p.W147 and p.1224 residues into the GSTM3 protein causes minor changes to 
the overall structure. (B). Magnification of residue 224 and neighbouring residues. 
A. 
B. 
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(Table 4.8). Introduction of p.Wl47 into the GSTM3-3 protein in combination with the 
p.V224 residue (GSTM3C) did not dramatically alter the specific activity of the 
GSTM3A protein [p.G147;V224] , only causing a 1.3- to 1.5-fold decrease in specific 
activity towards the three substrates. This decrease was only significant for the 
substrate t-nonenal (p=0.009). Introduction of p.1224 into the GSTM3-3 protein 
containing the p.Gl47 residue (GSTM3B) significantly increased the specific activity 
towards CDNB by 2.8-fold (p=0.0015) and was responsible for a marginal, but non-
significant, increase in the specific activities towards CuOOH and t-nonenal. In 
combination with the p.W147 residue, the p.1224 residue (GSTM3D) was responsible 
for an approximate two-fold decrease in specific activity towards CDNB (p=0.0129), a 
1.8-fold decrease in CuOOH specific activity (p=0.0435) and a 1.7-fold decrease in 
specific activity with t-nonenal (p=0.0017), all of which were found to be significant. 
Differences in specific activities between the GSTM3B and GSTM3C isoforms were 
found to be significant for the substrates CDNB (p=0.0003) and t-nonenal (p=0.0162), 
as were those between the GSTM3C and GSTM3D isoforms (CDNB, p<0.0001; t-
nonenal, p=0.0025). Significant changes were measured between the GSTM3B and 
GSTM3D isoforms for all substrates tested (CDNB, p=0.0002; CuOOH, p=0.0199; t-
nonenal, p=0.003). 
4.3.2.3 KINETIC STUDIES 
Due to the large effects the p.W147G and p.V224I polymorphisms exerted on the 
function of the GSTM3A protein [p.G147;V224], kinetic studies were carried out to 
determine how these variants altered the catalytic efficiency of GSTM3-3. Kinetic 
parameters for CDNB were measured and are listed in Table 4.9. This analysis showed 
that substitution of p.W147 (GSTM3C) for p.G147 (GSTM3A) in GSTM3-3 encoding 
p.V224 caused a two-fold decrease in catalytic efficiency (KcatlKm) for CDNB, due to a 
two-fold decrease in Keat· The Km values for CDNB remained unchanged, but there was 
a slight 1.3-fold reduction in Km for GSH. Introduction of the p.1224 variation into 
GSTM3-3 containing the p.G147 residue (GSTM3B) resulted in a 2.9-fold and 8.5-fold 
increase in catalytic efficiency for CDNB and GSH respectively, due to a three-fold 
increase in Keat· The Km values for CDNB remained unchanged, whilst that for GSH 
Table 4.8 - Activities of recombinant GSTM3-3 variants towards various substrates. 
Substrate GSTM3A GSTM3B GSTM3C GSTM3D 
[p.G147; V224] [p.G147;1224] [p.W147;V224] [p. Wl 4 7 ;1224] 
(µmol/min/mg) 
1-chloro-2,4-dinitrobenzene 3.5 + 0.91 9.76 + 1.06 2.35 + 0.01 1.24 + 0.06 
Cumene hydroperoxide 0.93 + 0.27 1.02 + 0.23 0.70 + 0.24 0.38+0.18 
t-nonenal 1.72 + 0.20 1.76 + 0.26 1.16+0.01 0.70 + 0.12 
The data represented are the mean+ S.D. for three determinations. 
ANOV A analysis on Table 4.8 
Significant differences in Enzyme activity were observed between the four different 
GSTM3 variants with the following substrates: 
CDNB: p = 0.0001 
CuOOH: p = 0.0401 
t-N: p = 0.0002 
Table 4.9 - Kinetic parameters of recombinant GSTM3-3 proteins with the substrate 
CDNB. 
Protein Km CDNB KmGSH Keat Kea/Km CDNB KcatfKm GSH 
(mM) (mM) (sec-1) (s-lmM-1) (s-lmM-1) 
GSTM3A 1.50 ± 1.05 0.65 ± 0.11 4.85 ± 2.75 3.23 4.98 
[p.G147;V224] 
GSTM3B 1.60 ± 0.89 0.35 ± 0.034 14.86 ± 2.96 9.26 42.07 
[p.G 147:1224] 
GSTM3C 1.56 ± 0.87 0.50 ± 0.06 2.36 ± 0.40 1.51 4.71 
[p.W147;V224] 
GSTM3D 1.79 ± 0.77 0.43 ± 0.076 2.68 ± 0.43 1.50 6.23 
[p.W147;I224] 
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was reduced approximately 50%. When the 1224 variation was introduced into 
GSTM3-3 containing the p.W147 residue (GSTM3D), a 1.3-fold increase, compared to 
GSTM3A, in the catalytic efficiency for GSH was observed due to a 1.2-fold decrease 
in the Km for GSH. A 50% decrease in the catalytic efficiency for CDNB due to a 1.2-
fold increase in the Km for CDNB, and a two-fold decrease in Keat were also observed 
when GSTM3D was compared to GSTM3A. 
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4.4 DISCUSSION 
The Mu class GSTs are believed to exert protective effects against numerous diseases 
ranging from epoxide induced cancers through to neurodegenerative disorders, in 
addition to 1naintaining PGE2 regulated neurophysiological functions. Numerous 
studies have demonstrated weak associations between the well characterised GSTM 1 *O 
polymorphism with an increased risk to various epoxide induced cancers and have more 
recently found that the GSTM3 *B intronic polymorphism confers a protective effect by 
reducing the risk of developing these cancers due to linkage with GSTMJ *A. 
Polymorphism in other GST Mu isoenzymes could also possibly alter susceptibility to 
these diseases in addition to altering drug responses mediated by these GSTs. 
Polymorphisms were detected in each of the Mu class GSTs by combining results 
obtained through searching the EST database with the BLAST alignment tool, and 
Uni Gene clusters using the SNP Finder program (Table 4.1 ). The BLAST alignment 
tool was able to detect variants in each of the five Mu· class genes. Only one variant 
was detected in the GSTM2, GSTM4 and GSTM5 genes, however as these three genes 
were well represented in the EST database, detection of more variants could be 
expected. This lack of variation may be explained by the deficiency of full-length 
cDNA sequences. Only ten GSTM2, eight GSTM4 and seven GSTM5 partial cDNA 
sequences covered a particular section of the coding region of the respective genes. In 
contrast, the SNP Finder program detected many variants in the GSTM2 and GSTM3 
genes, but not in the GSTM4 and GSTM5 genes despite their representation by five and 
13 cDNA sequences respectively. The GSTMJ UniGene cluster could not be 
downloaded or analysed due to unexplained problems with the database. 
The lack of polymorphism detected by the SNP Finder program and BLAST alignment 
tool in the GSTM4 and GSTM5 genes, and to a lesser extent the GSTM2 gene, may 
reflect a true absence of polymorphism. However the poor representation of full-length 
cDNA sequences encoding these genes in the two respective databases provides a more 
likely explanation. Under-representation of the GSTM4 and GSTM5 genes in particular 
n1ay have been due to low expression levels. Although the GSTM4-4 and GSTMS-5 
proteins are expressed in multiple tissues, neither is expressed at significant levels 
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[Comstock et al., 1993; Takahashi et al., 1993; Rowe et al., 1997]. The other GST Mu 
isoenzymes are also expressed in multiple tissues to varying degrees [Warholm et al., 
1980; Laisney et al., 1984; Beckett et al., 1990; Cainpbell et al., 1990; Takahashi et al., 
1993; Rowe et al., 1997], but unlike GSTM4-4 and GSTMS-5 they are expressed at 
significant levels in selective tissues and are therefore better represented in the EST and 
UniGene databases. GSTMl-1 is one of the major liver isoenzymes [Strange et al., 
1989; Rowe et al., 1997], GSTM2-2 is abundant in skeletal muscle [Laisney et al., 
1984; Suzuki et al., 1987] and GSTM3-3 is primarily expressed in the testis and brain 
[Rowe et al., 1997]. As discussed in Chapter 3, a large number of full-length cDNA 
sequences derived from diverse sources is required to enable detection of 
polymorphisms in low expressing genes. 
A number of GST Mu class variants were also detected in various SNP databases. As 
was found with the sequence database-mining methods, the GSTM5 gene was poorly 
represented in these SNP databases suggesting that this gene is not highly polymorphic. 
The one coding region variant and the few 3 '-UTR and-intronic variants detected ( data 
not shown) were only found in two SNP databases: HGBASE and refseq, and by the 
SNPper program. Due to the low expression levels and the paucity of information 
available about this gene it is possible that the generation of more sequence information 
will reveal the existence of other GSTM5 polymorphisms. 
As with the Alpha class GSTs, problems relating to sequence identity assignations were 
encountered when analysing data within the public SNP databases and some UniGene 
clusters. GSTMJ and GSTM2 gene sequences were commonly confused, resulting in 
the false identification of a variation at residue 210 in both genes, p.S2 l OT in GSTMJ 
and p.T210S in GSTM2. This residue is in fact one that distinguishes GSTMJ, which 
encodes p.S210, from GSTM2, which encodes p.T210. In addition, polymorphisms in 
the GSTM4 gene verified by the CGAP were found to be GSTMJ polymorphisms. 
Sequences found at the san1e site listed as being GSTMJ were of an unknown identity 
and mapped to chro1nosomes 19 and X. These problems highlight the necessity to be 
aware of the similarities that exist between members of multi-gene families. 
Overall, each SNP detection 1nethod was able to detect variants not identified by other 
methods. Three novel variants altering amino acids were identified and verified in the 
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coding regions of the GSTM2 and GSTM3 genes using the BLAST alignment tool and 
SNP Finder program (Table 4.1) and seven novel variants ( excluding silent 
polymorphisms) were detected in all five GST Mu genes in the SNP databases (Table 
4.2). Four sequence discrepancies were also detected in the EST database by the 
BLAST alignment tool. Of these, the GSTM5 p.M135L and the silent GSTM2 p.N74N 
variants were subsequently detected independently in other databases (Table 4.2), whilst 
the GSTM3 p.W147G and silent GSTM4 p.L55L variants had been previously noted 
[Comstock et al., 1993; Pearson et al., 1993; Ross & Board, 1993; Zhong et al., 1993a]. 
In addition, three GSTM4 sequence discrepancies were detected by the BLAST 
alignment tool: p.T4I, p.D37G and p.L63L. These were found to be sequence 
anomalies between the GSTM4 sequences published by Zhong and colleagues [1993a] 
and Comstock and colleagues [ 1993]. As these have only been observed in the 
sequence published by Zhong and colleagues [1993a], it is likely that these represent 
sequencing errors. 
Of the ten GST Mu class variants found, only two -GSTM3 polymorphisms were 
identified in the three ethnic populations tested: the p.W147G and p.V224I 
polymorphisms. Some variants not detected during the population screening 
experiments may represent rare alleles. Others may be specific to ethnic populations 
not screened here, however as the ethnic origin of the cDNA in the EST and UniGene 
databases is unknown, the relevant population cannot be identified. In contrast, 
frequencies calculated by the LeeLab at http://www.bioinformatics.ucla.edu/snp for the 
GSTM2 p.Q129E, p.A130E and p.Ml34K variants and the GSTM4 p.V212M variant 
indicate that these variants are relatively common (GSTM2: p.Q129E, C=0.74, G=0.26; 
p.A130E, C=0.71, A=0.29; p.M134K, T=0.75, A=0.25; GSTM4 p.V212M, G=0.8, 
A=0.2). The LeeLab identified these variants in the UniGene database using a 
combination of various computer based analysis programs and Bayesian inference 
[Irizarry et al., 2000]. It would appear however, that these variants were not validated 
in any population sets and that the allele frequencies were calculated based purely on 
the EST data in the Uni Gene database. In the absence of such validation studies, these 
frequencies should not be considered representative of the true situation. 
Th~ two GSTM3 polymorphisms identified in this study have been reported elsewhere. 
The p.Wl47G polymorphism has previously been noted as a sequence alteration 
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unlikely to have any effect on the function of the protein [Pearson et al., 1993; Ross & 
Board, 1993]. The existence of the GSTM3 p.V224I polymorphism discovered using 
the SNP detection methods described above was independently confirmed by two 
groups undertaking large scale sequencing efforts, one on a subset of genes associated 
with neurodegenerative disease [Emahazion et al., 1999] and the other interested in 
testing a new genome search engine [Iida et al., 2001]. However, further investigations 
were not undertaken into characterising either of these polymorphisms. As a third 
polymorphis1n is known in the GSTM3 gene, IVS6+22-24delAGG [Inskip et al., 1995], 
the Australian European, Bantu African, Creole African and Southern Chinese 
populations were also screened for this polymorphism out of interest. 
Determination of allele frequencies revealed variations in the allele distribution between 
the four ethnic groups, with the Southern Chinese population showing unique allele 
distributions. Only the Southern Chinese population encoded the extremely rare 
p.Wl47 variant, with three heterozygous individuals detected. Rare variants, those that 
occur at a :frequency below 5%, are more likely to be restricted to specific ethnic groups 
[Cargill et al., 1999; Halushka et al., 1999; Risch, 2000] hence it is possible that the 
p.Wl47 variant is unique to the Southern Chinese population. Two of these individuals 
were also ho1nozygous for the GSTM3 p.1224 polymorphism, but the other showed 
heterozygosity at residue 224, leading to the conclusion that the p.Wl47 residue is 
always seen in combination with the p.1224 variant. However, as the p.Wl47 residue 
has also been seen in combination with the p.V224 residue in published GSTM3 
sequences [Ca1npbell et al., 1990; Patskovsky et al., 1999c], this finding may only be 
true for the Southern Chinese population. Alternatively, these results may be 
confounded by the population size tested here. Testing larger population sets is required 
in order to determine whether the p.Wl47 variant is unique to the Southern Chinese 
population and to dete1mine linkage of this polymorphism with the polymorphism at 
residue 224. Unlike the two African and the Australian European populations, where 
the p.V224 residue was observed at a frequency of approximately 66%-89%, the p.1224 
variant was found at a frequency of 7 4% in the Chinese population. Unusually, the 
entire Chinese population tested here was homozygous for the known the GSTM3 * A 
allele. Another study has found similar results in the Asian/Pacific Island population 
and although the GSTM3 *B allele was detected, it was extremely rare(* Al* A= 98.1 %, 
*AJ*B = 1.9%, *B/*B = 0%) [Cortessis et al., 2001]. Both the known GSTM3*A and 
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GSTM3 * B alleles were seen in the Australian European and two African populations, 
although the GSTM3 * B allele was much more frequent in the Bantu African samples, at 
80%. The Australian European frequencies were comparable to those reported in a 
British study in which the polymorphism was defined (* A/* A = 70.9%, * A/*B = 
25.8%, *B/*B = 3.4%) [Inskip et al., 1995] and an American study (* A/* A = 58%, 
* AJ*B = 37%, *B/*B = 5%) [Park et al., 2000], as were the Creole African frequencies 
when compared to frequencies determined for African-American subjects (* A/* A = 
37.3%, *A/*B = 44.6%, *B/*B = 18.1%) [Cortessis et al., 2001]. However African-
American frequencies determined in another study were different to those reported by 
Cortes sis and colleagues [2001], and were found to be more comparable to the Bantu 
African frequencies typed in this study (* A/* A = 11 %, * A/*B = 41 %, *B/*B = 48%) 
[Park et al., 2000]. This de1nonstrates the difficulty that exists when defining racial 
groups, for differences in prevalence rates are not only observed between similar racial 
groups located in different countries as shown here (Bantu and Creole Africans 
compared to Alnerican Africans), but are also observed in similar racial groups in the 
same country due to regional differences (Bantu Africans compared to Creole Africans) 
[Kawajiri et al., 1990; Park et al., 2000]. Based on the genotyping results, there appears 
to be no apparent association between the intronic deletion with either the p.W147G or 
p.V224I polyn1orphisms. Unfortunately, definitive associations could not be made, but 
these could be further clarified using allele specific a1nplification. 
Significant changes in the catalytic ability of the GSTM3-3 protein [GSTM3A: 
p.G147;V224] were observed when the p.W147 (GSTM3C) and p.1224 (GSTM3B) 
variants were introduced singly and in con1bination (GSTM3D). Overall, the results in 
Table 4.8 demonstrate that the p.1224 residue was responsible for a significant change in 
enzyme activity and that this was dependent upon the amino acid encoded at residue 
147 (GSTM3B, [p.G147;I224]; GSTM3D, [p.W147;I224]), whereas the substitution of 
the p.G147 residue for the p.W147 residue in combination with the p.V224 residue 
(GSTM3A, [p.G147;V224] and GSTM3C, [p.W147;V224]) only had a very small 
effect on the protein function. The latter substitution did not appear to dramatically 
alter the specific activity of GSTM3-3, only causing a 1.3- to 1.5-fold decrease in 
specific activity (Table 4.8). However, analysis of the kinetic parameters using CDNB 
as a_ substrate revealed an overall two-fold decrease in catalytic efficiency (Keat/Km) in 
GSTM3C for CDNB, brought about by a two-fold decrease in Keat (Table 4.9). This, 
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along with the unchanged Km value for CDNB, indicated that the protein retains its 
ability to bind this substrate in the presence of the p.W147 residue, but catalysis 
proceeds less efficiently. In contrast, the slight increase in the Km for GSH, provided 
evidence for enhanced GSH binding. Combining the p.1224 residue with the p.G147 
residue (GSTM3B) marginally increased the specific activity of the GSTM3A protein 
for the substrates CuOOH and t-nonenal, but caused a significant increase in activity 
towards the aromatic substrate CDNB (Table 4.8). This was due to a 2.9- and 8.5-fold 
increase in the catalytic efficiency for CDNB and GSH respectively, caused by a three-
fold increase in Keat• No difference in the Km for CDNB was observed, implying that 
the binding affinity for this substrate had not altered however, the Km for GSH 
decreased by approximately 50%, i1nplying enhanced affinity for this substrate (Table 
4.9). In contrast, when the p.1224 residue was combined with the p.W147 residue 
(GSTM3D), the specific activity of the GSTM3C protein with the three substrates tested 
was halved (Table 4.8). In this case, kinetic analyses with CDNB revealed an unaltered 
catalytic efficiency for CDNB, but a very slight 1.3-fold increased catalytic efficiency 
for GSH brought about by a combination of a small 1.2-fold decrease in Km for GSH, 
and a 1.1-fold increase in Keat• This implies that p.I224 in combination with p.W147 
marginally increases the proteins affinity for GSH and therefore the conjugation 
between GSH and the electrophilic substrates would also be slightly increased. The 
kinetic data presented here is generally comparable to that reported for previous kinetic 
parameters determined for the GSTM3A protein [Rowe et al., 1997; Patskovsky et al., 
1999c]. These studies both reported an approximate eight-fold lower Km for GSH than 
found here, although K111 values for CDNB were relatively comparable (2.8 mM and 1.1 
mM), as were the Keat values. The catalytic efficiencies however varied between the 
literature and with the measurements obtained in this study, perhaps due to variations in 
the calculated n1olecular mass. It is possible that the hexyl-glutathione used to elute the 
GSTM3-3 proteins may not have been fully removed from the G-site during dialysis 
and hence competed with GSH binding, although attempts to prevent this by extensive 
dialysis were carried out. Differences in laboratory environments may also have 
contributed to these variations. Despite the inter-laboratory differences, specific 
activities measured here were consistent between the different batches of proteins 
purified, and the results are intended to show relative differences in activity. 
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Overall, the kinetic results are in keeping with the predictions based on 3-D structural 
modelling. The kinetic data show that the p.Wl47 residue decreases the catalytic 
efficiency of GSTM3-3 isoenzyines encoding the p.V224 residue (GSTM3C) for 
CDNB, despite previous assumptions that this polymorphism would have no functional 
effect on the protein [Pearson et al. , 1993; Ross & Board, 1993]. Predictive modelling 
indicates that the despite the substitution of tryptophan, a bulky residue with a non-polar 
ring structure side chain for glycine, a small uncharged polar residue at residue 147, 
relatively minor confonnational changes were created in the protein structure (Figure 
4.5A). Although alterations were introduced in the area neighbouring residue 147 
(Figure 4.5B), its external orientation on the loop between the a5 and a6 helices, which 
is located away from the active sites [Raghunathan et al. , 1994], makes it unlikely that 
this residue exerts any direct effect on the protein function. However, the reduced 
flexibility of the environment around residue 14 7 that is caused by the introduction of 
tryptophan, and the collective differences in residue interactions in this environment, 
may indirectly influence the ability of the protein to easily adopt different 
conformations during catalysis. In addition, as seen in Figure 4.5C, conformational 
changes are introduced in the environment surrounding the catalytically essential p.Yl 1 
residue, resulting in the introduction of a new H-bond, changes which could affect the 
ability of GSH to enter or orient itself in the G-site of the protein, and explain the slight 
enhance1nent in GSH binding affinity observed. Although kinetic parameters were not 
measured for CuOOH and t-nonenal due to time constraints, it is likely that changes in 
the catalytic efficiency towards these substrates would also be observed. 
Introduction of the p.1224 variation into the GSTM3-3 protein also influenced the 
catalytic efficiency of GSTM3-3 towards CDNB. When combined with the p.G147 
residue (GSTM3B), the catalytic efficiency was increased. However, considering that 
residue 224 is located in the three ainino acid C-terminal extension unique to GSTM3-3 
[Patskovsky et al. , 1999c], and the fact that this extension is oriented away from the 
protein and the active site, it would seem unlikely that this conservative substitution 
would have a large effect on either the function or the structure of the protein. In 
addition, a previous study has shown that the stability of GSTM3-3 was increased when 
the extension was re1noved, although the catalytic properties of the enzyme remained 
unchanged [Patskovsky et al. , 1999c]. Predictive modelling however, demonstrates that 
this substitution caused moderate conformational changes to the structure of GSTM3-3 
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(Figure 4.6A). It is possible that the p.1224 residue alters the stability of the protein, 
hence influencing the ability of substrates to access and/or fit into the active site. 
Notably, the conformation of the catalytically essential p.Yl 1 residue was considerably 
altered, resulting in a new H-bond interaction between p.Yl 1 and a neighbouring p.Ll 7 
residue (Figure 4.6C), which is believed to make up part of the catalytic site 
[Patskovsky et al., 1999c]. This could effectively alter the dynamics of GSH binding, 
perhaps explaining the enhanced binding affinity observed for GSH. Although kinetic 
parameters were not measured for CuOOH or t-nonenal, and no change in specific 
activity was observed, it is possible that the ability of GSTM3B to catalyse these two 
substrates may also be affected by the presence of the p.1224 polymorphism. 
Combining p.1224 with p.Wl47 (GSTM3D) appeared to marginally increase the 
binding ability of the GSTM3C protein [p.Wl47;V224] for GSH. Predictive modelling 
demonstrated that the combined effect of these variants were not responsible for any 
major stn1ctural differences to GSTM3-3. p.Wl47 showed similar conformational 
differences when combined with p.1224, as when seen in combination with p.V224 
(Figure 4.5B). In addition, the conformational alterations observed around p.Yl 1 were 
similar to that seen in GSTM3C [p.Wl47;V224] (Figure 4.5C). As discussed above, 
these changes could affect the ability of GSH to enter or orient itself into the G-site of 
the protein. In contrast, the orientation of p.1224 in combination with p.Wl47 was very 
different to that adopted in combination with p.Gl47, resulting in different local 
conformational alterations. Again, as discussed above, this could possibly affect the 
stability of the protein. Although kinetic parameters were not measured for CuOOH 
and t-nonenal, it is likely that the decreased specific activities observed are also due to 
sin1ilar effects. 
GSTM3-3 possesses the highest peroxidase activity of the GST Mu class family 
towards organic hydroperoxides and, unlike the Alpha class GSTs, is also able to reduce 
H20 2 [Campbell et al., 1990; Comstock et al., 1994]. Since a two-fold decrease in 
specific activity towards CuOOH was observed in GSTM3-3 containing both the 
p.Wl47 and p.1224 polymorphisms (GSTM3D), it is possible that an increased 
susceptibility to disease related to oxidative stress might be observed in individuals 
carrying these alleles. On the basis of the kinetic studies reported here, it can also be 
speculated that GSTM3-3 proteins encoding only one of these alleles may also alter the 
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peroxidase activity of GSTM3-3, with the p.W147 residue decreasing the catalytic 
efficiency and the p.1224 residue increasing catalytic efficiency. However, due to the 
lack of kinetic data confirming these speculations, the individual contribution of these 
polymorphisms to the peroxidase activity of GSTM3-3 will not be considered further. 
Disease or damage related to altered GSTM3-3 activity is most likely to be manifested 
in the testes and brain, both of which possess a blood barrier and high expression levels 
of GSTM3-3 [Campbell et al., 1990; Rowe et al., 1997]. GSTs expressed at these 
barriers are believed to provide the first line of defence against endogenous compounds 
and xenobiotics [Abramovitz et al., 1988; Cammer et al., 1989; Beuckmann et al., 
2000]. As brain cells are not able to regenerate and germ cell generation requiring high 
fidelity DNA replication is constantly occurring in the testes, polymorphisms affecting 
the function of the GS Ts that protect these organs may alter susceptibility to irreparable 
cellular damage. 
The effects of the decreased peroxidase activity exhibited by the variant GSTM3D 
protein may also affect the reduction and isomerisation of the prostaglandin PGH2 to 
PGE2 in the brain, a reaction catalysed by GSTM3-3 [Beuckmann et al., 2000]. PGE2 is 
one of the two major arachidonic acid metabolites in mammalian neurons and glial cells 
and plays several neurophysiological roles in the central and peripheral nervous 
systems, including neuroendocrine function (sedation, catatonia, hypertension), body 
ten1perature regulation including mediation of fever [Coceani & Akarsu, 1998] and 
hyperthermia [Onoe et al., 1992], nociception and allodynia [Minami et al., 1994]. It is 
also involved in the regulation of sleep-wakefulness, where in combination with the 
sleep inducer PGD2, it promotes wakefulness [Onoe et al., 1992]. The high expression 
levels of GSTM3-3 in the brain imply that this isoenzyme may be of importance in the 
production of PGE2 in the brain [Beuckmann et al., 2000]. It can therefore be 
postulated that polyinorphis1ns in GSTM3-3 that affect peroxidase activity may directly 
interfere with PGE2 synthesis and indirectly influence the various roles of PGE2. 
The Mu class GSTs have a protective role in detoxification of the nitrosoureas, a group 
of alkylating antineoplastic drugs, and over-expression of the Mu class GSTs is 
suggested to be involved in the development of resistance to the nitrosoureas in tumour 
cell_s [Tew, 1994]. For example, increased expression of GSTM3-3, along with 
GSTMl-1, has been 1neasured in human lung cancer lines resistant to doxirubicin and 
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cisplatin [Hao et al., 1994]. Of particular interest however, is the finding that GSTM3-3 
over-expression inactivates the chloroethyl nitrosourea BCNU [Berhane et al., 1993; 
Egyhazi et al., 1997], the drug of choice for treating brain tumours. The implications of 
polyinorphisms within GSTM3-3 are vast, considering it is found expressed at high 
levels in the brain, and these polymorphisms could possibly alter resistance to this 
hydrophobic drug. 
When considering the effects the GSTM3-3 polymorphisms may have on protein 
function, it is important to take interindividual variation of protein expression into 
account, as discussed in Chapter 3. Various studies have demonstrated distinct 
interindividual variation of GSTM3-3 expression within tissues [Anttila et al., 1995; 
Nakajima et al., 1995] and it is thought that this may be regulated by the intronic 
GSTM3 polymorphism encoded by the GSTM3 * B allele due to the presence of the YYl 
transcription factor in GSTM3*B [Hariharan et al., 1991; Shi et al., 1991; Inskip et al., 
1995]. Another possibly more important consideration to take into account however, is 
the linkage disequilibrium that exists between the GSTM3*B and GSTMJ *A alleles 
[Inskip et al., 1995], an association believed to increase the expression, and thus the 
detoxification abilities, of GSTM3-3 [Yengi et al., 1996]. Through linkage with 
GSTMJ * A, GSTM3 * B is believed to confer protective effects on disease normally 
associated with the GSTMJ *0 allele such as skin cancers [Yengi et al., 1996] and 
vanous smoking related diseases such as lung [To-Figueras et al., 2000] and oral 
cancers [Jahnke et al., 1996; Matthias et al., 1998]. Oral cancer association studies 
have, however, been conflicting. No associations have been found between the GSTMJ 
and GSTM3 alleles with oral or pharyngeal cancers [Jourenkova-Mironova et al., 
1999a]. Ethnic differences have been observed in the incidence of laryngeal cancer 
[Worrall et al., 1998; Park et al., 2000] and an increased risk of laryngeal cancer has 
been reported due to the combined effects of the GSTMJ *0 and GSTM3*A *B or 
GSTM3*B*B alleles [Jourenkova-Mironova et al., 1999b]. It has been suggested that 
the negative and positive regulatory properties of YYl may be responsible for this 
conflict [Jouvenkova-Mironova et al., 1999b]. It may be possible that the two GSTM3 
polymorphisms detected in this study are also strongly associated with the expression of 
specific GSTMJ alleles, the GSTM3 intronic deletion or with other genes and thereby 
act as risk n1odifiers to various diseases. It would be of interest to determine whether 
the two GSTM3 polymorphisms detected in this study can be associated with the 
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GSTMJ polymorphisms or the GSTM3 intronic polymorphism and if they are, to 
determine whether these associations exert any functional effects or affect expression 
levels. 
A final point to take into consideration when determining the effects the GSTM3 
polymorphis1ns may have on protein function is the large variation in the distribution of 
allele frequencies among the ethnic groups studied here. The Chinese population 
presented a completely different GSTM3 polyinorphis1n profile to the Australian 
European and two African populations, and whilst this profile may be beneficial or 
contribute to a disease phenotype in the Southern Chinese population, the same profile 
in the Bantu African, Creole African or Australian European populations may be 
associated with different phenotypes. For example, a significant increase in 
susceptibility to head and neck cancer associated with the GSTMJ*0 allele has been 
observed in the Japanese population, but not in Caucasians [Kihara et al., 1993; Park et 
al., 1997]. Also, as discussed earlier, the distribution of allele frequencies is variable 
both between races and also within racial groups. This regional and international 
variation is influenced by differences in genetic, environmental or dietary interactions 
[Kawajiri et al., 1990; Garte, 1998; Park et al., 2000; Risch, 2000]. 
Using a con1bination of database-n1ining methods, a moderate level of genetic 
polymorphism was identified in the human Mu class GST genes. Although each 
method yielded results, this chapter has shown that identification of polymorphism 
should not be limited to one method or technique, especially since some genes are not as 
well represented as others in the various databases. Two polymorphisms exhibiting 
functional and stn1ctural differences were verified in three ethnic populations, the 
GSTM3-3 p.W147G and p.V224I polymorphisms. Further characterisation is required 
to detennine the physiological effects of each. 
CHAPTERS 
THE OMEGA CLASS GSTs 
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5.1 INTRODUCTION 
The two Omega class GSTs, GSTOl and GST02, represent the most recently 
discovered fainily of GST. Unlike many of the GSTs, which were discovered using 
traditional protein purification and characterisation methods, the Omega class GSTs 
were discovered through analysis of the EST database and the GenBank genomic 
sequence database [Board et al., 2000; Morel et al., 2001; Whitbread et al., In Press]. 
Difficulties with purifying the GSTO2-2 isoenzyme and a lack of GSTOl-1 activity 
with the typical range of GST substrates has made it difficult to characterise the role 
these GS Ts may play in detoxification. Despite this, GSTO 1-1 has been ascribed novel 
roles not seen before in any GST isoenzyme including weak thiol transferase and 
dehydroascorbate reductase activities, monomethylarsonic acid reductase activity and 
regulation of ryanodine receptor activity, which together with the broad expression 
profile suggests a fundamental role in cellular 1netabolism [Board et al., 2000]. 
When initially described, it was found that GSTOl-1 possessed weak thiol transferase 
and dehydroascorbate reductase activities [Board et al., 2000] normally associated with 
the glutaredoxin enzymes, which allows them to provide protection against oxidative 
da1nage [Holmgren, 1989; Hohngren, 2000]. Using their thiol-transferase activity, the 
glutaredoxins, and possibly GSTOl-1 [Board et al., 2000], are able to reduce S-thiolated 
proteins and thus restore enzyme activity [Flamigni et al., 1989; Seres et al., 1996]. S-
thiolation of proteins causes conformational changes and hence alters the activity of the 
thiolated protein, a process resulting from oxidative stress in order to provide protection 
against irreversible oxidative da1nage [Kono et al., 1990; Coan et al., 1992; Del Corso 
et al., 1994; Seres et al., 1996; Hanson et al., 1999]. Using this dehydroascorbate 
reductase activity, the glutaredoxins, and again possibly GSTO 1-1, are able to provide 
enough ascorbate to protect neutrophils from the oxidants they release when activated in 
order to protect against bacterial infections [Halliwell et al., 1987; Washko et al., 1993; 
Park & Levine, 1996]. 
GSTO 1-1 has also been in1plicated in the four-step methylation of the carcinogenic 
compound inorganic arsenic (Figure 5 .1 ). Arsenic has been commonly used in 
pesticides, rodenticides, herbicides and in industry, and is generated during mining and 
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Figure 5.1 - The inorganic arseruc biotransformation pathway (adapted from 
[Zakharyan et al., 2001]). SAM is S-adenosyl-L-methionine; SAHC is S-adenosyl-L-
homocysteine. (*) Purine Nucleoside Phosphorylase has recently been identified as 
Arsenate reductase. This reaction requires ( and prefers) DHLP ( dihydrolipoic acid) to 
proceed, not GSH as previously believed [Radabaugh et al., 2002]. 
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smelting activities and burning of fossil fuels [ Aposhian, 1997; Smedley & Kinniburgh, 
2001]. Inorganic arsenic contaminates the drinking water of many countries including 
Bangladesh and some Central American, North American, Asian and Eastern European 
countries in excess of the 1naximum permissible concentrations stipulated by the World 
Health Organisation (WHO) [Smedley & Kinniburgh, 2001; Yamamura et al., 2001] 
and has been associated with various cancers, in particular skin cancer [Bates et al., 
1992], vascular disorders such as Blackfoot disease [Tseng, 1977], hyperkeratosis, skin 
pigmentation changes, neurotoxicity and hepatoxicity [ Abernathy & Morgan, 2001]. 
Paradoxically, arsenical compounds have been used medicinally for thousands of years 
[Klaasen, 1996] and arsenic trioxide is currently used as an effective chemotherapeutic 
agent against many cancers, particularly AML [Soignet et al., 1998], although concerns 
have recently arisen over the use of this compound due to some unexpected deaths of 
acute pro1nyelocytic leukemia patients undergoing arsenic trioxide therapy [Westervelt 
et al., 2001]. Recently, GSTOl-1 was found to be 100% identical to human liver 
MMA v reductase, which is responsible for catalysing the GSH-dependent reduction of 
MMA v to MMAm, the rate limiting penultimate GSH-dependent step in this pathway 
[Zakharyan & Aposhian, 1999; Zakharyan et al., 2001]. The product, MMAm, has been 
found to be more toxic than the parent compound arsenite in mammalian tissues, 
suggesting that this may be responsible for the pathological effects usually attributed to 
arsenic [Petrick et al., 2000; Sampayo-Reyes et al., 2000]. Tolerance and variability in 
the metabolism of inorganic arsenic have been reported [Roscoe, 1862; Vahter et al., 
1995; Aposhian, 1997]. It has been suggested that polymorphisms in the enzymes 
involved in the arsenic biomethylation pathway, especially in the rate-limiting MMA v 
reductase, may be responsible for this observed variability [Zakharyan & Aposhian, 
1999]. It has also been suggested that variability in the toxicity of arsenic trioxide used 
for treatment of AML may have a genetic basis [Westervelt et al., 2001]. 
Unlike any of the other characterised GST isoenzymes, a recent study has shown that 
GSTO 1-1 is able to non-catalytically modulate the activity of ryanodine receptor (RyR) 
calcium release channels found in the endoplasmic reticulum [Dulhunty et al., 2001]. 
More specifically, GSTOl-1 was able to potentiate the activity of the skeletal muscle 
associated ryanodine receptor 1 (RyRl) and inhibit the activity of the cardiac muscle 
assqciated ryanodine receptor 2 (RyR2) [Dulhunty et al., 2001]. RyRs are responsible 
for regulating the release of Ca2+ from intracellular stores. Activation of RyRs during 
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oxidative stress is responsible for an increase in cytoplasmic Ca2+ levels, an event that 
can ultimately trigger apoptosis in both normal and tumour cells [Berridge et al., 1998; 
Mariot et al., 2000; Pan et al., 2000]. It has been suggested that through modulating 
activity of RyRl and RyR2, GSTO 1-1 may be involved in conferring protection against 
apoptosis and oxidative stress [Dulhunty et al., 2001]. 
This chapter describes the use of various database mining techniques to facilitate the 
discovery of novel Omega class polymorphisms. The distribution of the confirmed 
polymorphisms was determined in three ethnic populations and the recombinant 
proteins were characterised enzymatically to determine whether the different sequence 
variations had an effect on the function of the enzyme. 
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5.2 MATERIALS AND METHODS 
Research into the Omega class GSTs was carried out in collaboration with Astrid 
Whitbread, a PhD student in the Molecular Genetics Group. Specifically, all 
recombinant protein work and enzyi11atic characterisation was carried out by Astrid 
Whitbread. Database analysis, PCR/RFLP and structural analysis of the different 
GSTOl-1 variants was carried out by the author. Database analysis and standard PCR 
methods used in this chapter are described in Chapter 2. Techniques unique to this 
chapter are outlined below. 
5.2.1 DATABASE SCREENING 
Potential polyn1orphisn1s in the two O1nega class GSTs were identified and verified 
using the database mining methods described in §2.3, and are listed in Tables 5.1 and 
5.2. 
5.2.2 PCR/RFLP ANALYSIS 
Potentially polymorphic exons of the GSTOJ and GST02 genes were specifically 
amplified fro1n genomic DNA using PCR as described in §2.5 .6.2, in order to perform 
s1nall-scale population studies. The oligonucleotide sequences and the specific 
conditions for each PCR are listed in Table 5.3. The presence of variation in the PCR 
products was detennined by RFLP analysis (§2.5.4.2) using the appropriate restriction 
enzyn1es (Table 5.4). All variants detected altered restriction enzyme sites. Up to 100 
sainples fro1n the Australian European, Bantu African, Creole African and Southern 
Chinese population groups were amplified by PCR to allow allele and haplotype 
frequency determination for polymorphisn1s confirmed by the small-scale population 
screens. 
T a b l e  5 . 1  - G S T  0 1 n e g a  v a r i a n t s  d e t e c t e d  i n  t h e  E S T  d a t a b a s e  b y  t h e  B L A S T  a l i g n m e n t  t o o l  a n d  i n  t h e  U n i  G e n e  d a t a b a s e  b y  
t h e  S N P  F i n d e r  p r o g r a m .  
G e n e  
N u c l e o t i d e  R e s i d u e  E x o n  P r o g r a 1 n  E S T s  w i t h  c D N A  l i b r a r i e s  
S e q u e n c e  
C o n f i r m e d  i n  
a l t e r a t i o n  r e p r e s e n t e d  
c o n f i r m e d a , b  
p o p u l a t i o n  s t u d i e s  
G S T O J  
c . 9 8 C > G  p . P 3 3 R  2  B L A S T  
2  2  
N o - A I 0 5 7 5 4 1  N . S .  
c . 1 6 9 A > G  p . K 5 7 E  3  B L A S T  
2  2  
N o - A A 8 8 9 9 6 1  N . S .  
c . 1 7 3 A > T  p . N 5 8 I  
3  B L A S T  
2  2  
N o - A I 0 8 4 7 8 8 c  
N o  
c . 2 2 9 A > G  p . N 7 7 D  3  B L A S T  
2  1  
N o - A I 9 3 3 3 0 6  N . S .  
c . 2 5 2 C > G  
p . Y 8 4 X  3  B L A S T  
2  2  
N o - A W 1 5 0 1 0 7  N . S .  
c . 2 7 7 C > G  p . L 9 3 V  
3  
B L A S T  
2  2  
N o - A I 2 2 2 7 3 3  N . S .  
c . 2 9 7 G > A  p . G 9 9 G  
3  B L A S T  
2  2  
N o - A W 1 5 0 1 0 7  
N . S .  
c . 3 1  l C > G  
p . P 1 0 4 R  3  B L A S T  
2  2  
N o - A W 1 5 0 1 0 7  
N . S .  
c . 3 8 8 T > C  p . F 1 3 0 L  4  S N P  F i n d e r  
3  3  
Y e s - 0 . 2 0  N o  
c . 4 1 9 C > A  
p . A 1 4 0 D  4  
B L A S T  
2 0  1 6  
Y e s - B E 3 8 5 9 4 0  
Y e s  
c . 4 2 3 C > G  
p . G 1 4 1 G  4  S N P  F i n d e r  
2  2  
N o - 0 . 2 0  
N . S .  
c . 4 4 5 G > T  
p . E 1 4 9 X  4  
B L A S T  
2  2  
Y e s - B E 3 8 9 5 4 0  
N o  
c . 4 9 5 T > A  
p . F 1 6 5 L  
5  S N P  F i n d e r  
2  
1  
Y e s - 0 . 9 9  
N o  
c . 5 5 0 I n s G  
F r a n 1 e s h i f t  
5  B L A S T  
2  
2  
N o - B E 6 2 2 3 4 3  
N . S .  
c . 5 8 5 C > A  p . I -I l 9 5 Q  
6  
B L A S T  
2  
2  
N o - B E 5 6 0 1 4 1  
N . S .  
c . 5 8 7 C > A  
p . T 1 9 6 N  
6  
B L A S T  
1  1  
N o - B E 7 9 1 2 0 8  
N . S .  
c . 5 8 7 C > T  
p . T 1 9 6 I  
6  
B L A S T  
2  
2  
N o - B E 7 2 8 9 0 1  
N . S .  
c . 4 0 6 G > A  p . W 2 0 2 X  
6  S N P  F i n d e r  
1  1  
Y e s - 0 . 9 6  N o  
c . 6 1 4 C > G  
p . A 2 0 5 G  
6  B L A S T  
2  2  
N o - B E 2 5 1 8 9 7  
N . S .  
c . 6 3 6 C > T  
p . V 2 1 2 V  
6  
S N P  F i n d e r  
1 1  1 1  
Y e s - 0 . 6 1  
N . S .  
c . 6 5 0 C > A  
p . T 2 1 7 N  
6  
S N P  F i n d e r  
1  1  
Y e s - 0 . 9 9  
N o  
c . 6 6 9 A > G  
p . Q 2 2 3 Q  
6  B L A S T  
2  
1  
N o - B E 5 6 0 1 4 1  
N . S .  
c . 6 9 9 C > G  
p . S 2 3 3 R  
6  
B L A S T  
3  3  
N o - B E 7 9 6 7 4 6  
N . S .  
G S T 0 2 d  
c . 2 0 7 T > G  
p . F 6 9 L  
B L A S T  
2  2  
N o - B E 3 0 4 9 9 0  
N . S .  
c . 4 2 4 A > G  
p . N 1 4 2 D  
4  
B L A S T  5  5  
Y e s - A W 3 0 1 0 7 4  
Y e s  
a The accession number of the I.M.A.G.E. Consortium (LLNL) cDNA clones sequenced to confirm the presence of potential polyinorphisms 
identified using the BLAST alignment tool is provided 
b Polymorphisms detected using the SNP Finder program are allocated a likelihood score. As the number approaches 1.0, there is a greater 
likelihood that this polymorphism will be real. Sequences were confirmed by viewing the sequence trace data made available at the site. 
c The incorrect I.M.A. G.E. Consortium (LLNL) cDNA clone was received. Small-scale population screening was performed instead to validate 
this sequence variation. 
d GST02 was not represented in the UniGene clusters, hence could not be analysed using the SNP Finder program. 
N.S.: Not Studied 
Table 5.2 - GSTO 1 polymorphisms detected in the SNP databases. 
Nucleotide Residue Exon Database Sequence Confirmed in 
confirmed population studies 
c.169A>G p.K57Ea 3 refseq (0.96)b Yes No 
c.361 T>C p.Sl21P 3 dbSNP (O.Olt Yes No 
c.406A>T p.Kl36X 4 dbSNP (0.1 lt Yes No 
c.419C>A p.Al40Da 4 dbSNP, refseq (0.9St, HGBASE Yes Yes 
c.423C>G p.Gl41Ga 4 dbSNP (0.02t No N.S. 
c.432A>G p.El44E 4 dbSNP, refseq, HGBASE Unablec N.S. 
c.445G>T p.El49Xa 4 refseq (0.96t Yes No 
c.462G>T p.El54D 4 dbSNP (0.02)b Yes No 
c.495T>A p.Fl65La 5 CGAPC (0.99), refseq (0.99)b Yes No 
c.606G>A p.W202Xa 6 refseq (0.96t Yes No 
c.636C>T p.V212Va 6 dbSNP (0.6l)b Yes N.S. 
c.636C>A p.V212V 6 dbSNP (0.6lt Yes N.S. 
c.650C>A p.T217Na 6 CGAPC(0.99), dbSNP (0.99)\ refseq· (0.99)\ HGBASE Yes No 
c.723C>T p .L241L __ 6 dbSNP, ref seq Unablec N.S. 
a These polyinorphis1ns were also detected by the BLAST aliginnent tool and the SNP Finder program. 
b If the SNP was sub1nitted by the GAI to different databases, links to the SNP Finder program were provided, allowing access to 
available sequence trace data. 
c Some sequences were unable to be confirmed directly through the databases, therefore small-scale population screens were used to 
confin11 these polymorphis1ns. 
Table 5.3 - Oligonucleotides used for GSTOJ and GST02 exon amplification. 
Primer 
GSTOJ 
O1Ex3F 
O1Ex3R 
O1Ex4F 
O1Ex4Reva 
O1Ex4Rev2b 
O1Ex4A2 
O1Ex4R2 
O1Ex5F 
O1Ex5R 
O1Ex6F 
O1Ex6R 
GST02 
O2Ex4F 
O2Ex4R 
Exon Primer sequence 
5' • 3' 
3 AGCTAAGTGGATGGCAAAGCC 
TCACTGAACCATAAATGGCAGC 
4 TCTAGGTGCCATCCTTG 
TGATAGCTAGGAGAAATAATTACCTC 
TGATAGCTAGGAGAAATAA 
4 CGATACAGTTAGCCATAAAC 
AACAGCAGTCTGCTGTAAAC 
5 GTGAGTCTTACTACATGCACAAG 
CCACCTGTCATCCTAAATTATGC 
6 TCATCCTAGTTGACCTAGCTCAC 
CTGTTGATGTCAAATCAGTCAGAG 
4 GATTAGGTCCCACATTTG 
GTACCTCTTCCAGGTTG 
Annealing Product 
Conditions Length 
60°C, 18 sec 394 bp 
56°C, 18 sec 127 bp 
48 °C, 18 sec 127 bp 
56°C, 20 sec 303 bp 
63 °C, 20 sec 207 bp 
57°C, 23 sec 334 bp 
50°C, 20 sec 112 bp 
a This primer was used in conjunction with 01Ex4F using the a1mealing conditions 
56°C, 18 sec. 
b This p1imer was used in conjunction with 01Ex4F using the annealing conditions 
48°C, 18 sec. 
Table 5.4 - Restriction Endonuclease Sites used to detect polymorphisms 
in GSTOJ and GST02. 
Variation 
GSTOJ 
p.N58I 
p.S121P 
p.F130L 
p.K136X 
p.A140D 
p.E149X 
p.E154D 
p.F165L 
p.W202X 
p.T217N 
GST02 
p.N142D 
Exon 
3 
3 
4 
4 
4 
4 
4 
5 
6 
6 
4 
Endonuclease 
Site 
Msel 
Bsu36I 
HindIII 
Msel 
Cac8I 
Apol 
BseRI 
Ddel 
Fok! 
Spel 
Sau3AI 
Fragment Size (bp) 
Common Allele Heterozygous Variant Allele 
221,136, 37 221 , 136, 118, 37, 18 221 , 118, 37, 18 
394 394, 310, 84 310, 84 
104, 23 127, 104, 23 127 
127 127, 83 , 44 83 , 44 
68 , 59 127, 68, 59 127 
72, 43 , 12 72, 55,43 , 12 72, 55 
127 127, 114, 13 114, 13 
207 207, 125, 82 125, 8233 
238, 96 334, 238, 96 334 
207, 127 334, 207, 127 334 
112 112, 63 , 49 63 , 49 
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5.2.3 IDENTIFICATION OF A DELETION POLYMORPHISM 
Electrophoresis of GSTO 1 Exon 4 PCR products on polyacrylamide gels revealed the 
presence of three different patten1s: (1) the expected 127 bp wild-type pattern, (2) a 124 
bp fragment and (3) a four-band pattern, with fragments of 124 and127 bp, and a 
doublet of approximately 130 and 131 bp (Figure 5.2). A PCR sample with the four-
band pattern was cloned into the pGEM® -T vector, following the manufacturers 
protocol (Promega). Clones with either the 127 bp or 124 bp insert were identified by 
PCR amplification as described in §2.5 .6.2 using the PCR primer pair O 1Ex4F and 
O1Ex4Rev2 (Table 5.3), followed by electrophoresis through 7% acrylamide gels 
(§2.5.2.2). Clones containing either the 127 bp or 124 bp insert were sequenced using 
the ThermoSequenase cycle sequencing kit as described in (§2.5.5.1). 
5.2.4 RECOMBINANT PROTEIN ANALYSIS 
5.2.4.1 GSTOl-1 
5.2.4.1.1 SITE-DIRECTED MUTAGENESIS 
The GSTOl-1 protein, identified as the GSTOl * A allelic isoform (Table 5.5), was 
expressed in E. coli in the plasmid pQE30 (Qiagen). Using the QuikChange Site-
Directed Mutagenesis Kit (§2.6.3), the GSTOl *B and GSTOl *C allelic isoforms were 
created from GSTOl * A using the primer pair O1A140DA and O1A140DB, and 
E155nulllhO1 and E155null2hO1 respectively (Table 5.6). All mutations were 
confirmed by cycle sequencing (§2.5.5.1). 
5.2.4.1.2 PROTEIN EXPRESSION AND PURIFICATION 
Plasn1ids encoding the GSTOl * A, G-STOl *B and GSTOl *C allelic isoforms were 
transfected into E.coli strain M15(pRep4) (§2.6.2). To express these, 10 mL of an 
overnight culture was diluted 1 :40 into LB supplemented with 100 µg/mL ampicillin 
242 bp-
190 bp-
147 bp-
110 bp-
1 2 3 4 
✓131 bp 
+--130 bp 
+--127 bp 
,124 bp 
Figure 5.2 - GSTO 1 exon 4 undigested PCR products showing the presence 
(GSTOJ *B), or absence (GSTOJ *A) of the three base pair deletion spanning the 
exon4/intron 4 boundary. Lane 1 - pUC/Hpall marker; Lane 2 - the 124 bp GSTOJ *B 
homozygote; Lane 3 - the GSTOJ *A *B heterozygote; Lane 4 - the 127 bp GSTOJ *A 
homozygote. 
Table 5.5 - Nucleotide and amino acid variations in GSTO 1. 
Haplotype Nucleotide 
c.419 c.464-IVS+ 1 
GSTOl *A C aag 
GSTOl *B C Deleted 
GSTOl *C A aag 
GSTOl *D A Deleted 
Residue 
p.140 p.155 
GSTOl*A Ala . Glu 
GSTOl *B Ala Deleted 
GSTOl *C Asp Glu 
GSTOl *D Asp Deleted 
GSTOl-1 
HaplQtype 
GSTOlB 
GSTOlC 
Table 5.6 - Mutagenesis primers used to create GSTO 1-1 recombinant protein variants. 
Primer Mutagenesis Primer Sequences 
Name 5' to 3' 
GSTO1A140Dl GCCAAAATAAAGAAGACTATGATGGCCTAAAAGAAGAATTTCG 
GSTO1A140D2 CGAAATTCTTCTTTTAGGCCATCATAGTCTTCTTTATTTTTGGC 
El55nulllhO1 
E 155null2h01 
GAATTTACCAAGCTAGAGGTTCTGACTAATAAGAAAGACGACC 
GGTCGTCTTCTTATTAGTCAGAACCTCTAGCTTGGT AAA TTC 
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and 20 µg/mL kanamycin. The 400 mL cultures were grown at 37°C to an OD600 of 
approximately 0.8 and protein expression was induced with 0.1 mM IPTG for five 
hours. The cells were harvested by centrifugation at 8.5 K for 10 minutes at 4°C (GSA-
1500 rotor) and resuspended in 20 mL resuspension buffer (50 mM NaH2PO4, 300 mM 
NaCl, pH 6). Cells were lysed by incubation with 200 µg/mL lysozyme on ice for one 
hour followed by sonication (3 x 30 second bursts). Cellular debris was removed by 
centrifugation atl OK for 10 minutes at 4 °C (SS-34 rotor). 
The proteins were all purified at 4 °C by affinity chromatography. Cleared lysates were 
incubated for one hour on a rotary mixer with nickel agarose. The agarose was 
collected by centrifugation at 1000 rpm for 5 minutes and washed with 50 mL of 50 
mM NaH2PO4, 300 mM NaCl, pH 6. The agarose was washed with a further 500 mL of 
50 mM NaH2PO4, 300 1nM NaCl, pH 6 on a scintered funnel, then transferred to a 
column and washed with a further 500 mL of 50 mM NaH2PO4, 300 mM NaCl, pH 6 
followed by 20 mL of 20 mM imidazole, 50 mM NaH2PO4, 300 mM NaCl, pH 7.5. 
The proteins were eluted from the nickel agarose with 500 mM imidazole, 50 mM 
NaH2PO4, 300 mM NaCl, pH 7.5. Fractions containing recombinant GSTOl-1 were 
identified by 12.5% SDS-PAGE (§2.5.2.3). The strongest fractions were pooled and 
dialysed in 20 mM Tris, 60 mM NaCl pH 8. Protein concentrations were determined 
using the Lowry method (§2.5.2.3). 
5.2.4.2 GST02-2 
5.2.4.2.1 AMPLIFICATION AND ISOLATION OF THE GST02 CDNA 
GST02 cDNA, later found to encode the GSTO2* A allelic isoform (p.N142), was 
isolated by PCR ainplification of the I.M.A.G.E. Consortium (LLNL) cDNA Clone 
BE908662, which encodes GST02, using the forward primer hGSTO2EXF 5'-
CACGGATCCTCTGGGGATGCGACCAG-3' and the reverse primer hGSTO2EXR 
5'-CTGAAGCTTTCAGCACAGCCCAAAGTC-3', which have a BamHI and HindIII 
restriction site incorporated respectively. A 25 µL reaction volume contained lx ABI 
reaction buffer IV, 0.2 mM dNTPs, 1.5 mM MgCh, 10 pmol of the forward and reverse 
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primers and 0.1 unit of Taq DNA polymerase. A negative control sample containing all 
components of the reaction except the template was included in each PCR to ensure the 
absence of contamination. PCR conditions involved an initial denaturation step at 95°C 
for 2 minutes followed by 30 cycles of a 95°C denaturation step (30 sec), 54°C 
annealing step (30 sec), and 72°C extension step (1 min), with a final 3 minute 
extension at 72°C. 
cDNA was also extracted from a human testis cDNA library Agtl 1 as described in 
§2.5.1.1 and GST02 cDNA was amplified by PCR using the primer pair hGSTO2EXF 
and hGSTO2EXR described above. This was later found to encode the GSTO2*B 
allelic isoform (p.D142). A 25 µL reaction volume contained lx ABI reaction buffer 
IV, 0.2 mM dNTPs, 1.5 mM MgCh, 5 pmol of the forward and reverse primers, and 0.5 
unit of Taq DNA polyinerase. A negative control sample containing all components of 
the reaction except the template was included in each PCR to ensure the absence of 
contamination. PCR conditions involved an initial denaturation step at 95°C for 2 
minutes followed by 30 cycles of a 95°C denaturation step (30 sec), 54°C annealing step 
(30 sec) and 72°C extension step (1 min), with a final 3 minute extension at 72°C. 
Agarose gel electrophoresis was used to confirm the absence of spurious bands and 
contamination and the presence of PCR product (3 µL). 
5.2.4.2.2 SUBCLONING 
The 747 bp GST02*A PCR product was digested with the restriction enzymes BamHI 
and HindIII and cloned into the BamHI and HindIII sites of the pQE30 expression 
vector, as described in §2.5.4.1 and §2.6.1, downstream and in-frame of the six-histidine 
coding sequence. The 747 bp GST02*B PCR product was similarly treated after 
initially being subcloned into the pGEM®-T (Promega) PCR cloning vector. Both 
constructs were confinned as the GSTO2A and GSTO2B allelic isofonns by cycle and 
auto1nated sequencing as described in §2.5.5.1 and §2.5.5.2. 
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5.2.5 GSTOl-1 ENZYME CHARACTERISATION 
5.2.5.1 STRUCTURAL ANALYSIS 
The GSTOl * A [p.A140;El55], GSTOl *B [p.A140;E155del] and GSTOl *C 
[p.D140;E155] allelic variants were built into the 3-D model of the GSTOl-1 protein 
(PDB file lEEM) as described in §2.6.5. 
5.2.5.2 ENZYMATIC ANALYSIS 
Activity for the GSTOl * A, GSTOl *B and GSTOl *C allelic isoforms was measured 
with the substrate CDNB and thioltransferase activity with the substrate HEDS as 
described in §2.6.4. Three preparations of each isoform were prepared. 
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5.3 RESULTS 
5.3.1 DETECTION OF OMEGA CLASS POLYMORPHISMS 
5.3.1.1 DETECTION USING DATABASE ANALYSIS PROGRAMS 
Polymorphisms in Omega class cDNA sequences located in the human EST and 
UniGene databases were detected using the BLAST alignment tool and SNP Finder 
program respectively. The EST database contained 100 GSTOJ and 46 GST02 cDNAs. 
The UniGene clusters contained 179 GSTOJ cDNA and mRNA sequences. A cluster 
for the GST02 gene was not available at UniGene, hence this could not be analysed 
using the SNP Finder program. From these sequence databases, 21 variants that altered 
amino acid residues were detected in both Omega genes (Table 5.1). Of these, seven 
were confirmed upon resequencing a representative I.M.A.G.E. Consortium (LLNL) 
cDNA clone or viewing existing electropherogra1ns. 
5.3.1.2 DETECTION USING SNP DATABASES 
The dbSNP, HGBASE, GeneSNPs, EGPSNPs and CGAP lists were examined for the 
presence of GSTOJ and GST02 sequences. The SNPper program was also utilised. 
Many GSTO 1 sub1nissions were found and when limited to SNPs that alter amino acid 
residues, three novel variants were identified (Table 5.2). Although some GSTOJ 
variants could be confinned through analysis of electropherograms, small-scale 
population analysis was undertaken for confirmation of all sequence variations 
identified. Eight variants that had been detected using the BLAST alignment tool and 
SNP Finder programs were also detected in these databases. GST02 was not found in 
any of the databases analysed. 
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5.3.1.3 DETERMINATION AND DISTRIBUTION OF ALLELE FREQUENCIES 
25 samples from three ethnic groups were tested for the presence of the ten variants. 
Determination of the nucleotide present at variant sites was achieved by amplification of 
the relevant exons followed by digestion with the appropriate restriction enzyme (Table 
5.4). Of these, only two polymorphisms: GSTOl p.Al40D (Figure 5.3) and GST02 
p.N142D (Figure 5.4), were found in the sample populations. Allele frequencies for 
these two polymorphisms were subsequently determined in up to 100 samples for the 
Australian European, Bantu African, Creole African and Southern Chinese populations 
(Table 5.7). For the GSTOl polymorphism, the p.D140 allele was relatively rare in the 
two African and Southern Chinese populations, being found at frequencies between 10-
18%. Homozygotes for this allele were absent in the Bantu African population. In 
contrast, the p.D140 allele occurred more frequently in the Australian European 
population, at 33.5%. Chi-square analysis provided support for genotypic differences 
between the four populations (x\ = 31.58, p<0.05). Notably, evidence was provided 
for a genotypic difference between the Australian European population with the 
remaining three groups (Australian European/Bantu African: x\ = 24.49, p<0.05; 
Australian European/Creole African x\ = 10.53, p<0.05; Australian European/Southern 
Chinese: x22 = 14.59, p<0.05). In GST02, the p.D142 allele was found to be quite 
common, and occurred most frequently in the two African populations, especially in the 
Bantu African population where it appears that this is the common allele 
(p.Dl42=83%). Evidence for significant genotypic differences between the four 
populations was found (x26 = 121.27, p<0.05), although there was no significant 
genotypic difference between the Australian European and Southern Chinese groups 
ex\ = 2.35, p>0.05). 
5.3.2 DETECTION OF A 3 BASE PAIR DELETION POLYMORPHISM 
Three bands of unknown origin, in addition to the wild-type 127 bp fragment, were 
detected whilst genotyping samples for the p.A140D polymorphism in GSTOl exon 4. 
The four bands were observed in the three combinations described as follows: (1) the 
expected 127 bp wild-type pattern; (2) a 124 bp fragment and (3) a four-band pattern, 
190 bp -
147 bp -
110 bp -
67 bp-
1 2 3 4 
Fragment (bp) 
127 
68 
59 
5 6 7 8 9 
CIC CIA A/A 
• 127 bp 
• 68bp 
• 59bp 
Figure 5.3 - PCR/RFLP analysis of the GSTOJ p.Al40D variant. A 127 bp PCR product 
spanning exon 4 of the GSTO 1 gene was digested with Cac8I for nucleotide 419 
determination. Lanes 1, 8 - Cl A heterozygotes; Lanes 3-7 - CIC homozygotes; Lane 9 -
Al A homozygote; Lane 2 - pUCI Hpall marker. 
190 hp -
110 hp -
67 hp-
1 2 3 4 5 6 7 8 9 10 11 
Fragment (bp) 
112 
63 
59 
A/A A/G GIG 
• 112 hp 
• 63hp 
• 59hp 
Figure 5.4 - PCR/RFLP analysis of the GST02 p.N142D variant. A 112 hp PCR 
product spanning exon 4 of the GST02 gene was digested with Sau3AI for nucleotide 
424 determination. Lanes 2, 4 - GIG homozygotes; Lanes 3, 5-7, 9, 11 - A/A 
homozygotes; Lanes 8, 10 - A/G heterozygotes; Lane 1 - pUC/Hpall marker. 
Table 5.7 - GSTOJ and GSTO2 allele and haplotype frequencies in three ethnic populations. 
Gene Polymorphism Population n Genotype Allele Frequency 
GSTOJ p.A140D Australian 100 C/C=45 C/A=43 A/A=12 p.A140=0.665 p.D140=0.335 
Bantu African 72 C/C=58 C/A=14 AIA=O p.A140=0.90 p.D140=0.10 
Creole African 81 C/C=55 C/A=23 A/A=3 p.A140=0.82 p.D140=0.18 
Chinese 100 C/C=71 C/A=25 A/A=4 p.A140=0.835 p.D140=0.165 
p.El55del Australian 100 A*/A*=94 A*/B*=6 B*/B*=0 p.E155=0.97 p.del155=0.03 
Bantu African 68 A*/A*=66 A*/B*=2 B*/B*=0 p.El55=0.99 p.dell 55=0.01 
Creole African 85 A*/A*=75 A*/B*=l0 B*/B*=0 p.El55=0.94 p.del155=0.06 
Chinese 100 A*/A*=91 A */B*=8 B*/B*=l p.El55=0.95 p.del155=0.05 
GST02 p.N142D Australian 100 A/A=49 A/G=40 G/G=l 1 p.N142=0.69 p.D142=0.3 1 
Bantu African 73 A/A=3 A/G=19 G/G=51 p.N142=0.17 p.D142=0.83 
Creole .A.frican 85 A/A=23 A/G=40 G/G=22 p.N142=0.51 p.D142=0.49 
Chinese 98 A/A=50 A/G=43 G/G=5 p.N142=0.73 p.D142=0.27 
Gene Population n Haplotype 
GSTOJ*A GSTOJ*B GSTOJ*C 
[p.A140;E155] [p.Al 40;dell 55] [p.D140;E155] 
GSTOJ Australian 100 0.635 0.030 0.335 
Bantu African 68 0.900 0.015 0.081 
Creole African 81 0.760 0.060 0.180 
Chinese 100 0.785 0.050 0.165 
Note: All polyn1orphisms are in agreement with the Hardy-Weinberg equilibriun1. 
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with fragments of 124 and 127 bp and a doublet of approximately 130 and 131 bp 
(Figure 5 .2). These bands persisted in the same samples with the use of two different 
sets of GSTOl Exon 4 primers (O1Ex4F and O1Ex4Rev2, and O1Ex4A2 and O1Ex4R2 
in addition to O1Ex4F and O1Ex4Rev) and upon digestion with various restriction 
enzymes, indicating that the bands were not PCR artefacts, but due to the presence of a 
polymorphism undetected by database analysis. 
One of the samples displaying the four-banded pattern was cloned into the pGEM® -T 
vector following the manufacturers protocol (Promega). The inserted DNA from the 
resulting clones was amplified by PCR and the products separated on 7% acrylamide 
gels. Clones containing either the 124 bp or 127 bp inserts were sequenced and 
revealed the deletion of three base pairs, AGg, spanning the exon4/intron4 boundary of 
GSTOl (Figures 5.5 and 5.6). Individuals with the 127 bp GSTOl exon 4 PCR products 
were found to be homozygous for the most common allele and termed GSTO 1 *A. 
Individuals with the 124 bp GSTOl exon 4 PCR products were found to be homozygous 
for the GSTO 1 * B allele. Samples displaying the four-band pattern were found to be 
heterozygous (GSTOl *A *B). When the two alleles combine, heteroduplexes are 
formed and give rise to the appearance of the two larger fragments. A similar 
occurrence has been reported in individuals heterozygous for the 3 bp deletion in 
GSTM3 intron 6 [Inskip et al., 1995]. 
There are two potential outcomes generated by the absence of the three bases at the 
exon 4/intron 4 boundary of GSTO 1. Firstly, the disruption of the existing splice donor 
site may result in the transcription of a truncated protein due to the introduction of a 
premature stop codon in intron 4 (Figure 5 .6A). Alternatively, deletion of AG from the 
p.El55 (GAG) codon, may allow the remaining G to form part of a new splice donor 
site (Figure 5.6B). The transcribed protein would lack the p.E155 residue. In order to 
determine the most likely outco1ne, GSTO 1 cDNA query sequences representative of 
each possible outcome were used to search the EST database. Query A represented the 
truncated version of GSTOl, and Query B the version lacking p.E155. The Query A 
sequence terminated 3 7 nucleotides early and ended with two nucleotides that are 
identical in both the intron 4 and exon 5 sequence (Figures 5.5 and 5.7 A). 48 out of 50 
ESTs ( only 23/25 are represented) tenninated at c.463, which corresponds to the third 
A. B. 
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Figure 5.5 - Autoradiograph of a sequencing gel showing the GSTO 1 * A and GSTO 1 * B 
sequences. (A.) Wild-type GSTOJ *A sequence. (B.) GSTOJ *B sequence showing the 
deletions of three bases: 5 '-A GG-3'. 
A. 
123 V P S L V G S F I R S Q N K E D Y A 
GTGCCATCCTTGGTAGGAAGCTTTATTAGAAGCCAAAATAAAGAAGACTATGCT 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
GTGCCATCCTTGGTAGGAAGCTTTATTAGAAGCCAAAATAAAGAAGACTATGCT 
123 V P S L V G S F I R S Q N K E D Y A 
141 G L K E E F R K E F T K L E E 
GGCCTAAAAGAAGAATTTCGTAAAGAATTTACCAAGCTAGAGGAGgtaattatt 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
GGCCTAAAAGAAGAATTTCGTAAAGAATTTACCAAGCTAGAGG---TAATTATT 
141 G L K E E F R K E F T K L E V I I 
tctcctagctatcatcagagtaaacgataactatatctaccc GSTOl*A 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
TCTCCTAGCTATCATCAGAGTAAACGATAActatatctaccc GSTOl*B 
158 S P S Y H Q S K R X 
B. 
149 E F T K L E E Splice site 
,-J., 
GAATTTACCAAGCTAGAGGAGgtaattatttctcctagctat GSTOl*A 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
GAATTTACCAAGCTAGAGG--- t aattatttctcctagctat GSTOl*B 
"--y-1 
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Figure 5.6 - The three base pair deletion spanning exon 4/intron 4 of GSTO 1 has two 
potential outcomes. Differences are highlighted in red. The exonic sequence is 
capitalised and the intronic sequence is shown in little letters. Residue names are 
centred above the middle nucleotide of the codon. (A). The 3 bp deletion 1nay 
introduce a premature stop codon in intron 4. Comparison of exon 4 and part of intron 4 
of the GSTO 1 * A and GSTO 1 * B sequences show the putative premature stop codon 
created in GSTOJ *B due to the 3 bp deletion. (B). The 3 bp deletion may destroy the 
existing splice donor site. Comparison of exon 4 and part of intron 4 of the GSTO 1 * A 
and GSTO 1 * B sequences demonstrate that the splice donor site may reform using the 
first codon position G from p.E155, causing the deletion of p.El55. 
Figure 5. 7 - Representative alignment of human EST sequences with the two possible 
consequences of the GSTOJ three base pair deletion used as the query sequence. 
Exonic sequences are capitalised, intronic sequences are represented by little letters. 
(A). Deletion of three bases across the exon4/intron 4 boundary of the GSTO 1 gene 
may disrupt the splice donor site hence the transcript will read through into intron 4 and 
create a pre1nature stop codon, as represented by Query A. Most of the ES Ts terminate 
at c.463, indicating that they do not read through into the intronic sequence. Two ESTs, 
highlighted in red, contain one extra nucleotide, which may represent part of the intron 
4 sequence or part of exon 5. The fact that Query A sequence terminates 3 7 nucleotides 
early and ends with two nucleotides that are identical in both the intron 4 and exon 5 
sequences indicates that no ES Ts read through into the intron 4 sequence of GSTO 1. 
(B). Deletion of three bases across the exon4/intron 4 boundary of the GSTO 1 gene 
may alternatively delete the gluta1nic acid encoded by residue 155. Only the two ESTs 
highlighted in red contain this deletion and continue with nonnal transcription. 
A. 
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position nucleotide in codon 154, indicating that they do not read through into the 
intronic sequence or exon 5. It was concluded that these ES Ts did not contain the 3 
base pair deletion. Two ESTs from different cDNA libraries, BI194912 and BQ068423, 
terminated at the same position as the Query A sequence. As these sequences all 
terminated 3 7 bases before the premature stop codon, it was assumed that these ES Ts 
contained the three base pair deletion and that splicing continued as normal. This was 
confirmed by using Query B, which lacked p.El55, as the BLAST query sequence 
(Figure 5.7B). 
As seen in Table 5. 7, the GSTO 1 * B allele was relatively rare in the Australian 
European, Bantu African, Creole African and Southern Chinese populations studied 
here, with only one Southern Chinese individual homozygous for the GSTO 1 * B allele 
identified. No evidence for different genotypic distributions between each race was 
observed (x2 6 = 7.25, p>0.05). The two allelic variants of GSTOl can be combined into 
four potential haplotypes, and these are described in Table 5.5. Only three of the four 
haplotypes were observed in the populations studied (Table 5.7). 
5.3.3 ENZYME CHARACTERISATION 
5.3.3.1 STRUCTURAL ANALYSIS 
To evaluate the potential effects of the p.A140D and p.E155del polymorphisms may 
have on the GSTO 1-1 protein, the substitutions were modelled into the 3-D structure of 
GSTOl-1 (Figure 5.8). Neither residue 140 or 155, both of which are located in the a5 
helix, interact with the active site. The p.A140D change involves the substitution of 
alanine, a small nonpolar amino acid with the larger charged, polar aspartic acid, yet 
this substitution does not majorly affect the overall protein structure (Figure 5.9A), with 
no evidence of altered H-bond interactions detected (Figure 5.9B). In contrast, the 
deletion of residue 15 5 disrupts not only the structure of the helix, but also the entire 
protein (Figure 5 .1 0A), causing substantial confonnational changes to the catalytically 
essential p.C32 residue and the subsequent introduction of two new H-bonds between 
p.C32 and p.A35, and p.S28 and p.M29 (Figure 5 .1 OB). 
Figure 5.8 - Ribbon diagram of GSTO 1 depicting the position of the polymorphic 
p.A140D substitution and the position of the deleted p.El55 residue. The most 
common amino acids, p.A140 and p.E155, are shown in black. The least common 
amino acid, p.D 140, is coloured red. Glutathione, shown in gold, is bound in the active 
site. The catalytically essential p.C32 residue is coloured green. 
Figure 5.9 - Carbon backbone of the GSTOl monomer encoding p.A140 overlaid with 
the protein encoding p.D140. GSTOl encoding the more common a1nino acid p.Al40 
( depicted in black) is coloured grey; GSTO 1 encoding the less conm1on amino acid 
p.D140 (depicted in red) is coloured blue. Glutathione, shown in gold, is bound in the 
active site. The catalytically essential p.C32 residue is coloured green. (A). 
Substitution of the p.D140 residue for the p.A140 residue does not alter the overall 
structure of the GSTOl protein. (B). Magnification of residue 140 and neighbouring 
residues. H-bonds common to both variants are coloured dark blue; those introduced by 
the substitution of p.A140 for p.D140 are shown in pink. 
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Figure 5.10 - Carbon backbone of the GSTOl monomer encoding p.El55 overlaid with 
the protein 1nissing p.El55. GSTOl encoding p.El55 (depicted in black) is coloured 
grey; GSTOl in which p.El55 is deleted is coloured blue, and the residues non11ally 
adjacent to p.El55 are depicted in red. Glutathione, shown in gold, is bound in the 
active site. The catalytically essential p.C32 residue is coloured green. (A). Deletion of 
the p.El55 residue introduces considerable alterations to the overall structure of the 
GSTOl protein. (B). Magnification of residue 32 and neighbouring residues. H-bonds 
common to both variants are coloured dark blue; those introduced by the deletion of 
p.El55 are shown in pink. 
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5.3.3.2 ENZYMATIC ANALYSIS 
Site directed mutagenesis was used to create the GSTOl * A, GSTOl *B and GSTOl *C 
allelic recombinant isoforms in order to determine whether these variants had an effect 
on the catalytic efficiency of the protein. As predicted by the structural modelling, no 
significant differences in activity were observed between the p.A140 and p.D140 
variants. However, significantly higher activities towards both CDNB and HEDS were 
measured for the GSTOl *B variant (p<0.001), with a 1.34-fold and 1.38-fold increase 
in specific activity respectively (Table 5 .8). 
The GSTO2 * A and GSTO2 *B reco1nbinant allelic isoforms were unable to be 
characterised enzymatically due to protein insolubility problems. 
Table 5.8 - Specific activities of recombinant GSTOl-1 variants towards the substrates 
CDNB and REDS . 
Substrate GSTOl*A GSTOl*B GSTOl*C 
[p.A140;E155] [p.A140;del155] [p.D140;El55] 
µmol/min/mg 
1-chloro-2,4-dinitrobenzene 0.047 ± 0.014 0.063 ± 0.011 0.039 ± 0.013 
2-hydroxyethyl disulfide 2.616 ± 0.262 3.604 ± 0.364 2.499 ± 0.177 
Results are the 1nean ± S.D. for at least ten determinations. 
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5.4 DISCUSSION 
Despite the lack of detoxification activities currently ascribed to the recently discovered 
Omega class GSTs, a number of novel physiological roles never before described in the 
GST superfamily have been attributed to GSTO 1-1. With its broad expression profile, 
weak thiol transferase and dehydroascorbate reductase activities, involvement in the 
biomethylation of inorganic arsenic and regulation of ryanodine receptor activity, it 
would appear that GSTO 1-1 has a fundamental role in cellular metabolism [Board et al., 
2000]. Polymorphisms in the GSTO 1 gene could potentially alter these activities with 
unknown consequences. By discovering novel polymorphisms in the GSTO 1 gene, the 
roles underlying these processes can be further investigated. Unfortunately, although 
polymorphisms can be identified in the GST02 gene, the function of this gene, and 
therefore any polymorphic consequences, remain unknown due to protein expression 
problems. This is currently being addressed in this laboratory. 
Polyinorphisms in the On1ega class GSTs were detected using an approach combining 
the use of computer based programs to search the EST and UniGene sequence 
databases, and the analysis of SNP databases for the presence of GST Omega variants. 
Variants were discovered in both the GSTOl and GST02 genes by using the BLAST 
aligmnent tool to search the EST database, although there was a distinct lack of 
variation detected in GST02 (Table 5.1) possibly due to poor representation in the EST 
database. In contrast to GSTOl, which was well represented by 100 ESTs, GST02 was 
moderately represented by 46 ESTs. As GSTO2-2 is moderately expressed in a range 
of tissues [Whitbread et al., In Press], the existence of other polymorphisms in this gene 
is unlikely to be detected until more full-length GST02 cDNA sequences are submitted 
to the EST database. 
Polymorphisms in the GSTOJ gene were discovered using the SNP Finder program to 
search the GSTOl UniGene cluster, which consisted of 179 EST and mRNA sequences. 
Analysis of GST02 could not proceed due to the lack of a representative GST02 
UniGene cluster (Table 5.2). UniGene clusters are designed using information 
pertaining to characterised genes, with each cluster composed of ESTs and full-length 
mRNA sequences that have been deposited in various sequence databases. Sequences 
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that cannot be clustered are considered novel [Boguski & Schuler, 1995; Schuler et al., 
1996]. The GST02 gene, which has only recently been identified [Whitbread et al., In 
Press], falls into this category. 
Analysis of the SNP databases for the presence of GST Omega sequences revealed the 
presence of GSTO 1 (Table 5 .2) in all but the EGSNPs and GENESNPs databases. The 
SNPper SNP detection program was also unable to detect any GSTOl variants in the 
main SNP databases. In contrast, GST02 was not represented in any of the SNP 
databases analysed. One possible explanation for the absence of GST02 variants could 
be that these had been mistakenly identified as GSTO 1 variants and hence listed with 
other GSTOl submissions. However, this is unlikely as the GSTOl and GST02 
sequences share only 64% sequence identity [Whitbread et al., In Press], and there was 
no evidence that this had happened. Therefore, as discussed above, the absence of 
GST02 is most likely to be due to its novel status. 
Using this combined database mining approach, a total of ten novel missense variants 
were identified and verified in the GSTOl and GST02 genes: seven were identified 
using the BLAST alignment tool and SNP Finder program, and three were detected in 
the SNP databases (Tables 5 .1 and 5 .2). Of these, only two were present in the 
Australian European, Bantu African, Creole African and Southern Chinese populations 
- the GSTOl p.A140D and the GST02 p.N142D polymorphisms. The remaining 
variants may be rare alleles, and it is most likely that the absence of the GSTO 1 
p.Sl21P, p.K136X and p.E154D polymorphisms in these populations fall into this 
category. These three variants were identified by CGAP with the use of the SNP Finder 
program and were subsequently submitted to dbSNP. All three variants have an 
extremely low likelihood score (Table 5 .2), which generally implies that these variants 
may not be real. Small-scale population screening was continued as analysis of the 
original trace data of the relevant sequences confirmed that these sequence alterations 
were real. Although only one sequence was verified for the GSTOl p.S 121P and 
p.Kl36X variants, three cDNAs generated from two different libraries were confirmed 
for the p.E154D variant. The absence of the remaining GSTOl variants, especially 
those with likelihood scores greater than 0.9 (Table 5 .2) may be due to associations with 
ethnic groups not screened in the present study, as the origin of the cDNA in the EST 
and UniGene databases is unknown. 
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The only confirmed GST02 polymorphism detected using this bioinformatic approach, 
the p.N142D polymorphism, was also detected during independent cloning of a GST02 
cDNA for characterisation studies of the GST02 gene [Whitbread et al., In Press]. This 
polymorphism was found to be quite common in the populations screened in this study. 
The p.Dl42 allele occurred n1ost frequently in the two African populations. This was 
found in approximately 50% of the Creole population screened, and at 83% appeared to 
be the common allele in the Bantu African population. The Australian European and 
Chinese groups showed similar allele distributions, with the p.Nl42 variant being the 
most common allele. Unfortunately, due to GST02 protein purification problems, 
subsequent enzymatic characterisation of this polymorphism was unable to be 
investigated in the course of this study. However, it can be hypothesised that although 
this polymorphism does not occur in the active sites of GSTO2-2, substitution of the 
uncharged, polar asparagine residue for the charged aspartic acid residue, which is also 
polar and of a similar size, may affect the structural integrity of the protein, perhaps due 
to indirect interactions with active site residues, packing or backbone stabilisation. 
The GSTOl p.Al40D polymorphism was also relatively common in all the populations 
tested, although the frequency of the p.D140 allele was notably lower in the Bantu 
African group at 10%. No significant alterations in thiol-transferase or GST activity 
were detected during enzymatic characterisation of the GSTO 1 * A and GSTO 1 *C allelic 
isoforms. Although the p.A140D polymorphism involves the non-conservative 
substitution of alanine, a small nonpolar amino acid with the larger charged, polar 
aspartic acid, the external orientation of residue 140 at the N-terminal end of helix a5 
makes it unlikely that this will influence GSTO 1-1 activity. These results are consistent 
with predictions based on 3-D modelling, which demonstrated that the A140D 
substitution had no effect on the structure of the protein (Figure 5.9). However, with the 
exception of MMA v, which could not be tested in this study, a unique GSTOl-1 
substrate has not been identified, hence the full effects of the GSTO 1-1 p.Al40D 
polymorphism will re1nain unknown until substrates specific for GSTO 1-1 are 
identified. 
During the GSTO 1 polymorphis1n screening process, a novel three base pair deletion 
occ_urring in a trinucleotide repeat was detected spanning the exon 4/intron 4 boundary 
of GSTOl (Figure 5.6). The 1najority of deletion polymorphisms occur within repetitive 
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regions with trimeric and tetrameric short tandem repeats, prime targets for DNA 
polymerase slippage, being especially polyinorphic within the human genome [Edwards 
et al., 1989; Edwards et al., 1991; Krawczak & Cooper, 1991]. The deletion of AG 
from GAG, the last codon in exon 4 (p.E155), allowed the Gin the first codon position 
to replace the deleted splice donor site G (Figure 5.6B). This in effect deleted the 
p.El55 residue and created a new splice donor site. Splicing was predicted to continue 
as usual, as the splice donor site consensus sequence containing the invariant GT 
dinucleotide [Mount, 1982] was not altered. This polymorphism was found to be 
relatively rare in the three populations genotyped in this study, with only one 
homozygous individual detected in the Southern Chinese population. Enzymatic 
characterisation of the GSTO 1 *B recombinant allelic isoform demonstrated a 
significant increase in enzyme activity when compared with the GSTOl * A protein. 
Although residue 155 is not located in the active sites, it is possible that its location near 
the C-tenninal end of helix a5 may be i1nportant for maintaining the structure and 
stability of the helix, hence deletion of this residue may disrupt protein stability and 
alter protein function. Conformational changes to the overall structure of the protein 
were supported by predictive modelling (Figure 5.1 0A). In addition, substantial 
conformational changes were introduced around the catalytically essential p.C32 
residue, causing the creation of three new H-bonds (Figure 5.1 OB). It is possible that 
the co1nbined effects of these changes are responsible for the observed alterations in 
enzymatic activity. 
Only one other small deletion polymorphism has been described in the GST superfamily 
- the three base pair deletion occurring in intron 6 of the GSTM3 gene [Inskip et al., 
1995]. This GSTM3 polyn1orphism has been associated with altered expression levels 
of GSTM3-3, and is strongly associated with another known Mu class polymorphism 
encoded by the GSTMl * A allele. Together these have been implicated in moderating 
susceptibility to va1ious diseases [Yengi et al., 1996; Jahnke et al., 1996]. It is possible 
that the GSTO 1 * A or GSTO 1 * B alleles could also be linked with other Omega class 
polyn1orphisn1s or with other loci. Further investigations are warranted. 
GSTO 1 has recently been identified as MMA v reductase, an enzyme involved in the 
bioactivation pathway of inorganic arsenic (Figure 5.1) [Zakharyan et al., 2001]. It is 
therefore possible that GSTO 1 polymorphisms could alter this activity. GSTO 1-1 
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catalyses the reduction of MMA v to MMAm, which is more toxic than the parent 
compound arsenite in mainmalian tissues, suggesting that this may be responsible for 
the pathological effects usually attributed to arsenic [Petrick et al. , 2000; Sampayo-
Reyes et al., 2000]. As many tissues have the capacity to produce the highly toxic 
intermediate MMAm, due to the wide tissue distribution of GSTO 1-1 [Board et al., 
2000] and the other enzyines involved in this pathway, each may be a potential target 
organ for arsenic toxicity and/or carcinogenicity [Sampayo-Reyes et al., 2000]. Many 
studies have reported correlations between high levels of arsenic in drinking water 
sources with various arsenic associated diseases such as cancers of the skin and various 
internal organs [Chen et al., 1985], Blackfoot disease in Taiwanese populations [Tseng, 
1977; Chen et al., 1985], cutaneous disorders in rural villages in North Mexico [Cebrian 
et al., 1983] and open lesions in West Bengal [Guha Mazumder et al., 1988]. 
Despite the toxicity of arsenic, tolerance to arsenic poisoning has been described in 
populations exposed to high levels of inorganic arsenic. Consumption of lethal doses of 
arsenic with no apparent ill effect was first reported in_ 1862 in the Styrian population 
located in the Austrian Alps [Roscoe, 1862; Aposhian, 1997]. Subsequent studies have 
concentrated on areas where the drinking water is contaminated with levels of inorganic 
arsenic exceeding the 10 µgAs/L recommended by WHO [Yamamura et al., 2001]. 
Residents in the Chilean village of San Pedro de Atacama were found to have a higher 
body burden of arsenic, but did not seem to develop arsenic associated disease despite 
the extre1nely high ( 600 ~tgAs/L) levels of arsenic contaminating their drinking water 
[ Aposhian et al., 1997]. Large variations in the urinary biomarkers used to measure 
arsenic exposure (MMA, DMA and inorganic arsenic) have also been reported in 
Andean women fro1n four different northern Argentinian village populations [V ahter et 
al., 1995], Ro1nanians, Chileans and Mongolians [Aposhian et al., 2000a; Aposhian et 
al., 2000b]. It has been suggested that arsenic tolerance and these variations may be 
associated with polymorphisms in the enzymes involved in the bioactivation pathway, 
especially in the rate-li1niting MMA v reductase GSTOl-1 [Vahter et al., 1995; 
Aposhian et al., 1997; Zakharyan & Aposhian, 1999; Aposhian et al., 2000a; Aposhian 
et al., 2000b]. It is possible that at least one of the GSTO 1 polymorphisms described in 
the present study may be associated with these observed variations. It would be of 
interest to genotype populations exposed to high levels of inorganic arsenic. These 
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populations could be further grouped into (1) those that develop arsenic associated 
disease, (2) those that do not develop arsenic associated disease and (3) those with 
variable urinary concentrations of MMA, DMA and inorganic arsenic. 
The role of GSTO 1-1 in the metabolisn1 of inorganic arsenic may also extend to the 
application of inorganic arsenic in chemotherapy. Inorganic arsenic is currently used as 
a chemotherapeutic agent for the treatment of 111any cancers, in particular AML. It is 
thought to act by causing partial cytodifferentiation of tumour cells, caspase activation 
and subsequent induction of apoptosis [Soignet et al., 1998]. Although this is an 
effective treatment, with only mild to moderate side effects usually reported [Shen et 
al., 1997; Ohnishi et al., 2000; Soignet et al., 2001], concern over its use has increased 
with the recent unexpected deaths of three AML patients receiving arsenic trioxide 
treatment [Westervelt et al., 2001]. Notably, these patients were all of African 
American descent. It is believed that the different susceptibility to the toxicity of 
arsenic trioxide, as manifested by varied side effects, may be due to polymorphisms in 
the genes responsible for arsenic metabolism [Westervelt et al., 2001]. It is possible 
that the polymorphisms identified in this study may also be associated with this 
variation, in particular the p.Al40D polymorphism. As seen in Table 5.7, homozygotes 
for the p.Dl40 allele were severely under-represented in the Creole African population, 
and absent in the Bantu African population. It is therefore important to determine 
whether this polymorphis111, in addition to the deletion polymorphism identified in this 
study, do in fact influence the bio111ethylation of inorganic arsenic in order that AML 
and other cancer patients carrying these polymorphisms can be administered a safer 
che111otherapeutic treatment. 
Polyn1orphisms in GSTO 1-1 may also be of importance in patients with radiation 
resistant tumours. An association between the over-expression of the mouse GSTO 1-1 
orthologue p28 with the observed resistance of mouse lymphoma cell lines to radiation 
and chemotherapeutics [Kodyin et al., 1999]. Over-expression of various classes of 
GSTs has been associated with resistance to different chemotherapeutic agents [Tew, 
1994], hence it is possible that over-expression of the GSTOl-1 protein may lead to 
tumour cell resistance to inorganic arsenic in addition to resistance to radiation. As 
mutations are known to alter drug resistance [Hayes & Wolf, 1990], the polymorphisms 
in GSTO 1-1 described in this study could hypothetically alter not only the 
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chemotherapeutic effects of inorganic arsenic, but also the effects of radiation in a wide 
range of target tissues. 
The two GSTOJ polymorphisn1s may also affect GSTOl-1 modulation of ryanodine 
receptors RyRl and RyR2, thereby regulating the release of Ca2+ from intracellular 
stores. RyRl and RyR2 have been detected in various tissues [Xu et al., 1998a] in 
addition to the skeletal and cardiac muscle tissue in which RyRl and RyR2 respectively 
are typically expressed [Takeshima et al., 1989; Otsu et al., 1990; Zorzato et al., 1990]. 
RyRl has also been detected in B-lymphocytes, which require Ca2+ for B-cell response 
determination [Sei et al., 1999]. Activation of RyRs increases cytoplasmic Ca2+ levels 
during oxidative stress [Dulhunty et al., 2000]. As an increased cytoplasmic Ca2+ 
concentration is an essential stage during the induction of apoptosis, RyRs activation 
could be responsible for triggering apoptosis in both normal and tumour cells [Berridge 
et al., 1998; Mariot et al., 2000; Pan et al., 2000]. The finding that GSTOl-1 is able to 
potentiate RyRl and inhibit RyR2 has also led to the suggestion that it may be involved 
in the modulation of B-cell immune responses in addition to conferring protection 
against apoptosis and oxidative stress through inhibition of RyR2 activation [Dulhunty 
et al., 2001]. Polymorphisms in GSTOl-1 could possibly alter these protective effects. 
As discussed in Chapters 3 and 4, there are three important points to consider when 
assessing the effects polymorphis1ns may have on protein expression and function. 
Firstly the effects of interindividual variation of protein expression must be taken into 
account as it has been suggested that the resultant variation in enzyme activity may be 
greater than that caused by genetic polymorphisms [Coles et al., 2000]. Although 
interindividual variation of GSTO 1-1 expression has not yet been reported, the marked 
variation observed for n1any members of the GST superfamily [Hayes et al., 1989; 
Singhal et al. 1993; Anttila et al., 1995; Nakajima et al., 1995; Mulder et al., 1999; 
Coles et al., 2000] suggests that this should not be overlooked. Secondly, linkage 
disequilibriun1 between polyinorphisms in both the Alpha and Mu class GSTs been 
shown to affect the expression levels of GSTAl-1, GSTA2-2 and GSTM3-3 [Inskip et 
al., 1995; Coles et al., 2001a]. The GSTOJ p.E155del polymorphism in particular may 
also exe1i a similar effect through tissue-specific alterations in splicing efficiency. 
Finally, small but significant differences in GST Omega allele distributions were 
observed between the four ethnic populations tested here. As variation between 
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populations 1s influenced by differences in genetic, environn1ental or dietary 
interactions [Kawajiri et al., 1990; Garte, 1998; Park et al., 2000; Risch, 2000], the 
effect one particular GSTO 1-1 polymorphism may have on protein function in one 
population will not necessarily be the same as the effect the same polymorphism has in 
another population. 
Using a combination of database mining strategies, two novel polymorphisms were 
identified in the human Omega class GST genes. Although each method yielded results 
for the GSTOl gene, polymorphisms in the newly characterised GSTO2 gene were only 
found in the EST database. The discovery of a novel three base pair deletion in the 
GSTO 1 gene through laboratory-based methods emphasises the point that identification 
of polymorphisms should not be limited to one method or technique. Functional and 
structural differences were observed for the GSTO 1 polymorphisms using the substrates 
currently available, however it is not currently known whether these polymorphisms 
have any clinical implications. The identification of other GSTO 1-1 specific substrates 
will help determine whether these polymorphisms exert ciny physiological effects. 
CHAPTER6 
FINAL CONCLUSIONS 
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Research into SNP detection has rapidly expanded in recent years largely due to the 
recent completion of the Human Genome Project, the advent of sequence databases and 
the recognition that some polymorphisms have physiological consequences in disease 
susceptibility and adverse drug reactions. Facilitating this research is the development 
of constantly evolving SNP databases and computer-based tools designed to detect 
SNPs within genes of interest. These recent advances in SNP detection were used to 
identify novel polymorphisms in the Alpha, Mu and Omega class GSTs, which 
comprise part of the GST superfamily ofxenobiotic metabolising enzymes. Overall, the 
combined use of various SNP databases, and the BLAST and SNP Finder computer 
algorithms to search the EST and UniGene databases respectively, has proved an 
efficient, cost-effective and rapid method of discovering novel coding region 
polymorphisms in the GST genes. 
No single program detected all of the polymorphisms described in this study. However, 
at least one novel polymorphism was isolated by each method. This suggests that the 
application of more than one SNP detection method should be used if a gene is to be 
comprehensively screened for polymorphisms present in the public sequence and SNP 
databases. The lack of overlapping entries between databases has also been emphasised 
in a recent study in which it was reported that when a search was limited to three SNP 
databases, only eight of the 893 SNPs the group had previously detected were common 
to all three selected databases [Marsh et al., 2002]. 
Using a combined approach, a total of eight uncharacterised polymorphisms were 
identified in this study. These include the GSTA2 p.Pl l0S, p.Tl 12S and p.E210A; the 
GSTA3 p.L71I; the GSTM3 p.W147G and p.V224I; the GSTOJ p.Al40D and the 
GSTO2 p.N142D polyn1orphisms. In addition, genotyping assays of putative GSTOJ 
polymorphisms subsequently revealed the presence of a novel three base pair deletion in 
the GSTOJ gene. Of these, the GSTA2 p.Pl l0S, the GSTM3 p.W147G and p.V224I, 
and the GSTOJ p.E155del polyinorphisms were found to have significant effects upon 
the protein function. The Pi, Theta 1 and Zeta class GSTs were also analysed for the 
existence of novel polymorphisms, although polymorphism in both the GSTP 1 and 
GSTZJ genes has been investigated extensively [Ali-Osman et al., 1997; Blackbum et 
al., 2000; Blackbum et al., 2001]. Preliminary population genotyping studies have 
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confirmed the presence of two novel polymorphisms in the Theta and Zeta class GS Ts -
the GSTTJ p.V95L and the GSTZJ p.N133H polymorphisms (Appendix 4). 
A number of advantages and disadvantages were encountered with the application of 
database mining techniques, especially during the detection of polymorphisms present 
in the public sequence databases. The greatest limitation is the high yield of false 
positive results, as observed in this study. The combined results from Chapters 3, 4 and 
5 demonstrate that only 35% of the Alpha, Mu and Omega class GST missense 
polymorphisms that were detected using the in silica BLAST Alignment tool and SNP 
Finder methods and subsequently verified, and only 18% of the missense 
polymorphisms identified in the SNP databases, could be confirmed in the four 
populations screened in this study. Other groups mining the EST and UniGene 
databases for SNP information have reported similar results despite the use of different 
computer algorithms designed to search these databases and the implementation of 
stringent filtering processes. The number of seemingly genuine polymorphisms 
confirmed in subsequent population studies has been found to range anywhere between 
20%-82% [Gu et al., 1998; Buetow et al., 1999; Forsberg et al., 1999; Garg et al., 1999; 
Picoult-Newberg et al., 1999; Irizarry et al., 2000]. 
If the success rate of SNP detection using methods based on database analysis is to 
improve, the source of the problems responsible for the high rate of false positives must 
be addressed. In respect to the EST and UniGene databases, the high error rate of the 
EST information contained within these databases partially contributes to this problem. 
The combination of single pass, high throughput automated sequencing of cDNA 
libraries of variable quality, and the use of error prone reverse transcriptase used to 
generate the ESTs automatically introduces an inherent 2%-3% en·or into each EST 
[Adams et al., 1991; Gu et al., 1998]. In addition, some cDNA libraries are constructed 
from tumour tissues, which could lead to the detection of spontaneous tumorigenesis-
associated polymorphisms [Gu et al., 1998]. Even though these spontaneous mutations 
can and will be validated in the relevant cDNA clones, they will not normally be found 
in the general population. 
In contrast to the high number of false SNPs detected in the EST and UniGene 
databases, the lack of SNP detection in some genes also constitutes a problem with 
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these databases. One explanation is that these genes may truly lack polymorphisms, 
possibly because they possess important physiological functions and are therefore 
highly conserved [Forsberg et al., 1999]. Alternatively, the problem could lie with the 
method of EST generation. ESTs are only 300-400 bp in length and, as only the 5' or 3' 
ends of the cDNA clone are sequenced, the sequence generated does not always cover 
the entire coding region of a gene of interest. Consistent with a previous study [Irizarry 
et al., 2000], only a few partial ESTs covered the coding region of the GSTA4, GSTM2, 
GSTM4 and GSTM5 genes at a particular point. The result is that many polymorphisms 
may not be detected during database mining. Polymorphisms may also be missed if the 
transcript of interest is rarely and/or weakly expressed, such as GSTA3-3. Although 
normalised cDNA libraries have been constructed in order to increase the representation 
of rare transcripts by reducing the number of highly expressed genes [Soares et al., 
1994; Bonaldo et al., 1996], many genes continue to be missed as they are not expressed 
in the tissues used to create the libraries [Schuler, 1997]. By increasing the overall 
quality and diversity of the cDNA libraries used to generate ESTs, the quantity of true 
SNPs in both highly expressed and rare genes is likely to increase, and the number of 
false positives should correspondingly decrease. 
Unlike the publicly available sequence databases, the SNP databases should contain 
sequence data of a relatively high quality. These databases contain data submitted by 
various laboratories working specifically on different aspects of SNP discovery. 
Usually, SNPs must be experimentally validated if they are to be accepted into the 
databases, for example dbSNP and HGVbase have implemented submission guidelines 
that ensure high sequence quality [Sherry et al., 200 l; Fredman et al., 2002]. EGPSNPs 
and GeneSNPs both resequence genes of interest generated from the Human Genome 
Project te1nplate using a PDR sample cohort for confirmation, and CGAP divides the 
polymorphisms predicted using the SNP Finder program into three groups based on 
different stages of verification. SNP information found in these databases can therefore 
be expected to be of higher quality than EST data and in tum have a higher likelihood of 
being real. Therefore, in theory there should be a smaller chance of detecting false 
positives however, high false positive rates was also a problem encountered when using 
the SNP databases. This is partly due to the failure of various SNP databases to 
regularly update and monitor their contents for the presence of SNPs that have 
subsequently failed further validation tests [Marsh et al. , 2002]. In addition, the 
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presence of paralogues, pseudo genes and duplications of sequences highly similar to the 
one of interest within the SNP databases can all contribute to the high rate of false 
positives associated with these databases [Gu et al., 1998; Marth et al., 1999; Marth et 
al., 2001; Marsh et al., 2002]. One of the main points emphasised by this study is that 
quite often, genes belonging to multi-gene families, such as the Alpha and Mu class 
GSTs, are not identified correctly due to high sequence identity with other members of 
the sa1ne gene family. It was found that genes from one gene family are often submitted 
to the SNP databases as another 1nember of the same gene family, leading to the 
identification of false polymorphisms. This occurrence has also been observed in other 
studies based on EST and UniGene searches [Marth et al., 1999; Picoult-Newberg et al., 
1999; Irizarry et al., 2000], and one based on the analysis of several SNP databases 
[Marsh et al., 2002]. Sequence identification problems should become less frequent 
with the completion of the human genome sequence and its subsequent use as a 
reference template [Marth et al., 2001]. 
Iinplementation of filtering processes during sequence database analysis, and the 
validity tests in place for submission to the SNP databases, suggests that the sheer 
number of false positives found in this and other studies cannot be blamed simply on the 
errors inherent in each individual database. Many of these supposed false positive 
polymorphisms have high sequence quality, but this and other studies have been unable 
to further confirm the polymorphisms identified by these means in different populations 
[Picoult-Newberg et al., 1999; Irizarry et al., 2000]. As discussed in the individual 
results chapters, there is a possibility that some of these false positives are rare alleles. 
Rare variants can be detected by database mining, yet these are often excluded and 
discarded as sequencing errors depending on the degree of filtering enforced. An 
example is the ranking system found in the SNP Finder program. Potential 
polyn1orphisn1s are given a probability score reflecting the likelihood that the nucleotide 
in question is truly polyn1orphic [Buetow et al., 1998]. However, as this score is 
influenced by the nun1ber and quality of sequences found at the polymorphic site, a 
poorly ranked putative sequence alteration can often be confirmed by 
electropherographic validation as being a true polymorphism. Depending on the 
ranking limit set by the user, these rare, but real polymorphisms may be missed. 
Ultimately, it is up to the researcher to choose between detecting common variants with 
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a low number of false positives, and risking a higher false positive rate in order to 
identify rare polymorphisms. 
Although rare alleles may be identified and confirmed, they will not necessarily be 
detected in particular populations. The absence of some of the possibly rare 
polymorphisms identified in this study in the three ethnic groups screened may be a 
reflection on the sample size and the choice of population used. Sample sets of 25 
individuals for each representative population were used in this study and several other 
groups have used sample sets ranging from six to 24 individuals in order to confirm the 
presence of polymorphisms [Forsberg et al., 1998; Buetow et al., 1999; Picoult-
Newberg et al., 1999; Lee et al., 2001]. These numbers are sufficient to identify 
common SNPs [Weiss, 1998], which are found at high frequencies worldwide. These 
common SNPs are believed to have emerged after speciation approximately 5 .5 million 
years ago [Kumar & Hedges, 1998] but before the divergence of modem human 
populations, which occurred when humans emerged from Africa approximately one 
hundred thousand years ago [Cavalli-Sforza et al., 1988.; Mountain et al., 1992]. Due to 
the low rate of genomic change, approximately 85% of the worldwide gene variation is 
common to all human populations [Barbujani et al., 1997]. The remaining 15% of the 
global gene variation is composed of rare variants, which tend to occur at a frequency 
below 5% [Barbujani et al., 1997]. It is believed these developed after human 
diversification and they are therefore more likely to be restricted to specific ethnic 
groups [Cargill et al., 1999; Halushka et al., 1999; Risch, 2000]. If these rare alleles are 
to be detected, larger sample sets representing a diverse number of populations are 
required. Unfortunately, it is difficult to choose representative populations when trying 
to confirm SNPs detected through database analysis for the following reasons. Firstly, 
the ethnicity of sainples in the EST and UniGene databases is unknown. Secondly, 
many polymorphisms submitted to the SNP databases have been identified in PDR 
sample sets. Although the diversity of this cohort is known, specific details , such as the 
ethnic origin of particular sainples, are withheld in order to prevent misuse of any 
genetic infon11ation that might promote ethnic or racial discrimination [Collins et al., 
1998]. 
The choice of populations used in polymorphism studies must be carefully considered. 
The four populations used in this study are representative of three major ethnic 
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populations - the Africans (Bantu and Creole), the South East Asians (Southern 
Chinese) and the Caucasians. (Australian European). As described above, the 1nodem 
human population first diversified approximately one hundred thousand years ago when 
the non-Africans split from the Africans [Cavalli-Sforza et al., 1988; Mountain et al., 
1992]. The rest of the global population, including the South East Asians and the 
Caucasoids (or Europeans) descended from the non-Africans, although the exact order 
of branch diversification remains unresolved [Cavalli-Sforza et al., 1988; Mountain et 
al., 1992; Nei & Roychoudhury, 1993]. As mentioned above, two African populations 
were tested in this study. The Bantu population represents a true African population. In 
contrast, whilst the Creole population is predominately Bantu African by descent, this 
group has been subject to mixed Caucasoid (European and Indian) and Asian and 
Oceania genetic influences [Hewitt et al., 1996]. 
The 1najority of the polymorphisms identified in this study were common 
polymorphisms and minor fluctuations between the allele distributions for the four 
populations were observed. However, evidence of popuJation specific allele distribution 
patterns was observed for some of the polymorphisms characterised in this study. The 
GSTA3 p.L 71 allele was seen in the African populations only, at a frequency of 5% in 
the Creole group and 15% in the Bantu group. Alleles specific to the African 
populations are not unusual [Zietkiewicz et al., 1997; Nickerson et al., 1998; Cargill et 
al., 1999; Halushka et al., 1999], as it is understood that the African populations are 
genetically 1nore variable than those of non-African descent [Cavalli-Sforza et al., 1994, 
Zietkiewicz et al., 1997; Clark et al., 1998]. The reduced allele frequency observed in 
the Creole group may be due to its genetic heterogeneity, and also provides evidence 
that regional differences within populations must be taken into account in SNP studies. 
In contrast, the Southen1 Chinese population showed significantly different GSTM3 
SNP profile patten1s to those of the Australian European and African populations, 
especially that of the Bantu African population. It is possible that this divergence 
occurred after the South East Asian populations branched from the other non-African 
populations. Interestingly, these polymorphisms were also found to alter the enzymatic 
properties of the GSTM3-3 protein. The distributions of these GSTM3 alleles were 
similar between the Creole African and Australian European populations, but not the 
Bantu Africans, which represent an earlier branch of diversification. This similarity 
between the Creole African and Australian European populations may be due to genetic 
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similarities between the two populations arising from the fact that the Caucasians are an 
admixture consisting of 35% ancestral Africans and 65 % ancestral Asians [Bowcock et 
al., 1991], and the Creoles, whilst mainly ancestral African, are also an admixture of 
Caucasians and Asians [Hewitt et al., 1996]. This may also explain why the GSTA2 
p.Tl 12 and GST02 p.D142 alleles were observed at similar frequencies in the Creole 
African and Australian European populations, but at frequencies that were lower than 
those observed in the Bantu African population. 
As discussed in the individual results chapters, the polymorphisms identified in this 
study, particularly those that altered the structure and catalytic activity of the protein, 
may be implicated in altering the various physiological roles possessed by the Alpha, 
Mu and Omega class GSTs. The next logical step into characterising the possible 
physiological effects of these polymorphisms will be to genotype various patient groups 
presenting symptoms that 1nay be associated with alterations in these different 
pathways. Based on the findings of previous association studies, it is probable that the 
polymorphisms identified in this study will not be dir~ctly responsible for a particular 
clinical phenotype, but instead will have an indirect effect through altering susceptibility 
risks and/or drug responses [Roulston, 1999; Hayes & Strange, 2000; Johns & 
Roulston, 2000; Strange et al., 2001]. The finding that some GST polymorphisms are 
associated with the regulation of other GST isoenzymes [Inskip et al., 1995; Coles et 
al., 2001a] emphasises that factors such as epistatic effects and linkage disequilibrium 
must be considered during association studies. Strange and colleagues [2001] have 
suggested that an exploratory patient group be initially genotyped. Confirmatory groups 
can subsequently be genotyped if the associations achieve significance. In order to do 
this successfully, the following criteria must be satisfied. Large patient sets from 
homogenous etlmic and/or geographical backgrounds, with well-matched controls are 
required. Patients should present with well-defined phenotypes, based on diagnosis 
following stringent criteria [Roulston, 1999; Hayes & Strange, 2000; Johns & Roulston, 
2000; Strange et al., 2000; Lai, 2001]. 
An i1nportant point to consider when assessing the effects these polymorphisms may 
have on disease aetiology is the variation of allelic distribution between the different 
ethnic groups. As discussed in Chapter 4, a polymorphism found in 100 individuals 
from one particular population is not necessarily representative of the rest of that same 
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population due to the existence of population substructures [Clark et al., 1998]. 
Although differences in SNP profiles can be expected between sin1ilar racial groups 
located in different countries, regional differences can also exist in one country. Hence 
differences can also be observed between similar racial groups in the same country 
[Kawajiri et al., 1990; Park et al., 2000]. Another point is that although similar SNP 
profiles may be observed in different racial groups, these may be associated with 
different phenotypes due to differences in linkage disequilibrium, epistasis and other 
exogenous factors such as environmental and lifestyle effects. 
Since this study was completed, the volume of sequence data submitted to the various 
databases has continued to increase at a great rate. Genes that were poorly represented 
in the EST and UniGene databases during initial screens in this study are now better 
represented. For exainple, the UniGene clusters for the GSTA4 gene now contains 215 
EST and mRNA sequences ( cf one) and the GSTM5 gene now has 5 8 representative 
sequences ( cf 13). The increase in the number of ESTs submitted to EST database, and 
subsequently collated into clusters in the UniGene database could be attributed to an 
increase in the number and type of cDNA libraries used to generate ESTs. In 1999, 
only 200-plus cDNA libraries were available compared to the 440 libraries currently 
available (6 th July 2002). This also represents an increase in the number of individuals 
represented, therefore increases the probability of finding novel polymorphisms. The 
various SNP databases are also undergoing constant development, and are now 
providing general inforn1ation about the populations in which SNPs have been detected 
in addition to frequency infonnation. Many, especially dbSNP and GeneSNPs, have 
newly improved user interfaces. Specifically, the location of any SNP within dbSNP 
can now be visualised on a colour-coded gene map. Links to ENSEMBL and the UCSC 
Geno1ne Assembly are also provided for each SNP. One of the newest features 
however is the haplotype database, which lists the frequency at which haplotypes for 
particular genes occur in different populations. New features of the GeneSNPs database 
include a nucleotide n1ap of the gene of interest in which the SNPs are highlighted, and 
a table containing genotype infonnation for some genes. Others such as the CGAP, 
EGPSNPs and refseq databases have not undergone significant changes. This continual 
expansion and development of the EST, UniGene and SNP databases will ensure that 
these become powerful and reliable tools in the field of SNP detection and, 
consequently, the application of SNP discovery to a wide range of fields. 
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APPENDICES 
Appendix 1. Common Reagents and their Sources 
a
33P[dATP] 
Acetic Acid 
REAGENT 
Accugel 29:1™: 40% (29:1) 
Acrylamide/Bisacryla1nide 
Agarose, Type II 
Alkaline Protease 
Ammonium Persulphate 
Ampicillin 
ii5 -Androsten-3, 17-dione 
~-1nercaptoethanol 
Bacto-agar 
Black and White Film 
Boric Acid 
Bovine Serum Albu1nin, Pierce Standard 
Calcium Chloride 
Chloramphenicol 
1-chloro-2,4-dinitrobenzene 
Chloroform 
7-chloro-4-nitrobenzo-2-oxa-1,3-diazole 
Coomassie Brilliant Blue 
Copper Sulphate 
Cumene Hydroperoxide 
Deoxycholic Acid 
2' -deoxynucleoside 5 '-triphosphate 
1,2-dichloro-nitrobenzene 
2-di thi o erythri o to 1 
Ethacrynic Acid 
SOURCE 
Amersham Pharmacia Biotech (UK) 
BDH AnalaR, Merck Pty Ltd (Australia) 
National Diagnostics (USA) 
BDH AnalaR, Merck Pty Ltd (Australia) 
Sigma-Aldrich (USA) 
BDH Laboratory Supplies (UK) 
Sigma-Aldrich (USA) 
Steraloids Inc. (USA) 
BDH AnalaR, Merck Pty Ltd (Australia) 
Bacto Laboratories Pty Ltd (Australia) 
Po_laroid Corp. (USA) 
BioRad (USA) 
PIERCE (USA) 
Mallinckrodt Inc. (USA) 
Sigma-Aldrich (USA) 
Fluka AG, Buchs SG (Switzerland) 
APS Ajax Finechem (Australia) 
Sigina-Aldrich (USA) 
BDH AnalaR, Merck Pty Ltd (Australia) 
BDH AnalaR, Merck Pty Ltd (Australia) 
Aldrich (USA) 
Sigma-Aldrich (USA) 
Life Technologies (USA) 
Sigma-Aldrich (USA) 
Sigma-Aldrich (USA) 
Sigma-Aldrich (USA) 
l ,2-epoxy-3(-4-nitrophenoxy)propane 
Ethylenediaminetetraacetic acid 
Ethanol 
Ethidium Bro1nide 
Ficoll 
Folin & Ciocalteu phenol reagent 
Glucose 
Glutathione Agarose 
Glutathione, reduced 
Glutathione Reductase 
Glycerol 
Glycine 
Hydrochloric Acid 
Isopropylthio-~-D-galactosidase 
11. DNA/HindIII 
Manganese Chloride 
Methanol 
p-nitrobenzyl chloride 
p-ni trophen ylacetate 
One Kb DNA Ladder 
One Kb Plus DNA Ladder 
Phenol 
4-phenyl-but-3-en-2-one 
Potassium Acetate 
Potassium Chloride 
Proto gel™: 3 7 .5: 1 acryla1nide: bisacrylan1ide 
pUC/HpaII Ladder 
Rainbow™ Marker 
Sequagel™: 19: 1 acrylainide:bisacrylamide 
Sigma-Aldrich (USA) 
BDH AnalaR, Merck Pty Ltd (Australia) 
BDH AnalaR, Merck Pty Ltd (Australia) 
Sigma-Aldrich (USA) 
Amersham Phannacia Biotech (UK) 
Sigma-Aldrich (USA) 
BDH AnalaR, Merck Pty Ltd (Australia) 
Sigma-Aldrich (USA) 
Sigma-Aldrich (USA) 
Sigma-Aldrich (USA) 
APS Ajax Finechem (Australia) 
APS Ajax Finechem (Australia) 
BDH AnalaR, Merck Pty Ltd (Australia) 
Progen Industries Ltd (Australia) 
Promega Corp. (USA) 
APS Ajax Finechem (Australia) 
BDH AnalaR, Merck Pty Ltd (Australia) 
Sigma-Aldrich (USA) 
Sigma-Aldrich (USA) 
Life Technologies (USA) 
Life Technologies (USA) 
Wako Pure Chemical Industries (Japan) 
Aldrich (USA) 
BDH AnalaR, Merck Pty Ltd (Australia) 
APS Ajax Finechem (Australia) 
National Diagnostics (USA) 
Gene Works (Australia) 
Amersham Life Science (UK) 
National Diagnostics (USA) 
Sequagel XR concentrate 
Sodium Acetate 
Sodium Carbonate 
Sodium Chloride 
Sodium di-hydrogen orthophosphate 
Sodium Dodecyl Sulphate 
Sodiun1 Hydroxide 
di-Sodium hydrogen orthophosphate 
Sodium-MOPS 
Sodium nicotinamide 
Sodium Tartrate 
Sucrose 
Taurine 
TEMED 
Tert-butyl hydroperoxide 
Trans-non-2-enal 
Trichoroacetic acid 
Tris 
Tryptone 
Urea 
Super RX Medical X Ray Film 
Yeast Extract 
National Diagnostics (USA) 
BDH AnalaR, Merck Pty Ltd (Australia) 
BDH AnalaR, Merck Pty Ltd (Australia) 
BDH AnalaR, Merck Pty Ltd (Australia) 
Fro nine Pty Ltd (Australia) 
BDH AnalaR, Merck Pty Ltd (Australia) 
Merck (Germany) 
BDH AnalaR, Merck Pty Ltd (Australia) 
Sigma-Aldrich (USA) 
Boehringer Mannheim (Germany) 
Mallinckrodt Inc. (USA) 
APS Ajax Finechem (Australia) 
Merck Schuchardt (Germany) 
Sigma-Aldrich (USA) 
Sigma-Aldrich (USA) 
Aldrich (USA) 
BDH AnalaR, Merck Pty Ltd (Australia) 
Life Technologies (USA) 
Bacto Laboratories Pty Ltd (Australia) 
BDH AnalaR, Merck Pty Ltd (Australia) 
Fuji, Hanimex Pty Ltd (Australia) 
Bacto Laboratories Pty Ltd (Australia) 
Appendix 2. Enzymes and their Sources 
ENZYME 
Restriction Endonucleases and 1 Ox Buffers 
Pfu Turbo DNA Polymerase and lOx Buffer 
Pfu DNA Polymerase and 1 Ox Buffer 
T4 DNA Ligase 
Taq DNA Polymerase and 1 Ox Buffer 
SOURCE 
Roche Diagnostics (Germany) 
New England Biolabs (U.S.A.) 
MBI Fermentas (Lithuania) 
Amersham Pharmacia Biotech (U.K.) 
Stratagene (U.S.A.) 
Stratagene (U.S.A.) 
Amersham Pharmacia Biotech (UK) 
Promega (U.S.A.) 
ABGene (U.K.) 
Promega Corp. (U.S.A.) 
Appendix 3. Buffers, Media and Solutions 
Table A3.l - Media 
Media Components 
Luria Broth (LB) 1 % tryptone 
0. 5 % yeast extract 
1 °/o NaCl, pH7.4 
LB plates 1.5% (w/v) agar 
LB 
LB-Amp plates 1.5% (w/v) agar 
100 µg/ml Ampicillin 
LB 
LB-Amp/Chlor plates 1.5% (w/v) agar 
100 µg/ml Ampicillin 
34 µg/mL Chloramphenicol 
LB 
Table A3.2 - Buffers for Making Competent Cells 
Buffers Components 
TFBI 30m11KAc 
50 mM MnCl2.4H2O 
100 mMKCl 
10 mM CaCl2.2H2O 
15% glycerol 
TFBII 101nM Na-MOPS pH7 
75 mM CaCl2.2H2O 
10 mMKCl 
15% glycerol 
Table A3.3 - Buffers and Solutions for DNA Work 
Solution Components 
5x BRL Buffer 250 mM Tris-HCl pH7.6 
50mMMgCh 
25% (w/v) PEG 
5 mMATP 
5mMDTT 
1 Ox Glycerol Tolerant Buffer 900 mM Tris base 
300 mM Taurine 
5mMEDTA 
Ficoll gel loading dye 0.25% bromophenol blue 
15% ficoll 
0.25% xylene cyanol FF 
Sucrose gel loading dye 0.25% Bromophenol Blue 
40% (w/v) sucrose 
5 Ox T AE buff er 2 M Tris-Acetate 
50 1nM EDTA, pH 8.0 
lx TBE buffer 900 mM Tris-Borate 
201nM EDTA, pH 8.0 
TE buffer 10 mM Tris-HCl pH7.5 or 8.0 
lmMEDTA 
Table A3.4 - Buffers and Solutions used for Protein Work 
Solution Component 
4x Resolving Gel Buffer 1.5 M Tris pH8.8 
0.4% SDS 
4x Stacking Gel buffer 500 mM Tris pH 6.8 
0.4% SDS 
1 Ox Running Buff er 50 mM Tris base 
192 M Glycine 
1% SDS 
3x SDS gel loading Buffer 187.5 mM Tris-HCl pH6.8 
6% SDS (w/v) 
30% glycerol (v/v) 
0.0075% bromophenol blue 
1 mM ~-mercaptoethanol 
Staining Solution 10 mL Coomassie® Blue R250 
5 0 mL destaining solution 
Destaining Solution 10% acetic acid 
30% methanol 
Appendix 4. Preliminary genotyping data for polymorphisms detected in the Zeta and Theta class GSTs 
Table A4.1 - GSTTJ and GSTZJ allele frequencies in three ethnic groups 
Gene Polymorphism Population n Genotype Allele Frequency 
GSTTJ p.V95L Australian 25 G/G=22 G/T=3 T/T=0 p.V95=0.94 p.L95=0.06 
GSTZJ p.N133H Australian 
Bantu 
Chinese 
100 A/A=I00 A/C=0 C/C=0 p.N133=1 p.H133=0 
68 A/A=I00 A/C=0 C/C=0 p.N133=1 p.H133=0 
99 A/A=94 AIC=S CIC=0 p.N133=0.98 p.Hl33=0.2 
